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CHAPTER I 
 
 
INTRODUCTION 
 
1.1 MicroRNAs 
MicroRNAs (miRNAs) are ~22 nucleotide (nt) non-coding RNAs that participate in gene 
regulation. MicroRNAs confer their regulation at a post-transcriptional level. Thousands of 
identified mature microRNAs with highly conserved sequences exist in species ranging from 
plants to humans, suggesting that they are ancient players in gene regulation. Approximately one 
percent of the human genome is dedicated to microRNAs. According to a study in silico, more 
than half of the mammalian mRNAs are under selective pressure and are conserved targets of 
microRNAs [1]. The known functions of microRNAs include cell differentiation, proliferation, 
apoptosis, anti-viral defense, lipid and fat metabolism. They are also involved in cancer, diabetes, 
and many other diseases [2-4]. Improved software programs are now able to predict the targets of 
microRNAs in a more efficient manner, thus facilitating the elucidation of microRNA function. 
Furthermore, methods such as real-time PCR and microarray have been enhanced for studying 
microRNA expression. Using these tools, scientists are able to discover novel functions for 
microRNAs. It is likely that microRNAs have a role in virtually every aspect of gene regulation. 
1.1.1 How are microRNAs generated? 
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MicroRNAs are now considered to be a general mechanism for gene regulation. The most 
important property of microRNA genes is that they are conserved throughout evolution, except 
for those found in viruses. More than half of the known mouse and human microRNAs have their 
homologs in puffer fish or zebrafish [5]. The locations of microRNA genes in the genome of 
these organisms are variable. Some exist individually and others are in clusters that are co-
expressed polycistronically. Studies of genomic positions of microRNAs in mouse and human 
have revealed that many microRNA genes are in the intergenic regions. Some microRNA genes 
are located in introns of coding regions, either in sense orientation or reverse orientation. This 
means that microRNAs can be transcribed from their own promoters or derived from the 
transcript product of other genes. The biogenesis of microRNAs occurs in a stepwise fashion in 
the nucleus and the cytoplasm. Mature microRNAs are shortened RNAs that are the result of a 
series of cleavage processes that begins with a primary microRNA (pri-miRNA) [6, 7]. First, pri-
miRNA is processed in the nucleus into a precursor microRNA (pre-miRNA) hairpin by Drosha, 
a double-stranded RNA (dsRNA)-specific ribonuclease [8-10]. Then, the hairpin RNAs are 
transported to the cytoplasm where they are digested into lengths of ~22 nt by another dsRNA-
specific ribonuclease called Dicer [11]. This mature form of microRNA is now available to bind 
to a RNA-induced silencing complex (RISC).  
1.1.1.1 Transcription of primary microRNAs 
The pri-miRNAs are transcribed as long, double-stranded unstructured precursors with a 
5’ cap and a 3’ poly(A) tail and are presumably dependent on the same regulatory machinery as 
encoded RNA destined for translation into protein [12, 13]. Many genes for microRNAs are 
separated from other genes, but some (~ one-third) are found within introns of protein-coding 
genes where they are likely controlled by a shared promoter [14]. As for transcription of 
microRNA genes, it remains unclear which RNA polymerase is responsible for the transcription. 
There are two polymerases possibly involved: Pol II is responsible for the transcription of 
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protein-coding genes, small nucleolar RNA genes, and some small nuclear RNA genes [15-17]. 
On the other hand, pol III transcribes small non-coding RNAs including tRNAs, 5S rRNA, some 
snRNAs, and other small RNAs [18]. Several studies have suggested that pol II may be the most 
important RNA polymerase engaged in microRNA gene transcription. First, the pri-miRNAs are 
longer than the ~70 nt pre-miRNAs and sometimes can be several thousand bases long. For 
example, pri-miR-21 is ~3433 nt in length. Therefore, it is too long for pol III- mediated 
transcription [13, 19]. Second, it is believed that the pri-miRNA gene sequences are flanked by 
promoters in the 5’ region that are able to transcribe heterologous mRNAs [19]. Third, stretches 
with more than four U’s, which terminate the transcription of pol III, widely exist in pri-miRNA 
sequences [20]. Forth, human pri-miRNAs are polyadenylated and capped, which are unique 
properties of pol II gene transcripts [21]. However, some new evidence indicates that, in some 
cases, microRNAs can also be transcribed by pol III. In the genome of mouse gamma herpes 
virus 68 (MHV68), microRNAs are embedded in the pol III tRNA primary transcripts and end 
with a stretch of oligo (T) [22]. The transcription of these microRNAs is largely unregulated as 
they are under the control of an unregulated tRNA-specific pol III promoter. From these 
observations we can speculate that both pol II and pol III may transcribe microRNA genes 
depending on the species and the evolutionary origins of these microRNAs. 
1.1.1.2 Processing of primary microRNAs by Drosha 
Ribonucleases serve as the post-transcriptional regulators that participate in the 
processing and decay of RNA. Thus, the rates of maturation and decay, along with transcription 
frequency, establish the steady-state level of an RNA. In the cell’s nucleus, a specific 
ribonuclease of the RNase III endonuclease family, Drosha, enzymatically cuts the pri-miRNA 
into a smaller (~70 nucleotides) product [8, 23]. Drosha is able to do this with the help of a 
cofactor called DGCR8 or Pasha, which is a dsRNA binding protein that dimerizes with Drosha 
[24]. Drosha is composed of two tandem RNase III domains, a dsRNA binding domain, and an 
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N-terminal segment [25]. It is a dsRNA-specific endonuclease that produces the 2- nucleotide 3’ 
overhang at the cleavage site [26]. Drosha cleaves both strands of pri-miRNA into an imperfect 
stem-loop structure, which predetermines one end of the mature microRNA. Mutagenesis studies 
revealed that the enzymatic activity of Drosha is dependent on cis-acting elements flanking the 
cleavage site, the length of the terminal loop, and the stem structure [8, 27]. However, the internal 
loop, or bulge, has little effect on the efficiency of Drosha. Recent knock-down studies have 
shown that Drosha cannot work without its partner, DGCR8 [28]. Human Drosha is found in two 
multi-protein complexes, with one being larger and containing several classes of RNA-associated 
proteins. The other smaller multi-protein complex is called a microprocessor, and contains both 
Drosha and DGCR8. The deletion of DGCR8 in humans has been shown to cause DiGeorge 
syndrome, a developmental disease characterized by specific cardiac malformations, facial 
abnormalities, and certain endocrine and immune anomalies [24]. Further in vivo and in vitro 
experiments have shown that this Drosha-DGCR8 microprocessor is necessary and sufficient for 
the processing of pri-miRNA to pre-miRNA [29]. The relative role for the larger Drosha multi-
protein complex remains unknown. An alternative mechanism of pri-miRNA processing was 
discovered recently. Some introns, where intronic microRNAs are located, serve as pri-miRNAs. 
These introns mimic the structures of pre-miRNAs and enter the pre-miRNA processing directly 
without Drosha-mediated cleavage [30]. Another mechanism has also been discovered recently. It 
has been reported that some small nucleolar RNAs (snoRNAs) in various species can be 
processed into microRNA-like RNAs by Dicer, without involvement of Drosha [31-33]. As with 
mRNA, the processing of pri-miRNA is regulated post-transcriptionally. The terminal loops of 
some pri-miRNAs are highly conserved [34]. In addition, there is experimental evidence that the 
processing of pri-miRNA by Drosha and pre-miRNA by Dicer, which will be discussed in the 
next section, can be regulated via the loop structures [35, 36]. 
1.1.1.3 Export of precursor microRNAs to the cytoplasm 
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After being cleaved by Drosha, pre-miRNA is transported to the cytoplasm by Exportin-5, a 
nuclear export factor, in a Ran-GTP dependent manner [37, 38]. This type of nuclear export 
factor is known to shuttle transfer RNAs, short hairpin RNAs, and ribosomal RNAs to the 
cytoplasm [39]. Exportin-5 was first examined for its involvement with the nuclear transport of 
adenovirus VA1, a viral non-coding RNA with an 18 base pair stem [40]. The binding of 
Exportin-5 to pre-miRNA is specific because an RNA stem must be larger than 14 base pairs with 
a base-paired 5’ end and a short 3’ overhang in order for Exportin-5 to bind efficiently [41]. In 
addition, the binding of Exportin-5 to the pre-miRNAs in vitro prevents their degradation by a 
bacterial exonuclease, suggesting that the export factor provides protection of the pre-miRNA 
from nucleases as it is being transported out of the nucleus [41].  
1.1.1.4 Maturation of microRNA in the cytoplasm 
Once the pre-miRNA is transported into the cytoplasm, it is cleaved into an imperfect 
dsRNA duplex designated microRNA: microRNA*. Eventually, an extension of the stem-loop is 
cut off to yield the active ~22 nt microRNA. This process is carried out by Dicer, an RNase III 
endonuclease, which defines the other end of the mature microRNA [13, 42]. Dicer is an 
evolutionarily conserved enzyme found in mammals, worms, fungi, flies, and plants. It is 
composed of a helicase domain, a Piwi-Argonaute-Zwille (PAZ) domain, two RNase III motifs, a 
Domain of Unknown Function (DUF283), and a dsRNA binding domain (dsRBD) [42, 43]. Dicer 
forms an intramolecular dimer with its two RNase III domains, which generates an active 
catalytic site at the interface of the RNase III dimer for single dsRNA cleavage. This process is 
unlike Drosha because Dicer’s second RNase III domain contains substitutions at a critical active 
site, which makes it partially inactive [44]. The crystal and NMR structures of the PAZ domain 
have been solved [45, 46]. It contains a five-stranded central β-barrel, which is a topological 
variation of the oligonucleotide/oligosaccharide-binding (OB) fold. The OB structure 
predominantly functions in single stranded nucleic acid binding. The PAZ domain has a weak but 
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consistent affinity for nucleic acids. Moreover, it has specificity for the 3’ two-nucleotide 
overhang resulting from RNase III cleavage [46]. This suggests that the PAZ domain may make a 
major contribution to the substrate specificity of Dicer.  
1.1.1.5 Species variation in microRNA maturation  
There are two Dicer homologues in Drosophila melanogaster, Dicer1 and Dicer 2 [47]. 
Dicer1 plays an important role in pre-miRNA processing as Dicer1 deficiency blocks this process. 
A dsRNA binding protein, R3D1, forms a stable complex with Dicer1 and is necessary for pre-
miRNA processing [48]. In contrast, Dicer2 does not have an effect on microRNA maturation but 
rather affects short interfering RNA (siRNA) production. It forms a complex with the dsRNA 
binding protein, R2D2, that initiates RISC assembly and enhances mRNA degradation mediated 
by RISC [47, 49, 50]. The orientation of this complex determines which siRNA strand is 
assembled into RISC [51]. The maturation of microRNA in plants is much different from that in 
animals as no Drosha homologue has been identified in plants thus far [52]. However, four Dicer 
homologues exist in the flowering plant, Arabidopsis thaliana. Two of these Dicer-like proteins 
are likely localized in the nucleus [53, 54]. Dicer-like protein-1 (DCL1) possibly performs both 
Drosha and Dicer-like activities for microRNA maturation inside the nucleus [55]. Interestingly, a 
miR162 target sequence is predicted near the middle of the DCL1 mRNA, suggesting that DCL1 
is dependent on negative feedback regulation by a microRNA [56]. Therefore, A. thaliana as well 
as other plants that have existed over the past 100 million years utilizes redundant regulatory 
mechanisms for processing microRNA [57]. The complexity of microRNA maturation in animals 
is likely an evolutionary byproduct. Because cellular microRNAs have become increasingly 
complex in mediating post-transcriptional regulation, viruses have also evolved to encode 
microRNAs in order to successfully infect cells. Few studies have reported on the maturation of 
viral microRNA; however, it is generally thought to be similar to that of the host cell. Because 
microRNAs act at the mRNA level, it is not likely that viruses that possess RNA as their genetic 
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material would encode microRNAs. The more probable choices are DNA viruses, such as 
herpesviruses, that establish long term latent infections in cells. Other candidates include large 
lytic DNA viruses like human adenoviruses. Indeed, microRNAs have been found in both 
herpesviruses as well as human adenovirus [22, 58-60]. The pol II-transcribed product of most 
viral encoded microRNA genes is processed in the nucleus by Drosha and transported by 
Exportin-5 to the cytoplasm where it is processed by Dicer [22, 61, 62]. One of the arms of the 
processed microRNA is incorporated into RISC [63]. This maturation process may not be true in 
the case of MHV68, since MHV68 pre-miRNAs have an unusual short hairpin structure, which 
means the maturation and export mechanism may be different from that of the host cell [22]. 
Furthermore, studies on adenovirus have shown that the viral microRNA has the ability to mimic 
the stem loop structure of host microRNAs in order to bind and sequester Dicer [60]. The same 
study demonstrated that Dicer not only binds to viral pre-miRNA, but also cleaves it to yield a 
~22 nt mature microRNA. Viral microRNAs not only target mRNAs that allow the virus to 
remain in the latent stage or to become lytic without being recognized by the host’s immune 
system, but also target host mRNAs to escape recognition by the host immune system [61, 64, 65]. 
1.1.2 How do microRNAs work? 
1.1.2.1 Formation of RISC 
After pre-miRNA is processed into a microRNA: microRNA* duplex by Dicer, one of 
the RNA strands is incorporated into RISC for target recognition [66]. RISC has strand bias and 
always incorporates the microRNA strand with the less stable 5’ end in comparison with the 
microRNA* strand [67]. The microRNA* strand is degraded in most cases. This strand bias may 
be the result of the relative ease of unwinding from one end of the duplex. A helicase likely 
carries out multiple trials from both ends in order to unwind the duplex. Occasionally, these trials 
lead to unwinding at the easier end of the complex, rendering a strong bias for the easier end. This 
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is supported by the finding that in rare cases where microRNAs have 5’ ends with similar stability, 
both strands are incorporated into RISC [66]. RISC is composed of Dicer, Argonaute (AGO), 
PW182 (a P-body protein), the human immunodeficiency virus transactivating response RNA-
binding protein (TRBP), fragile X mental retardation protein (FMR1), and other non-specified 
proteins [68-70]. TRBP is required for the recruitment of AGO2 to RISC [69]. AGO proteins 
bind to either microRNAs or siRNAs to create the core of the complex. They have both Ago and 
Piwi domains. The Ago domain, which is a PAZ domain, binds to the 2-nt overhang at the 3’ end 
of RNA duplexes [46]. The Piwi domain mediates interactions between Argonaute proteins and 
Dicer [51]. Different Ago paralogs exist across species, and the Ago-associating proteins are also 
variable among species. Furthermore, variants of the AGO protein within the same animal can 
have different functions. For example, among RISC with any of the 4 human AGO proteins 
(AGO1-AGO4), only AGO2-associated RISC can direct the cleavage of target mRNA [71]. 
Drosophila AGO2 acts to cleave target mRNA, while AGO1 functions in translational repression 
[72]. Some of the other proteins that associate with AGO proteins are the Vasa intronic gene 
(VIG), an endonuclease like protein (TSN-1), and a homolog of fragile X mental retardation 
protein (dRXR) [73, 74]. Most AGO-associated proteins have unknown functions, but some are 
required to mediate mRNA cleavage [75]. It is likely that the different AGO homologues along 
with the variable associating factors allow for different subtypes of RISC in order to provide a 
specific response to a particular siRNA or microRNA. RISC has many diverse functions in both 
siRNA and microRNA mechanisms. It acts as an effector complex in mRNA cleavage, translation 
suppression, and heterochromatin formation [76, 77]. The details of the molecular mechanisms 
that make RISC work are still not clear. However, some observations have been made that will be 
discussed below.  
1.1.2.2 Translational repression 
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MicroRNA-associated RISC can repress mRNA translation in a couple of ways. 
MicroRNAs in animals mostly suppress translation of their target mRNAs due to an imperfect 
base-pairing within 3’ untranslated regions (UTRs) [78, 79]. By binding to the 3’ UTR of the 
mRNA, the microRNA has the ability to inhibit translation by directly interfering with translation 
initiation factors or by disrupting poly (A) tail function [80-82]. However, polyribosomes co-
purify with RISC, indicating that RISC may also interrupt the continuation of translation by 
forming a stable complex with polyribosomes [83, 84]. The distinction between translational 
repression and mRNA cleavage mediated by microRNA relies on the degree of complementarity 
between the microRNA/siRNA and its target. Plant microRNAs function in mRNA cleavage due 
to their near complete complementarity in base-pairing to their target mRNA [85-88]. When 
mammalian microRNAs have high enough complementarity with their target mRNA, they 
perform mRNA cleavage instead of translational repression as in the case of miR-196 and its 
target Hoxb8 [88, 89]. Although most plant microRNAs cleave and destroy their target mRNAs 
with nearly perfect complementarity between them, one plant microRNA, miR-172, acts as a 
translational suppressor [87, 90]. Furthermore, when the base-pairing between siRNA and its 
mRNA target does not have strong complementarity, siRNA can perform translation repression 
just as microRNAs do, suggesting that microRNAs and siRNAs are functionally interchangeable 
[91].  
1.1.2.3 mRNA cleavage 
Perfect base-pairing is thought to be the critical feature of microRNA-mediated mRNA 
cleavage, but it is not always sufficient in plants, suggesting the need for supplementary catalytic 
activity by RISC [90]. Regardless of the species, a perfect match between a microRNA and its 
target mRNA is required for efficient cleavage, especially considering the precise location of the 
cut between residues 10 and 11 of the microRNA [87, 92, 93]. Once the mRNA is efficiently cut, 
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the intact microRNA has the ability to cut other target mRNAs or guide mRNAs to mRNA 
processing bodies (P-bodies) for subsequent degradation [85, 93].  
1.1.2.4 mRNA degradation 
MicroRNAs can also act upon their target mRNAs by increasing the rate of mRNA 
degradation. By transfecting miR-1 and miR-124 into human cells and using microarray, Lim et 
al. [94] showed that a significant number of mRNAs are down-regulated in accordance with the 
microRNA expression. Another study reported that miR-16 contains an AU-rich sequence 
complementary to the AU-rich element (ARE) in the 3’ untranslated region of unstable mRNAs, 
a sequence that is known to increase mRNA decay rates [95]. This finding suggests that 
microRNAs are required for ARE-RNA turnover. Furthermore, Bagga et al. [96] demonstrated 
that the expression of two of the earliest identified microRNAs, let-7 and lin-4, significantly 
decrease the levels of their target mRNAs. In addition, some studies have shown that microRNAs, 
such as miR-125 and let-7, can induce deadenylation of their target mRNAs, leading to rapid 
mRNA decay [97, 98]. All these studies provide evidence that microRNA can directly affect the 
turnover of their target mRNAs.  
MicroRNAs are also associated with P-bodies. Cytoplasmic P-bodies are compartments 
in the cell that contain decapping enzymes and exonucleases for the degradation of mRNA. RISC, 
particularly AGO proteins, co-localize with P-bodies. Recent studies have shown that localization 
of targeted mRNAs to P-bodies is microRNA-dependent [99-101]. It is still not clear what 
functional capacity RISC possesses in P-bodies. Although P-bodies are primarily known for 
retaining targeted mRNAs for degradation, they contain several factors that are associated with 
translational repression [102]. Once the targeted mRNAs are sequestered in the P-bodies, they 
generally undergo deadenylation by removal of the 3’ poly (A) tail, decapping by Dcp1/Dcp2, 
and degradation by an Xrn exonuclease [102, 103]. Deficits in the expression of the Xrn 
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exonuclease lead to an inefficient RNAi response [104, 105]. The microRNA-mediated 
degradation pathway is now known to be dependent upon the GW182 protein that interacts with 
the Piwi domain of AGO [106]. Taken together, this indicates that microRNAs can contribute to 
mRNA turnover by transporting mRNAs to P-bodies.  
1.1.2.5 Activation of protein expression 
In most cases, microRNAs inhibit the expression of target genes at the post-
transcriptional level via the three mechanisms discussed above. However, inhibition is not always 
the case. It has been reported that microRNAs can actually activate expression of proteins in 
quiescent cells at cell-cycle arrest [107, 108]. The AU-rich element (ARE) in the 3’ UTR of 
tumor necrosis factor-α (TNF-α) mRNA turns into a translation activating signal. The up-
regulation of protein expression relies on recruitment of FMR1 and AGO2 to the 3’ UTR.  
1.1.3 How do scientists study microRNAs? 
1.1.3.1 Expression studies of microRNAs 
One of the prominent characters of microRNAs is that their expression is spatially and 
temporally regulated. Many microRNAs are highly expressed in certain organs or cell types and 
some are only expressed at certain stages during development. These regulations in expression 
patterns obviously coordinate with their functions; therefore, much research has concentrated on 
expression of microRNAs. The technology of microRNA expression detection ranges from 
simple to complex. One popular method uses small RNA cloning and sequencing to identify 
microRNA in tissues and cells [7, 109-113]. Although this method has potential to find novel 
microRNAs, the rates of discovery depends on the expression levels of the microRNAs. In 
general, cloning methods are not sensitive enough and are not suitable for high throughput 
microRNA expression profiling. Furthermore, it is possible that microRNAs have bias at various 
steps including ligation, reverse transcription, amplification and cloning. By far the most reliable 
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technique to detect expression of microRNA remains to be Northern blotting. After all, results 
from all other methods are always validated using Northern blots. For example, Sempere and 
colleagues [114] made an extensive effort to uncover the expression profiling of mammalian 
microRNAs using Northern blots and showed that some microRNAs are specifically expressed or 
highly enriched in certain organs. In situ hybridization has also been a reliable technique for 
evaluating the relative expression level as well as temporal and spatial patterns of microRNAs 
[115]. MicroRNA microarrays have been widely used to analyze microRNA expression. 
Krichevsky and colleagues [116] used a membrane spotted with antisense sequences to mature 
microRNAs. The RNA samples were end-labeled with gamma-
32
P and hybridized to the 
membrane oligonucleotide array. Of the probed microRNAs, 20 percent were significantly 
changed during mammalian brain development. In most microRNA microarray platforms, glass 
slides are utilized for spotting antisense or sense probes. There are many variations of this 
technique that differ in several respects such as probe choice, RNA sample processing, and 
detection method. Some researchers use Cy3 or Cy5 labeled cRNA transcribed from cDNA of 
microRNA to hybridize with chips [117]. Others have developed their own microarray systems 
for microRNA detection using cDNAs from adapter ligation and reverse transcription of 
microRNAs [14, 118-121]. There are compelling advantages for using microRNA microarrays. 
They are very sensitive and, more importantly, high throughput. In some microarray designs, 
microRNAs with concentrations as low as the femto-mole range can be detected [121]. Also, 
microarrays are less time-consuming compared to Northern blots. However, the challenge in 
using microarrays is data analysis. One potential problem is data normalization, where 
housekeeping genes are not suitable for data normalization. Unlike DNA microarrays, in which 
there are between 10 to 30 thousand probes on the slide, microRNA microarrays only contain 200 
to 300 probes. Furthermore, the overall microRNA expression levels may be variable in different 
tissues. Therefore, global normalization used for DNA microarrays may not be appropriate in 
some cases. Real-time PCR has been adapted to monitor microRNA expression. One such 
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adaptation uses stem-loop RT primers that are more efficient and specific than conventional 
primers [122]. It is now possible to analyze over 300 different gene profiles, which is comparable 
to the high throughput of microarrays [123]. Jiang et al. [124] successfully profiled the expression 
of 222 microRNA precursors in 32 cancer cell lines using real-time PCR. Their results showed 
that some microRNA precursors have significantly higher or lower expression in certain cell lines. 
They also reported that the expression of pre-miRNA parallels that of mature microRNA in most 
of the cells that they tested. Another study used real-time PCR to evaluate the expression 
profiling of several mature Arabidopsis microRNAs, where as little as 100 picograms of total 
RNA was used [125]. The increased sensitivity of real-time PCR surpasses that of both Northern 
blots and microarrays, making this technique desirable. 
1.1.3.2 Function studies of microRNAs 
Functional studies of microRNAs can be carried out by several approaches. The first 
approach is forward genetics which starts with a phenotype and moves toward the identification 
of a microRNA [126-128]. The second approach is reverse genetics where the study starts with a 
microRNA and assays the effect of the microRNA gene’s disruption [129, 130]. Since most 
microRNA research begins with identification of a microRNA, another important approach to 
study microRNA function is to predict the microRNA’s target gene(s) by computational 
algorithms and experimental validation.  
1.1.3.2.1 Target prediction 
It is crucial to identify microRNA targets in order to uncover the functions of microRNAs 
during in normal physiological and pathogenic conditions. As mentioned before, most plant 
microRNAs have nearly perfect complementarity with their target mRNA sequences leading to 
target mRNA cleavage, which makes target identification relatively easy. However, identification 
of target sequences in animal genomes is impossible by standard sequence comparison because 
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microRNAs are very short in length and their complementarity to target sequences is imperfect 
[131, 132]. For this reason, computational approaches for finding animal microRNA targets are 
very useful. Currently there are several web servers that contain computationally predicted targets 
for microRNAs across many species. Among them is the miRanda software (www.microrna.org) 
[133]. This program uses the miRanda algorithm to identify potential binding sites and then 
checks the potential target site in the 3’ UTR to see whether the sites are conserved in 
orthologous transcripts. Another algorithm, PicTar, predicts microRNA targets in vertebrates and 
Drosophila species and has the ability to predict targets for single microRNAs and for 
combinations of microRNAs (http://pictar.bio.nyu.edu/) [134]. The TargetScan algorithm 
identifies mRNAs with conserved pairing to the 5' region of the microRNA and assesses the 
quantity and quality of these complementary sites (http://genes.mit.edu/targetscan) [131]. These 
programs have allowed for the creation of target databases that may potentially facilitate 
functional studies of microRNAs. One such database for predicted targets is TarBase 
(http://www.diana.pcbi.upenn.edu/tarbase), which contains target mRNAs tested in human, 
mouse, fruit fly, worm, and zebrafish [135]. Another such database is Argonaute 
(http://www.ma.uniheidelberg. de/apps/zmf/argonaute/interface/).  
1.1.3.2.2 Target validation 
After finding potential targets for microRNAs, the targets need to be validated by 
experimental methods. To test whether the target mRNA is cleaved by the microRNA, the target 
mRNA is reverse-transcribed, cloned and sequenced. The cleavage site should be at the site 
predicted according to the microRNA: mRNA duplex [93, 136]. To test whether the target is 
inhibited by translational repression, several methods have been used. The 3’ UTR segment with 
predicted complementary sites or those with point substitutions that disrupt the base-pairing are 
fused with a reporter gene. If the microRNA inhibits translation, disruption of the base-pairing 
will abolish translation inhibition of the target mRNA. The correct unmutated 3’ UTR segment 
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with the complementary sites is used concurrently as a control [90, 137]. Another method uses 
RNA inhibition to repress the activity of the microRNA to see if the effect on the target mRNA is 
real [138]. 
1.1.3.2.3 Over-expression and down-regulation of microRNAs 
Studies also over-express microRNAs to elucidate their effect on their target mRNA and 
the physiological consequence on the cell [139, 140]. Over-expression of microRNAs should 
significantly reduce the expression of the target mRNA. To observe the reverse effect, 
microRNAs are blocked by a 2’-O-methyl oligoribonucleotide complementary to the microRNA 
[141, 142]. A screen of microRNAs involved in cell growth and death has been reported using a 
library of these modified oligonucleotides [143]. Krutzfeldt et al. [144] developed a new method 
to silence microRNAs in vivo with “antagomirs”. Instead of using antisense 2’-O-methyl 
oligoribonucleotides, they designed chemically modified, cholesterol-conjugated antisense RNAs. 
Whether the microRNA is over-expressed or silenced, the target protein should have coincident 
expression with the microRNA. If the microRNA is over-expressed, the expression of target 
mRNA should be depressed. Conversely, if the microRNA’s function is blocked, the translation 
inhibition should be released. 
1.1.4 What do microRNAs do? 
The previous section described the mechanisms of microRNA-mediated gene regulation. 
In this section, we will briefly discuss some of their physiological functions. MicroRNAs have 
been implicated in biological processes ranging from developmental timing to apoptosis. As 
scientists discover the role of microRNAs in even more processes, it will become clear just how 
important these tiny RNAs really are. One unique aspect of microRNAs is that they can 
synchronously inhibit a group of genes that are functionally related. Thus, microRNAs can work 
as an efficient molecular switch to turn on or turn off a biological process. For example, as 
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discussed below, let-7 targets a group of genes in C. elegans, including lin-14, lin-28, lin-41, lin-
42, and daf-12 [145]. 
1.1.4.1 Developmental timing 
Most of ous knowledge of the biogenesis and function of microRNAs stems from the 
paradigm provided by the discovery of lin-4 and let-7, which were identified as microRNAs 
implicated in the function of C. elegans developmental timing [126, 145]. Lin-4 and let-7 bind to 
multiple conserved sites in the 3’ UTR of the lin-14 and lin-41 transcripts, respectively, through 
direct but imprecise base-pairing, thus inhibiting translation into protein [78, 126, 146]. In C. 
elegans, the down-regulation of the protein lin-14 at the end of the first larval stage initiates the 
second larval stage [126]. lin-41, on the other hand, regulates the developmental transition from 
the last larval stage to the adult stage [146]. Computational analysis reveals that let-7 is 
evolutionarily conserved throughout metazoans [147]. Lin-4 and let-7 also regulate two other 
genes, lin-28 and lin-57, respectively [148, 149]. Lin-28 encodes a RNA-binding protein that is 
important for neuronal differentiation of embryonic carcinoma cells [150] while lin-57 encodes a 
protein responsible for the terminal differentiation of the hypodermis in C. elegans [149]. Since 
the original C. elegans experiments, the regulatory abilities of lin-4 and let-7 have been extended 
to flies and mammals [151]. In mice, these microRNAs inhibit expression of lin-41, which is 
involved in key developmental events such as limb formation [151]. Studies of three microRNAs 
in Drosophila (let-7, miR-125 (the lin-4 homolog) and miR-100) not only show their up-
regulation during major points of development but also demonstrate their requirement for 
concurrent expression of a hormone in order to be functionally expressed [152]. Important mRNA 
targets responsible for developmental timing have also been found in Arabidopsis, suggesting that 
microRNA regulation in morphogenesis is a primitive mechanism [153, 154]. 
1.1.4.2 Cell proliferation and differentiation 
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In addition to guiding timing events, microRNAs have also been established as potent 
controllers of cell proliferation and differentiation. Although the division of cells is imperative for 
the growth of an organism, it can also be detrimental when occurring at inappropriate times. The 
latter is the hallmark of cancer, and several microRNAs have been shown to be up-regulated in 
tumors, a concept that will be discussed later along with microRNA-associated diseases. It is 
important to understand the significance of cell division during organismal growth beginning with 
stem cells. Mutation studies of Drosophila show that disruption of microRNA processing causes 
stem cells to be locked between the G1 and S phases, thus halting division [155]. A neuron-
specific microRNA, miR-132, is a target of the transcription factor, cAMP-response element 
binding protein. It regulates neuronal growth by decreasing the levels of a GTPase-activating 
protein [156]. Another brain-specific microRNA, miR-134, is expressed in the synaptodendritic 
compartment of rat hippocampal neurons, where it is capable of down-regulating Limk-1, a 
protein responsible for spine development [157]. Regulatory roles of microRNAs are not limited 
to the brain. Adipose cell differentiation has been shown to be partially controlled by the 
expression of miR-143 [158]. Also, miR-1 and miR-133 are important regulators of skeletal 
muscle proliferation and differentiation [138]. Because cell growth and differentiation are such 
dynamic biological processes, it is no wonder that microRNA with its specific and fast-acting 
regulatory ability is vital for shaping these processes.  
1.1.4.3 Apoptosis 
Apoptosis (programmed cell death), is an integral part of animal tissue development. 
Apoptosis is an evolutionarily conserved process that allows animals to remove cells that are 
useless or that are detrimental to survival. Once apoptosis is activated, caspase proteins cleave 
both structural and functional elements of the cell. Therefore, cell death vs. survival depends 
largely on the control of active caspases in the cell. Because caspases are ubiquitous, it makes 
sense that microRNAs would play a role in their regulation. Indeed, in the Drosophila eye, the 
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absence of miR-14 leads to an increase in the cell death effector, Drice, suggesting that miR14 is 
an inhibitor of apoptosis [159]. Likewise, the bantam gene encodes a microRNA that when over-
expressed, suppressed apoptosis in the Drosophila retina. One of the targets for bantam was 
identified as the pro-apoptotic gene, hid, which possesses sequences complementary to bantam 
[127]. It has been known for quite some time that viruses must prevent apoptosis in order to 
survive in the host cell. Recently, it has been discovered that herpes simplex virus-1 inhibits 
apoptosis through a latency-associated microRNA (miR-LAT) that modulates TGF-β signaling 
[160]. By using microRNAs as well as proteins in the inhibition of apoptosis, viruses are able to 
survive as well as evade immune detection. As functional studies of microRNA continue, the list 
of targets involved in apoptosis will likely grow radically.  
1.1.4.4 Regulation of signaling pathways 
With more functions of microRNAs being identified experimentally, it is now clear that 
microRNAs regulate almost all conserved signaling pathways that are important in physiology 
and pathology. It has been reported that miR-21 activates the MAPK/ERK signaling pathway in 
cardiomyocytes by directly repressing expression of Spry1 and Spry2, which are negative 
regulators of the MAPK/ERK signaling pathway [161, 162]. The Notch signaling pathway 
mediates local cell-cell communication and is pivotal to proper pattern formation in development 
[163]. Two large families of Notch target genes in Drosophila, basic helix-loop-helix (bHLH) 
repressor genes and Bearded genes, contain conserved motifs (GY-box, Brd-box, and K-box), in 
their 3’ UTR. MicroRNAs from three different families (miR-2, miR-4, miR-7, miR-11, and miR-
79) regulate the activities of these target genes and Notch signaling via binding to these motifs 
[164]. The TGF-β signaling pathway is known to stimulate epithelial-mesenchymal transition 
(EMT). It has been shown that the miR-200 family represses expression of the transcription 
factors ZEB1 and ZEB2, which are down-stream mediators of TGF-β signaling, resulting in the 
inhibition of EMT [165]. The Hedgehog (Hh) signaling pathway is another pivotal pathway in 
19 
 
development. It gives out signals for proper organogenesis of embryos. It has been reported that 
miR-125b and miR-326 inhibit Hh signaling by targeting to and repressing expression of 
Sommthened (Smo), which is an activator of the Hh signaling pathway. In addition, miR-324-5p 
also targets to Gli1, a downstream transcription factor in this pathway [166]. The Wnt signaling 
pathway will be discussed in detail in section 1.5. It has been reported that miR-8 regulates Wnt 
signaling in Drosophila at multiple levels. miR-8 inhibits the activity of this pathway by 
repressing expression of its targets, include Wingless (Wg), TCF, and CG32767, which is a 
positive regulator of this pathway [167]. 
1.1.5 Conclusions and perspectives 
Since the discovery of the first microRNA in 1993, remarkable progress has been made 
in the area of identification, high throughput microRNA expression profiling, computational 
target prediction, and experimental confirmation. With the increasing knowledge through 
observation and confirmation of more microRNA-target relationships, the empirical parameters 
for target recognition will be modified and made increasingly powerful and unambiguous. 
However, questions still linger in the microRNA world. What are the exact mechanisms for 
microRNA-mediated cleavage of target mRNAs? What other proteins are involved in microRNA-
mediated gene regulation? Most importantly, can synthetic microRNAs be used as a therapeutic 
intervention to diseases? These questions and many more will be the focus of future research for 
many laboratories. In the past few years, the understanding of microRNA function has increased 
dramatically. How widespread is the function of microRNAs? Perhaps clues will come from 
experiments that disrupt the function of Dicer homologues, AGO family proteins, or other 
important factors such as GW182 that have principal functions in microRNA function [168]. 
Although thousands of microRNAs have been identified in 39 species, only a small percentage of 
microRNAs have been tested for their function. Finding new functions for microRNAs is the new 
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frontier of molecular science. Many suspect that microRNAs will be revealed as the most 
important players in gene regulation: a tall order for a tiny string of nucleotides. 
1.2 microRNAs and diseases 
As discussed above, microRNAs are involved in the regulation of almost all 
developmental processes and cellular functions. It is therefore not surprising that the aberrant 
expression of microRNAs is closely linked with human diseases including cancers, central 
nervous system disorders, and liver, cardiovascular, and pulmonary diseases. The development of 
two powerful high-throughput microRNA detection techniques (solid-based microRNA 
microarray platform and liquid-based flow cytometry method) makes it possible to detect 
abnormal microRNA expression in diseases at a large scale [169, 170]. In this section, we mainly 
focus on those microRNAs whose functions in the pathogenesis of diseases have been confirmed 
by experimental evidence. Understanding the functions of microRNAs in diseases will provide 
potential therapeutic targets as well as prognostic and diagnostic tools. 
1.2.1 MicroRNAs and cancers 
MicroRNAs play important roles in cell proliferation, differentiation, and apoptosis. 
Their disrupted expression is associated with human cancers. Aberrant expression patterns of 
microRNAs have been profiled in a wide range of cancers, including ovarian, liver, pituitary, 
thyroid, lung, breast, stomach, prostate, colon, and pancreatic tumors [171-173]. The dysregulated 
microRNAs in different types of cancers have been summarized in several reviews [4, 173]. 
Although the aberrant expression of many microRNAs in cancer cells has been observed, 
there is a little evidence that microRNAs play a causal role in cancer pathogenesis. The study of 
miR-15 and miR-16 in chronic lymphocytic leukemia (CLL) is the first to establish a direct 
connection between microRNAs and tumorigenesis [174]. Hemizygous and/or homozygous 
deletions of the chromosomal region 13q14 are observed in most cases of CLL. It has been 
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suggested that there are some tumor suppressor genes located in this chromosome region [175]. 
In a study in 2002, miR-15 and miR-16 were found to be located within the lost region at 13q14 
[174]. The expression of these two microRNAs are depleted or reduced in a majority of CLL. In 
many cases of CLL, the 13q14 loss is the sole genetic aberration. It is reasonable to conclude that 
the deletion or reduction of miR-15 and miR-16 is of pathogenic significance in CLL [174]. In 
later studies, more evidence was found to support this conclusion. Several oncogenes, such as 
BCL2, MCL1, CCND1, and Wnt3a are direct targets of miR-15 and miR-16. Over-expression of 
these two microRNAs leads to the inhibition of cell proliferation, the promotion of apoptosis, and 
the suppression of tumorigenesis [176, 177].  
Another example is cluster miR-17-92, which has been intensively studied and is 
considered as an oncogene [178]. This cluster is located at chromosome 13q31, a region that is 
amplified in lymphomas and lung cancers [179]. The amplification of this region leads to the 
overexpression of cluster miR-17-92 in these cancers. Expression of the miR-17-92 cluster 
accelerates tumor development and inhibits apoptosis in lymphomas. 
Metastasis is a major cause for death of cancer patients. MicroRNAs can function as a 
metastasis suppressor as well as an activator. It has been reported that miR-335, miR-126, and 
miR-206 are lost during human breast cancer cell metastasis. Restoration of these microRNAs 
suppresses metastasis by human breast cancer cells in vivo [180]. Silencing of miR-148a, miR-
34b/c, and miR-9 by CpG island hypermethylation is frequently observed in metastasis formation 
in human primary malignancies, such as colon, lung, breast, and head and neck carcinomas and 
melanomas [181]. Furthermore, reintroduction of miR-148 and miR-34b/c inhibits cancer cell 
motility, growth, and metastasis, with the down-regulation of their target oncogenes, including C-
MYC, E2F3, CDK6, and TGIF2 [181]. In contrast, it has been shown that miR-375 functions as a 
metastasis activator and stimulates cancer cell migration in vitro and in vivo, probably by 
repressing expression of its target CD44. miR-375 is significantly up-regulated in metastasis of 
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breast cancer, corresponding with down-regulation of CD44 [182]. Another example is miR-10b, 
which is up-regulated in metastatic breast carcinomas. miR-10b stimulates cancer cell migration 
and invasion by directly targeting homeobox D10 (HOXD10), which is a transcriptional repressor 
of a pro-metastatic gene, RHOC [183]. 
1.2.2 MicroRNAs and liver diseases 
MicroRNAs are involved in different kinds of liver diseases, including viral hepatitis, 
drug-induced injury, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, primary 
biliary cirrhosis, liver fibrosis, and hepatocellular carcinoma (HCC) [184]. For example, miR-122, 
a liver-specific microRNA, has been shown to enhance the replication of Hepatitis C virus [185]. 
miR-122 is also up-regulated in NAFLD. It may play a critical role in NAFLD since miR-122 is 
known to regulate the genes involved in fatty acid biosynthesis and the antagonist of miR-122 
decreases the synthesis of hepatic fatty acid and cholesterol [186].  
1.2.3 MicroRNAs and cardiovascular diseases 
Some microRNAs have been shown to play roles in ventricular hypertrophy, fibrosis, 
heart failure, and arrhythmogenesis [187-189]. For example, the heart-specific microRNAs, miR-
1 and miR-133, have been reported to have critical regulatory roles in cardiac hypertrophy [188]. 
Expression levels of these two microRNAs are down-regulated in both mouse and human models 
of cardiac hypertrophy and suppression of miR-133 can induce hypertrophy [188]. RhoA (a G-
protein), Cdc42 (a kinase), and Nelf-A/WHSC2 (a nuclear factor) have all been confirmed as the 
targets of miR-133 in the regulation of cardiac hypertrophy. In addition, miR-1 exacerbates 
arrhythmogenesis by targeting GJA1 and KCNJ2, which encode the K
+
 channel subunit Kir2.1 
and connexin 43, respectively [189]. Elimination of miR-1 relieves arrhythmogenesis. In contrast, 
expression of miR-195 is up-regulated during cardiac hypertrophy. It has been shown that 
overexpression of miR-195 leads to cardiac hypertrophy and heart failure in vivo [190]. 
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1.2.4 MicroRNAs and central nervous system disorders 
The aberrant expression patterns of microRNAs have been profiled in many 
neurodegenerative disorders such as Alzheimer’s disease (AD), Huntington’s disease (HD), 
Schizophrenia, and Parkinson’s disease (PD) [191-198]. Some of the microRNAs that are 
important in pathogenesis of these neurodegenerative disorders will be discussed below. 
AD is a neurodegenerative disease with progressive loss of cognitive function and 
memory. This disease is characterized by the deposit of amyloid beta-peptide (Aβ) in plaques, the 
production of which is controlled by beta-site APP-Cleaving Enzyme (BACE) [199]. A 
microarray analysis revealed that the expression patterns of three microRNAs (miR-9, miR-125b, 
and miR-128) are changed in AD compared with those in the age-matched controls [200]. miR-
146a is up-regulated in AD brains and may regulate the inflammatory response in AD by 
targeting to complement factor H (CFH) [201]. Thirteen microRNAs are dysregulated in sporadic 
AD. The loss of miR-29a/b-1 is associated with increased expression of BACE1 [202]. miR-
29a/b-1 can target to BACE1 and down-regulate the level of Aβ. The expression of BACE1 is 
also regulated by miR-107, whose expression is progressively decreased in the patients of AD 
[203]. 
miR-133b is specifically expressed in midbrain dopaminergic neurons and is deficient in 
the patients with PD because of the loss of dopaminergic neurons in midbrain tissues. 
Overexpression of miR-133b leads to reduction of the dopaminergic neuron maturation marker, 
DAT and dopamine release mediated by potassium-induced depolarization. miR-133b is 
regulated during maturation of dopaminergic neurons through a negative feedback circuit that 
involves the paired-like homeodomain transcription factor, Pitx3 [195]. In addition, it has been 
shown that miR-433 is involved in etiology of PD. One of the single nucleotide polymorphisms 
(SNPs) of Fgf20 within the binding site for miR-433 in the 3’UTR abolishes the inhibition of 
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miR-433, resulting in an elevated level of Fgf20. Dysregulated Fgf20 subsequently enhances 
expression of α-synuclein, which accumulates in PD brains and has been confirmed to cause PD 
[204]. 
So far, there has been no evidence that microRNAs cause HD. However, some 
microRNAs, such as miR-9/miR-9*, are involved in this disease. REST is a transcription factor 
that represses expression of neuronal genes with RE1 repressor sequences. In neurons, it stays in 
the cytoplasm by binding to Huntingtin (Htt). Polyglutamine expansion in Htt disrupts this 
binding, resulting in nuclear translocation of REST and development of HD. In the nucleus, 
REST, together with the REST corepressor 1 (CoREST), inhibits expression of miR-9/miR-9* by 
binding to upstream RE1 sites. In turn, miR-9 targets REST and miR-9* targets CoREST [192]. 
1.2.5 MicroRNAs and lung diseases 
In addition to lung cancer as mentioned previously, microRNAs also play important roles 
in many other chronic lung diseases, such as cystic fibrosis (CF), chronic obstructive pulmonary 
disease (COPD), asthma, and idiopathic pulmonary fibrosis (IPF) [205]. Most of these diseases 
are associated with chronic airway inflammation and/or systemic inflammation. 
COPD is usually induced by cigarette smoking and/or chronic exposure to particulate 
matter. Alteration of microRNA expression has been reported in mice, rats, and humans exposed 
to cigarette smoke [206-208]. For example, miR-146a is down-regulated in COPD fibroblasts. It 
causes the degradation of COX-2 mRNA [209]. The reduced expression of miR-146a prolongs 
the half-time of COX-2 mRNA, resulting in the increase of the inflammatory mediator, 
prostaglandin E in COPD fibroblasts. 
miR-21 is the most up-regulated microRNA in a mouse model of asthma [210]. 
Introduction of miR-21 inhibits the expression of its predicted target IL-12p35, indicating that 
miR-21 is involved in allergic airway inflammation. 
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miR-21 is also up-regulated in human IPF. An enhanced expression of miR-21 promotes 
TGF-β-induced fibrosis, while the inhibition of miR-21 reduces the severity of fibrosis [211]. let-
7d is down-regulated in IPF lungs. TGF-β inhibits let-7d expression through SMAD3. The 
inhibition of let-7d causes increases in mesenchymal markers in vitro as well as alveolar septal 
thickening and increases in collagen in vivo [212]. miR-155 is another microRNA involved in IPF 
pathogenesis. Expression of miR-155 is up-regulated in the lungs of IPF patients and is correlated 
with the degree of lung fibrosis in a bleomycin-treated mouse model [213]. Induction of miR-155 
expression causes fibroblast migration, probably by directly targeting angiotensin II type I 
receptor (AT1R), which has been indicated to contribute to fibrosis [214]. Expression of miR-29 
is reduced in IPF and the bleomycin-treated mouse model. It has been shown that knockdown of 
miR-29 leads to an increase in genes associated with pulmonary fibrosis, including integrin, alpha 
11, etc. [215]. 
miR-126 is significantly down-regulated in CF [216]. It can regulate the expression of 
TOM1 (the target of Myb1), which is a negative regulator of IL-1β and TNF-α induced signaling 
pathways [217]. Knockdown of TOM1 leads to an increase in NF-κB regulated IL-8 secretion 
[216]. These results indicate that miR-126 is involved in immune responses in CF lungs. In 
addition, miR-126 is also involved in pathogenesis of allergic asthma [218]. Expression of miR-
126 is stimulated in an experimental allergic disease model, in which house dust mite induces 
allergic disease through activation of toll-like receptors (TLRs). miR-126 blockade results in 
suppressed asthmatic phenotype and diminished T helper-2 (TH2) lymphocyte responses [218]. 
1.2.6 MicroRNAs as potential therapeutic targets 
With more knowledge of microRNA functions in diseases, microRNAs have the potential 
to be new therapeutic targets. Systemic delivery of adeno-associated virus (AAV) overexpressing 
miR-26a in a mouse model of hepatocellular carcinoma leads to inhibition of cancer cell 
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proliferation and induction of apoptosis [219]. Administration of the locked-nucleic-acid (LNA)-
modified oligonucleotide complementary to miR-122 in mice reduces plasma cholesterol and 
increases hepatic fatty acid oxidation. The synthesis of hepatic fatty acid and cholesterol is also 
depressed [220]. Systemic delivery of the same antagonist of miR-122 by intravenous injection 
also effectively depletes mature miR-122 and reduces plasma cholesterol in African green 
monkeys [221]. These studies raise the possibility of use of this miR-122 inhibitor to treat 
NAFLD. 
1.2.7 MicroRNAs as diagnostic and prognostic tools 
MicroRNAs could be a powerful tool to diagnose and classify cancers. MicroRNA 
profiles have been demonstrated to be highly informative and more accurate than mRNA profiles 
in cancer diagnosis. MicroRNA profiles can reflect the developmental lineage and differentiation 
state of tumors. Because each organ has its own specific microRNA expression pattern, 
microRNA profiles can also be used to classify poorly differentiated tumors and to trace the 
tissue origin of tumors of unknown primary origin [170, 222]. In addition, the expression patterns 
of microRNAs can also be identified in serum, plasma, and saliva of patients, which makes early 
detection of colon and other occult cancers possible [223-227]. 
1.2.8 Anti-viral defense 
Although microRNAs are implicated in diseases caused by malfunctions in the cellular 
machinery, they also serve an important role in preventing diseases caused by viruses. Scientists 
studying plants first proposed microRNAs as being able to induce post transcriptional gene 
silencing of viral mRNAs [228, 229]. In plants, microRNAs have an anti-viral capability with 
short-lived effects because evolved viral factors eventually inactivate the microRNAs [230]. In 
fact, many viruses have the capability to evade silencing by the host, but some viruses are better 
adapted for evading cellular machinery than others. In humans, for example, adenovirus can 
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block host microRNA biogenesis, thus squelching the very anti-viral microRNAs that are meant 
to stop adenovirus replication [231]. Also, tissue culture experiments show that the primate 
foamy virus type I (PFV-1) can escape silencing by miR-32 by production of a silencing 
suppressor protein called Tas [232]. These observations suggest that host microRNA-mediated 
defense cannot always overcome viral attacks. However, these experiments do not account for the 
possibility of defense responses mounted by multiple microRNAs working together. A study of 
the hepatitis C virus demonstrates that the introduction of multiple siRNAs targeted to different 
areas of the viral genome prevents the virus from escaping siRNA-silencing [233]. Future 
experiments with microRNAs will likely produce similar results, considering that microRNAs are 
functionally similar to siRNAs. Due to the accelerated mutational activity of some viruses, 
microRNA-mediated anti-viral therapies are ideal. After all, the effectiveness of small RNAs is 
based on nucleic acid sequence, making the development of new therapeutic small RNAs 
expeditious, which is a far cry from conventional drug-based therapies. 
1.3 Fetal lung development 
1.3.1 Stages of fetal lung development 
Development of the fetal lung can be divided into early stages and late stages. The early 
stages are those when the initiation of the air-conducting system occurs and the late stages are 
those when the gas exchange unit forms. The early stages include embryonic phase and glandular 
or pseudoglandular phase. The late stages include canalicular phase and saccular phase. In rats, 
the embryonic phase is from gestation day 0 to day 13, the glandular phase from gestation day 13 
to day 18, the canalicular phase from day 18 to day 20, and the saccular phase from day 20 to full 
term.  
1.3.2 Development of lung structure 
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In the early embryonic phase, lobar division takes place. A ventral diverticulum from the 
primitive esophagus gives rise to the origination of the lung. A pair of endodermal rudiments 
develop from this diverticulum and each primitive lung bud produces many branches by 
dichotomous division of terminal buds. Fetal lung development transits into glandular or 
pseudoglandular phase when air passage resembling tubes are formed. At this time, the lung 
appears like a gland under a microscope. During this phase, the pseudostratified epithelium of the 
lung buds is reduced to a columnar form and the proliferation of epithelial cells is very active. 
Meanwhile, there is little or no lumen in those epithelial tubes. At this stage, the primitive airway 
epithelium begins to differentiate and ciliated goblet, nonciliated goblet, and basal epithelial cell 
types can be recognized. Cartilage and smooth muscle cells are formed from mesenchymal cells 
[234]. With continued epithelial branching, the development transits into the canalicular phase 
marked by the production of bronchioles. In this phase, the mesenchymal tissue becomes thin and 
a lumen can be recognized in many tubules, as epithelial cells become more cuboidal. The 
formation of alveolar ducts and air sacs happens in the saccular phase. The mesenchymal tissue 
thins out further. Most of the epithelial cells flatten and others remain cuboidal. Many developing 
air sacs open. The flattened epithelial cells produce a thin air-blood barrier. At this stage, 
epithelial proliferation decreases and differentiation becomes more evident. Distinctive lamellar 
bodies can be observed in the cytoplasm of the cuboidal epithelial cells. These epithelial cells 
begin to synthesize and secrets pulmonary surfactant and are now defined as alveolar epithelial 
type 2 cells (AEC II). The markers for these cells include surfactant-related proteins, specific 
cytokeratins, and various membrane-associated proteins. Many AEC II lose the ability to 
synthesize surfactant and undergo a thinning process to become the squamous type 1 cells (AEC 
I). T1α and Aqp5 are the markers for AEC I [235]. There are also other differentiation markers 
widely used to identify different cell types. CD31 is a marker for endothelial cells and is 
expressed in all pulmonary endothelial cells [236]. α-smooth muscle actin and the smooth muscle 
myosin heavy-chain are reliable markers for smooth muscle cells [237, 238]. CC10 is a cell-
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specific marker of airway Clara cells. Neuroendocrine cell markers include neuron-specific 
enolase, chromogranin A, and protein gene product 9.5 [239]. SP-A is a lung epithelial cell 
marker. Vimentin is a widely used mesenchymal marker. 
1.3.3 Molecular regulation and signaling pathways 
Before the lung separates from the foregut, TTF-1 (thyroid transcription factor-1) is the 
earliest known marker that exists in the endodermal cells committed to the prospective lung [240]. 
This region is marked by the coexpression of TTF-1 and FOXA2 [241, 242]. Outgrowth and 
branching of cells in this region require fibroblast growth factors (Fgf’s) emanating from the heart, 
which arises from the mesoderm [243]. 
In the embryonic and pseudoglandular phase, Fgf10 in the mesenchyme and Fgfr2 in the 
endoderm are crucial for the formation of lung primordial buds [244, 245]. Gli2 and Gli3 are 
transcriptional effectors of the Shh signaling pathway and have been demonstrated to play 
important roles in the formation of the lung primordium [246-248]. It is believed that Shh at the 
bud tips limits bud outgrowth by inhibiting expression of Fgf10 when the bud grows toward the 
Fgf10-expressing mesenchyme. Retinoic acid (RA) and retinoic acid receptors (RARs) are critical 
in bud formation, as the expression of Fgf10 is dependent on RA [249, 250]. TTF-1 is required 
for peripheral branching morphogenesis [251]. The Wnt/β-catenin pathway regulates branching 
morphogenesis and peripheral airway cell differentiation [252, 253]. This pathway functions at a 
point upstream of N-myc, BMP4, and FGF signaling [253]. FOXA1 and FOXA2 play critical 
roles in branching and later cell differentiation. Deletion of both Foxa1 and Foxa2 inhibits the 
Shh signaling pathway [254]. Other protein factors that regulate branching morphogenesis 
include GATA-6, nuclear factor-1 (NF-1), and N-Myc [255-257]. There are also some important 
transcription factors identified in the pulmonary mesenchyme, which regulate branching 
morphogenesis, such as FOXF1, FOXM1B, POD1, HIF, GLI, T-BOX, and HOX family 
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members. T-box transcription factors (Tbx) like Tbx4 have also been implicated in the early stage 
of embryonic lung development [258]. Inhibition of TBX4 and TBX5 suppress the expression of 
FGF10 [259]. 
TTF-1, NF-1β, GATA-6, RB, ETS, SOX, and FOX family members play roles in 
controlling epithelial cell differentiation in the conducting airways. p63 is important in the 
formation of normal tracheobronchial epithelium and deletion of p63 results in the abnormal 
epithelium without basal cells [260]. FOXJ1 is required for ciliogenesis by regulating the 
expression of genes necessary for ciliogenesis, such as ezrin and calpastatin [261, 262]. The 
development of pulmonary neuroendocrine cells is influenced by several transcription factors, 
such as MASH1/HASH1, HES1, GFI1, and pRB [263, 264]. The members of SOX family are 
expressed in the developing lung include SOX2, 4, 9, 11, and 17. The ETS family members, 
including ETS-1, SPDEF, ELF-3, ESE-3, ERM, and PEA3, are also found in the fetal lungs. 
ERM and SPDEF bind to TTF-1 and regulate transcriptional target genes synergistically [265]. 
The transcriptional factors that regulate perinatal lung maturation in the saccular and 
alveolar phases include TTF-1, FOXA2, NFATc3, C/EBPα, and the glucocorticoid receptor 
(GRα). Deletion of TTF-1, Cebpα, and Foxa2 genes influence the expression of some regulating 
genes, such as Abca3, Scd-1, Pon-1, Kdap, Sftpa, Sftpb, Sftpc, Sftpd, Aq5, Scnn1g, Scl34a2, Vegfa, 
Lys, and Scgb1a1 [243]. Other partners of TTF-1 such as NF-1, NFATc3, and GATA-6 also play 
roles in the perinatal lung maturation in a similar way. Glucocorticoids increase surfactant lipid 
synthesis by increasing the expression of enzymes for lipid synthesis [266]. They can also 
influence the expression of epithelial sodium channels and Na
+
-K
+
-ATPase, resulting in the 
modulation of lung liquid resorption at birth [267]. Three members of the FOXP family (FOXP1, 
FOXP2, and FOXP4) are expressed in epithelial cells and repress activity of the CCSP and SP-C 
promoters [268]. 
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Other transcription factors and signaling pathways also regulate the development of fetal 
lung, including E2F1, RB, SMADs, the TGF-β superfamily, BMPs, and the Notch signaling 
pathway. SMAD1 and SMAD7 positively regulate pulmonary branching morphogenesis, while 
SMAD2, 3, and 4 negatively regulate this process [269-272]. Inhibition of TGF-β type II receptor 
stimulates branching morphogenesis in lung organ cultures [270]. These observations indicate 
that the activation of TGF-β signaling pathway is inhibitory for branching morphogenesis [273]. 
In addition, TGF-β1 is a potent inhibitor of epithelial cell proliferation and differentiation in vivo 
[274]. 
Functions of the BMP signaling pathway in developing lungs are different from those of 
the TGF-β signaling pathway. BMP4 is highly expressed in the distal epithelium of branching 
airways and regulates epithelial proliferation and proximal-distal pattern formation during 
branching morphogenesis. A high level of BMP4 stimulates distal lung formation, while a low 
level of BMP4 initiates proximal differentiation [275]. 
The Notch signaling pathway modulates embryonic branching morphogenesis and cell 
differentiation. The Notch receptors are Notch1-Notch4, while the ligands include Jagged1, 2 and 
Delta-like 1, 3, 4 (Dll1, 3, 4). Expression of Notch1-Notch4, DLL1, and Jagged1 in the mouse 
lung is increased from E11.5 to adulthood [264, 276]. HES1 is a transcription factor and also a 
downstream effector of the Notch signaling pathway. HES1 is essential for Clara cell 
differentiation, while loss of HES1 results in aberrant lung neuroendocrine differentiation [264]. 
Silencing Notch-1 increases mouse lung branching morphogenesis on E11.5. In addition, 
silencing of Notch-1 or Jagged-1 results in an increase in the amount of neuroendocrine cells 
[277]. 
1.3.4 Epithelial-mesenchymal communications 
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The development of pulmonary epithelium is under the control of inductive stimuli from 
the mesenchyme, at least in the embryonic and glandular phases [278]. If the mesenchyme is 
removed from lung rudiments before branching happens, there is no branching and all further 
lung morphogenesis is blocked. Whether the pulmonary epithelium acquires a proximal or distal 
phenotype also depends on the instructive cues from its associated mesenchyme [279].On the 
other hand, platelet derived growth factor A (PDGF-A) secreted from lung epithelial cells 
provides survival signals to mesenchymal cells during alveolarization [280]. Taken together, 
communications between the epithelium and mesenchyme occur in both directions [281]. 
Epithelial-mesenchymal communications are carried out by short-range interactions mediated by 
soluble and diffusible signals. These signals have already been discussed in the section of 
molecular regulation, which include Fgf factors (e.g. Fgf10) and Fgfr receptors (e.g. Fgfr2), 
proteins in Shh signaling pathway (e.g. Shh and Gli2/3), components in the canonic Wnt pathway 
(e.g. Wnt7b, Wnt5a, and β-catenin), and members of the TGF-β superfamily (e.g. BMP4). 
1.4 Acute lung injury and repair 
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is characterized by 
acute onset of respiratory failure, non-cardiogenic edema, and hypoxemia [282, 283]. The 
definition for ALI and ARDS are the same except that ALI is characterized by less severe 
hypoxemia (a ratio of the partial pressure of arterial oxygen to that of inspired oxygen of ≤ 300). 
Based on the clinic disorders associated with the development of ALI/ARDS, there are two forms 
of ALI/ARDS. Primary ALI/ARDS is caused by direct lung injuries, for example, pneumonia, 
aspiration of gastric contents, pulmonary contusion, etc. Secondary ALI/ARDS results from 
indirect lung injuries, such as sepsis, acute pancreatitis, etc. [282].  
There are two stages of ALI/ARDS: the acute/exudative phase and the reparative phase. 
The acute phase is characterized by diffuse damage of the alveolar-capillary barrier and influx of 
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protein-rich edema fluid. The later reparative phase is characterized by fibroproliferation and 
remodeling of the lung. In some patients with ALI/ARDS, the injury may be resolved and 
repaired completely, while in others, the injury cannot be repaired normally and progresses to 
fibrotic lung injury and often fibrosing alveolitis, with persistent hypoxemia, alveolar space filled 
with fibroblasts, decrease in lung compliance, and an increase in mortality [284-286].  
1.4.1 Alveolar-capillary barrier damage 
The alveolar-capillary barrier consists of the alveolar epithelium and the lung 
microvascular endothelium. It prevents the exchange of components between the alveolar space 
and the capillary. Influx of protein-rich edema fluid into the alveolar space results from increased 
permeability of the alveolar-capillary barrier [282, 287]. The endothelial injury in the acute phase 
of ALI/ARDS leads to an increase in vascular permeability and flux of fluid and proteins from 
pulmonary capillaries to the lung interstitium [288]. The ultra-structural basis of increased 
microvascular permeability lies in cell rounding, interruption of interendothelial junctions, and 
interendothelial gap formation [289, 290]. There are at least two mechanisms of increased 
permeability: (1) Inflammatory mediators induced during ALI activate RhoA by G-protein-
coupled receptors, leading to actin polymerization and formation of stress fibers. Phosphorylation 
of myosin light chain by myosin light chain kinase (MLCK) activates myosin, providing the force 
required for cytoskeletal contraction [291]. (2) TNF-α destabilizes endothelial junctions and 
induces pulmonary vascular permeability by a MLCK independent mechanism. TNF-α induces 
phosphorylation of vascular endothelial cadherin by activating Src-family tyrosine kinase [292]. 
Tyrosine phosphorylation of cadherin impairs cadherin ectodomain hemophilic adhesion [293, 
294]. 
As with endothelial injury, the epithelial integrity is also disrupted in ALI/ARDS. Ultra-
structural alterations of alveolar epithelium in ALI/ARDS include cytoplasmic swelling, bleb 
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formation, necrosis, and denuding of epithelial cells, leaving a mainly intact basement membrane 
with an overlying hyaline membrane [284, 285, 288]. This disruption of lung epithelium 
contributes to pulmonary edema in several ways. First, the epithelial barrier is damaged, which 
means the fluid and proteins from the lung interstitium are able to move into the alveolar space. 
Second, upon injury, AEC II lose their ability to transport fluid. Thus the capacity to remove 
edema fluid from the alveolar space is impaired, which may contribute to the severity and 
duration of pulmonary edema [295, 296]. Besides pulmonary edema, epithelial injury has other 
consequences which lead to additional symptoms observed in ALI/ARDS. First, a major function 
of AEC II is to synthesize and secrete pulmonary surfactants. These functions are impaired after 
AEC II damage, contributing to the surfactant dysfunction observed in ALI/ARDS [297, 298]. 
Second, as described in more detail later, abnormal repair of the alveolar epithelium during the 
reparative phase may lead to fibrosis [299]. Finally, injured AEC II in bacterial pneumonia 
produce pro-inflammatory mediators, which may leak into blood circulation through the 
permeabilized alveolar epithelium, resulting in septic shock [300].  
1.4.2 Inflammation 
An inflammatory response is another hallmark of the acute phase of ALI/ARDS. It 
involves endothelial and epithelial cells, macrophages, monocytes, and neutrophils, as well as 
cytokines and chemokines secreted by these cells. Alveolar macrophages secrete pro-
inflammatory cytokines, such as interleukin-8 (IL-8) and tumor necrosis factor α (TNF-α). These 
cytokines and various chemokines stimulate chemotaxis, which attracts and activates neutrophils. 
The activated neutrophils are recruited to the injured capillary endothelium and migrate into 
interstitial and alveolar spaces through the disrupted alveolar-capillary barrier. These activated 
neutrophils also release pro-inflammatory mediators, proteases, and reactive oxygen species 
(ROS), which causes further damage to the tissue. Neutrophils are the first immune cells to arrive 
on the scene after lung injuries. Circulating monocytes arrive at the injury site after neutrophils. 
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They migrate across the endothelium and transform into macrophages. As with alveolar 
macrophages and recruited neutrophils, these macrophages transformed from monocytes also 
produce inflammatory factors [282, 286, 301]. 
1.4.3 Resolution of ALI/ARDS 
Resolution of ALI/ARDS includes several events. Alveolar edema fluid and proteins 
must be cleared from the alveolar space. Inflammation must be cleared and the inflammatory 
cells removed from alveolar space and interstitium. Injured endothelial and epithelial cells must 
also be repaired and the disrupted alveolar-capillary barrier must be restored. Functional alveolar 
structure must be restored for efficient gas exchange to occur. 
The removal of alveolar edema is driven by active transport of sodium and chloride 
between alveolar spaces and nearby interstitium [302]. In order to keep the isosmotic stasis, water 
follows sodium by passive transportation into lung interstitium through aquaporins, which are 
transcellular water channels located primarily on AEC I [303].  
Proteins in the alveolar edema fluid are cleared from the alveolar space in several 
different ways. The clearance of most of soluble proteins occurs through diffusion across alveolar 
epithelial cells, a process that is protein size dependent [304]. Some other proteins are cleared 
from alveoli through endocytosis or transcytosis by epithelial cells. This mechanism is mediated 
by receptors and is protein specific, but not size dependent. Some proteins are also degraded by 
enzymes on the surface of the alveolar epithelial cells with absorption of smaller fragments. In 
addition, alveolar macrophages can remove insoluble proteins from alveoli through endocytosis 
and degradation [304]. 
Inflammatory cells must be cleared from alveolar space to prevent further damage to 
endothelium and epithelium. Thus, the clearance of neutrophils is considered to be the first step in 
resolution of ALI/ARDS [305]. Apoptosis is thought to be the mechanism for neutrophil 
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clearance. The apoptotic neutrophils are then engulfed by macrophages via recognition of certain 
surface receptors (e.g. phosphatidylserine receptors), which switches the role of neutrophils from 
pro-inflammatory cytokine production to secretion of pro-resolution mediators (for example 
TGF-β) [305-308]. An alternative theory is that egression of neutrophils removes them from lung 
tissue, and they migrate into the airway lumen, where they were then undergo apoptosis and 
engulfment by macrophages. The mixture of secretions and exudates is removed by mucociliary 
escalator mechanisms [309]. 
The mechanism for resolution of endothelial damage is not well known. It is likely that 
endothelial cell migration and proliferation are involved in this process. It is also known that 
circulating endothelial cell progenitors participate in the repair of injured endothelium [310]. 
Based on current knowledge, the restoration of alveolar epithelium after injuries is 
mainly dependent on AEC II. AEC II are considered as the progenitors of alveolar epithelial cells. 
After injuries and loss of cell-cell contact, normally quiescent AEC II regain the ability to 
proliferate. AEC II migrate, proliferate, and trans-differentiate into AEC I cells. The denuded 
base membrane is then covered by AEC II and AEC I and the epithelium barrier is restored. In 
recent studies, researchers have found that there may be a population of bronchioalveolar stem 
cells (BASCs) located at the bronchioalveolar duct junction [311]. These BASCs can self-renew 
and maintain the population of bronchiolar Clara cells. However, whether these cells contribute to 
the re-epithelialization after epithelial injury is unknown. Several groups have reported that bone 
marrow-derived stem cells (BMSC) can differentiate into lung epithelial cells after injury [312]. 
However, none of them are conclusive. Restitution of alveolar epithelium has at least two roles. 
First, it restores the normal alveolar architecture and gas exchange function. Second, proliferation 
of AEC II facilitates the clearance of pulmonary edema from alveolar space by increasing the 
fluid-transport capacity. 
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1.4.4 Factors and pathways in epithelial repair 
The restitution of alveolar epithelium involves multiple factors, such as cytokines, 
chemokines, growth factors, matrix components, and cell surface proteins. Several signaling 
pathways are also involved in epithelial wound healing after ALI/ARDS.  
Epidermal growth factor (EGF) family proteins, including EGF and transforming growth 
factor-α (TGF-α) participate in epithelial repair. These EGF factors and their receptors are up-
regulated in response to lung injury. They promote proliferation, migration, and spreading of 
AEC II and are likely to contribute to epithelial recovery in vivo after ALI/ARDS [313-316]. 
Some members of the fibroblast growth factor (FGF) family are also involved in alveolar 
epithelial repair, including keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), 
and FGF-10. KGF is a mitogen for AEC II and promotes AEC II migration and adhesion as well 
as proliferation [317-321]. Instillation of KGF into the lung leads to hyperplasia of AEC II, which 
differentiate into AEC I or undergo apoptosis [322, 323]. Similar to KGF, it has been shown in 
vitro and in vivo that HGF is a mitogen for rat AEC II [324, 325]. In addition to promoting 
epithelial repair, FGF-10 can prevent and attenuate epithelial cell DNA damage induced by 
asbestos, H2O2, and mechanical stretch through activating the MAPK/ERK pathway [326-328]. 
Inflammatory mediators are another group of factors that regulate epithelial repair. However, 
their functions are context-sensitive. For example, pro-inflammatory interleukin IL-1β has been 
shown to stimulate the repair of injured rat AEC II [329]. Because cell spreading and migration 
are important in epithelial restitution, it is reasonable to anticipate that the coordination between 
integrin and the underlying matrix are important for epithelial repair. It has been shown that 
migration of rat AEC II on fibronectin and type I collagen depends on different combinations of 
integrin subunits [330]. Several matrix metalloproteinases (MMP) have been shown to be 
involved in remodeling of the extracellular matrix, thus facilitating lung epithelial cell migration 
in lung epithelial repair. These MMPs includes MMP-1, MMP-7, and MMP-9 [331-333]. Rho 
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GTPases, which are involved in the increase of endothelial permeability in the acute phase of 
ALI/ARDS, regulate cytoskeletal remodeling and wound healing of epithelial cells in the 
reparative phase. For example, as mentioned previously, RhoA is responsible for actin bundle 
organization and formation of stress fiber and large focal adhesions. Expression of constitutively 
activated RhoA inhibits epithelial cell recovery from injury by inhibiting attachment and 
migration of AEC II [320]. 
The signaling pathways that are involved in epithelial repair after ALI/ARDS include 
sonic hedgehog (Shh) signaling pathway, mitogen-activated protein kinase (MAPK) pathways, 
Wnt pathway, and TGF-β signaling pathway. The Shh pathway is activated in epithelial cells 
during airway epithelial repair from acute injury and is implicated in epithelial-mesenchymal 
transition (EMT) [334]. MAPK signaling pathways are well known to be important in cell 
proliferation, differentiation, and migration. However, the studies of MAPK functions in 
epithelial repair after ALI/ARDS are controversial. Their functions depend on the context. For 
example, macrophage migration inhibitory factor (MIF) induces phosphorylation of ERK1/2 and 
proliferation of AEC II through binding to CD74. However, MIF cannot activate ERK1/2 in AEC 
I that lack CD74 [335]. TGF-β signaling pathway is another one that plays important and multiple 
roles in repair. It regulates cell proliferation, differentiation, apoptosis and extracellular matrix 
production [336]. It is also well known for its capability to stimulate epithelial-mesenchymal 
transition (EMT), which is discussed below in detail. The target genes induced by TGF-β 
signaling include connective tissue growth factor (CTGF), α-smooth muscle actin (α-SMA), 
collagen 1A2, and plasminogen activator inhibitor-1 (PAI-1) through Smad-dependent signaling 
[337]. Some of these targets, such as CTGF and α-SMA, are used as markers of EMT. TGF-β can 
stimulate migration and scratch wound repair in AEC II [338, 339]. In addition, it has been shown 
that TGF-β promotes AEC II repair after hyperoxic injury [339]. The Wnt signaling pathway is 
critical in fetal lung development and is discussed in detail in section 1.5. It is also involved in 
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injury healing in ALI/ARDS as repair from injury is considered to recapitulate ontogeny. The 
target genes of Wnt signaling include several MMPs, such as MMP2, MMP3, MMP7, and MMP9 
[340]. As discussed previously, these MMPs are pivotal to tissue remodeling, cell migration, and 
repair from injury. Proteolytic degradation of extracellular matrix facilitates migration of 
fibroblasts to the site of lesion.  
1.4.5 Abnormal repair and fibrosis 
After the acute phase of ALI/ARDS, some patients have a rapid resolution of lung 
damage. The inflammation is cleared, the denuded base membrane is re-epithelialized and re-
endothelialized, and the interrupted alveolar-capillary barrier is restored. However, in some 
patients, the disorders cannot be resolved and progress to fibrotic lung injury or fibrosing 
alveolitis. The alveolar space is filled with mesenchymal cells and proliferating fibroblasts, 
together with new blood vessels [341]. The content of collagen types I and II and fibronectin is 
increased in the lungs of these patients [342]. The decision whether ALI/ARDS results in a rapid 
resolution of abnormal fibroproliferative repair is made at the early point of the disorder and 
depends on the integrity of alveolar-capillary barrier base membrane [282]. If the base membrane 
is intact, the functional alveolar-capillary barrier can be reestablished with re-epithelialization and 
re-endothelialization on the intact base membrane. However, if the integrity of base membrane is 
disrupted by severe lung injury and prolonged inflammation, the alveolar structure is lost. 
Without the intact base membrane and alveolar structure, the proliferation and migration of AEC 
II, endothelial cells, and fibroblasts lead to alveolar fibrosis [343]. 
1.5 Wnt/β-catenin signaling pathway 
Since the first Wnt ligand, Wnt-1/int-1, was discovered by Nusse and Varmus in 1982 
[344], the Wnt signaling pathway has been demonstrated to be a key regulatory mechanism for 
cell proliferation and cell fate determination during embryogenesis and in adult tissue 
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homeostasis. The Wnt signaling pathway is a pleiotropic pathway that can be divided into two 
categories: the canonical Wnt pathway in which Wnt signaling goes through its receptors 
Frizzleds to β-catenin, and the non-canonical Wnt pathways which do not require β-catenin 
involvement. 
1.5.1 Wnt ligands 
Wnts are a family of secreted cysteine-rich glycolipoproteins that have conserved 
sequences in all metazoan animals. There are 19 Wnt ligands in mammals. They have a highly 
conserved distribution of cysteines and contain an N-terminal signal peptide for secretion. 
Although they are secreted proteins, Wnt proteins are palmitoylated and thus more hydrophobic 
than predicted from their amino acid sequences [345]. The glycosylations and lipid modifications 
are indispensable for the activity and secretion of Wnt proteins. For example, glycosylation is 
required for active Wnt3a secretion [346]. Wnt3a without glycosylation is retained in 
endoplasmic reticulum (ER), while Wnt3a with glycosylation is present in both ER and Golgi. 
Two types of palmitoylations of Wnt3a have been reported. One is palmitoylation at cysteine 77, 
which is required for Wnt3a to bind with its receptors and to activate β-catenin signaling [346]. 
The other lipid modification happens at serine 209. Wnt3a mutated at this site cannot be secreted 
from cells and accumulates in the ER [347].  
The palmitoylations and the hydrophobic character of Wnt proteins raise an issue for 
their diffusion and distribution in the aqueous extracellular space. For long range Wnt signaling, 
Wnt proteins may form multimers to bury hydrophobic parts inside, or bind with lipoprotein 
particles [348, 349]. 
1.5.2 Activation and inactivation of Wnt/β-catenin signaling 
Wnt/β-catenin is inactivated in the absence of Wnt ligands. Cytoplasmic β-catenin is 
phosphorylated and degraded by the destruction complex. The destruction complex contains Axin, 
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adenomatous polyposis coli (APC), glycogen synthase kinase 3 (GSK3), and casein kinase 1 
alpha (CK1α) amongst other factors. The scaffolding protein Axin binds with GSK3, CK1α, and 
β-catenin using different domains, which bring these core components into proximity. β-catenin 
is phosphorylated at serine 45 by CK1α and then at threonine 41, serine 37, and serine 33 
successively by GSK3 [350]. In addition, GSK3 and CK1 phosphorylate Axin and APC, which 
enhance their binding with β-catenin and further promotes β-catenin phosphorylation. β-catenin 
phosphorylation at the N-terminus creates a binding site for β-TRCP (beta-transducin repeat 
containing protein), causing the ubiquitination of β-catenin by an E2 ligase. The ubiqutinated β-
catenin is then degraded by proteosomes [350, 351]. 
In the canonical Wnt/β-catenin pathway, Wnt ligands bind to seven-pass transmembrane 
receptors, Frizzled (FZD) and the co-receptors LRP5/6 (low-density lipoprotein receptor related 
protein 5/6) [351, 352]. This binding leads to the activation of Dishevelled (DVL) and 
phosphorylation of LRP. The binding of Wnt with FZD and LRP recruits Axin to the membrane. 
Wnt signaling activation inhibits β-catenin phosphorylation by GSK3, through Axin-GSK3 
dissociation, inhibition of GSK3, or Axin degradation [351]. The stabilized β-catenin then 
accumulates in the nucleus to form complexes with transcription factors TCF/LEF (T cell 
factor/lymphoid-enhancing factor) and regulates the expression of downstream β-catenin 
dependent genes, such as cyclin D1 and c-myc. 
1.5.3 Wnt/β-catenin signaling pathway and fetal lung development 
Given that the Wnt/β-catenin signaling pathway is important in the regulation of cell 
proliferation and differentiation, it is not surprising that Wnt/β-catenin signaling pathway plays 
important roles in fetal lung development. It has been reported that Wnt3a represses growth and 
proliferation of the lung, while knockdown of Wnt signaling results in more branches and cell 
proliferation [353]. However, it has also been shown that Wnt/β-catenin signaling is required for 
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the formation of the distal airways, but not proximal airways [252]. Without β-catenin in the 
epithelial cells, the proximal lung tubules grow and differentiate normally. However, the 
peripheral airways fail to develop normally and the mice die at birth of respiratory failure. 
Another study has shown that this regulation of the proximal-distal differentiation of airway 
epithelium by Wnt/β-catenin signaling is in part through N-myc, BMP4, and Fgf signaling [253]. 
The differentiation of the respiratory epithelium is also regulated by the Wnt/β-catenin signaling 
pathway [354]. An activated form of β-catenin causes ectopic differentiation of alveolar type II-
like cells in conducting airways. Goblet cell hyperplasia and air space enlargement are also 
observed in early postnatal lungs with activated β-catenin. The mesenchymal proliferation and 
vascular development in the lung are regulated by Wnt7b [235]. Wnt7b is expressed in the airway 
epithelium and knockout of Wnt7b leads to perinatal death due to respiratory failure. Wnt7b 
knockout causes defects in both mesenchymal proliferation and the smooth muscle component of 
the major pulmonary vessels. 
1.5.4 Cross-talk between the Wnt signaling pathway and other pathways in fetal lung 
development 
Although the Wnt signaling pathway plays an important role in fetal lung development as 
discussed above, it does not function independently. Some studies have shown that the Wnt 
signaling pathway is involved in cross-talk with other signaling pathways, such as the TGF-β, 
Shh, and FGF pathways, which makes their regulation more specific and versatile. 
The Wnt signaling pathway interacts with the TGF-β signaling pathway in the regulation 
of cell differentiation during fetal lung development [355]. Inactivation of a BMP type I receptor 
disrupts lung morphogenesis, cell proliferation and differentiation. In the meantime, the Wnt 
signaling pathway is stimulated, probably through down-regulation of Wnt inhibitor factor-1 
(WIF-1) after Alk3 inactivation [356]. On the other hand, the Wnt/β-catenin pathway functions 
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upstream of BMP4. Activation of the Wnt signaling pathway with stabilized β-catenin in lung 
epithelial cells also activates BMP4, resulting in inhibition of cell differentiation [357]. 
Meanwhile, inhibition of this pathway with Wnt inhibitor Dkk1 or deletion of β-catenin depresses 
expression of BMP4 [253]. 
The non-canonical Wnt pathway stimulated by Wnt5a interacts with the Shh signaling 
pathway and FGF signaling. It has been shown that loss of Wnt5a increases expression of Shh 
and its receptor Ptc, while overexpression of Wnt5a in lung epithelium inhibits the activity of 
epithelial Shh signaling and increases expression of Fgf10 in the mesenchyme [358, 359]. 
1.6 Purpose and significance of this research 
microRNAs are a group of small RNAs that regulate their target gene expression at the 
post-transcriptional level. The functions of microRNAs have been studied extensively in recent 
years. They cover almost every aspect of cell physiology and are extensively involved in human 
diseases. Studies on microRNA functions help us to understand gene regulation in physiology and 
pathology from a novel perspective. The discoveries shed light on development of new 
therapeutic interventions for human diseases. 
The purpose of the first part of my study (Chapter 2) was to set up an efficient high-
throughput method to profile expression patterns of microRNAs. When I started my study, little 
was known about microRNA expression in the lung, as well as microRNA expression profiles in 
various processes in the lung, such as alveolar epithelial trans-differentiation, fetal lung 
development, and recovery after injuries. Characterization of the microRNA expression profile 
was still a great challenge at that time. In order to resolve this problem, I set up a microRNA 
microarray platform and profiled the expression of microRNAs in different organs of the rat. A 
novel data mining method was used in microarray data analysis. The method was tailored 
according to the unique characters of our microRNA microarray slides. I further verified the 
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microRNA microarray data with microRNA Northern blots, which showed that the microRNA 
microarray was surprisingly sensitive and specific. The data were extremely reliable and 
reproducible. This microRNA microarray platform was then used in my later studies. 
In the second part of my study (Chapter 3), we selected miR-127 from our microarray 
data for further study. We found that it was most highly expressed at the late stage of fetal lung 
development and the expression of miR-127 shifted from mesenchymal cells to epithelial cells 
during this development process. We further found that overexpression of miR-127 led to 
disruption of fetal lung branching morphogenesis. 
The goal of the third part of my study (Chapter 4) was to figure out how microRNAs 
regulate alveolar epithelial trans-differentiation. In this part, I profiled the expression of 
microRNAs during alveolar epithelial trans-differentiation with the microRNA microarray 
platform described in Chapter 2. The result showed that miR-375 was significantly down-
regulated during alveolar epithelial trans-differentiation, which was verified with qRT-PCR. 
Furthermore, I demonstrated that miR-375 interrupted alveolar epithelial trans-differentiation 
through inhibiting the Wnt/β-catenin signaling pathway by directly targeting FZD8. This is a new 
mechanism that regulates alveolar epithelial trans-differentiation. This discovery helps to 
understand the mechanism of the recovery process after lung injury from a new angle and may 
provide a new target for therapy. 
The fourth part of my study (Chapter 5) focused on microRNA functions in fetal lung 
development. qRT-PCR showed that miR-124a was down-regulated during fetal lung 
development. I demonstrated that miR-124a inhibited epithelial cell maturation during late stages 
of fetal lung development. miR-124a and its targets NFIB, could be potential therapeutic targets 
to improve epithelial maturation in  the lungs of premature babies.
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CHAPTER II 
 
 
IDENTIFICATION OF RAT LUNG-SPECIFIC MICRORNAS BY MICRORNA 
MICROARRAY: VALUABLE DISCOVERIES FOR THE FACILITATION OF LUNG 
RESEARCH 
 
2.1 Abstract 
An important mechanism for gene regulation utilizes small non-coding RNAs called 
microRNAs (miRNAs). These small RNAs play important roles in tissue development, cell 
differentiation and proliferation, lipid and fat metabolism, stem cell function, exocytosis, diseases 
and cancers. To date, relatively little is known about functions of microRNAs in the lung except 
in the setting of lung cancer. 
In this study, we utilized a rat microRNA microarray containing 216 microRNA probes, 
printed in-house, to detect the expression of microRNAs in the rat lung compared to the rat heart, 
brain, liver, kidney and spleen. Statistical analysis using the Significant Analysis of Microarray 
(SAM) and Tukey Honestly Significant Difference (HSD) tests revealed 2 microRNAs (miR-195 
and miR-200c) that were expressed specifically in the lung, and 9 microRNAs co-expressed in 
the lung and another organ. Twelve selected microRNAs were verified by Northern blot analysis. 
The identification of lung-specific microRNAs from this work will facilitate functional 
studies of microRNAs during normal physiological and pathophysiological processes of the lung.
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2.2 Introduction 
MicroRNAs (miRNAs) include a large group of regulatory, non-coding small RNAs that 
measure ~22 nucleotides (nt) in length [1, 2]. In animal cells, microRNAs are first transcribed 
from genes by the RNA polymerase, pol II, as primary microRNAs, which are then cleaved by an 
RNase III enzyme, Drosha, into hairpin-like precursor microRNA (pre-miRNA) [3]. The pre-
miRNAs are transported into the cytoplasm with the help of a protein called Exportin 5 [4]. In the 
cytoplasm, the pre-miRNAs are cut into double-stranded RNA duplexes by another RNase III 
enzyme, Dicer [5]. Typically, one of the strands becomes mature microRNA and is incorporated 
into a RISC complex with other components for target recognition [6]. The RISC complex then 
binds to its target mRNA through base pairing and carries out its functions. Customarily, in the 
target mRNAs of an animal microRNA, there are multiple complementary sites, which 
correspond to the same microRNA. This cooperative action makes inhibition more efficient [7, 8]. 
On the other hand, one microRNA usually inhibits multiple target mRNAs [9, 10]. This property 
enables microRNA to regulate many genes in a pathway or physiological process at the same 
time. The action of microRNAs includes cleavage of target mRNA, translational inhibition, and 
mRNA deadenylation [11-15]. Several studies have shown that the degree of complementarity 
between the microRNA and its target determines the mode of how a microRNA works [11, 13-
16]. Since the discovery of the first microRNA, lin-4 [9], much progress has been made in the 
elucidation of microRNA mechanisms [1, 2, 9, 17-20]. However, only a handful of microRNAs 
have been studied for their precise functions. The microRNAs in animals function in tissue 
development, cell differentiation, apoptosis, fat and lipid metabolism, exocytosis, stem cell 
division and differentiation, diseases and cancers [17, 21-33]. These known functions may 
represent just a small part of a much bigger picture. One third of the genes in the human genome 
are predicted to be microRNA targets [34]. With the continuing discovery of new microRNA 
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functions, it is possible that microRNAs will be associated with the regulation of almost every 
aspect of cell physiology. 
Spatial and temporal expression patterns of microRNAs can provide clues for their 
possible functions. Profile studies have already shown that many microRNAs are specifically 
expressed in certain organs, cell types, and developmental stages. In a recent study, microRNA 
expression patterns among different pancreas cell types were compared [28]. One of the detected 
microRNAs in the study was identified as a pancreas islet-specific microRNA, which was later 
demonstrated to function in insulin secretion [28]. 
In order to study the expression profiling of microRNAs in mice and humans, several 
high throughput platforms have been developed. Microarrays on either membranes or slides are 
widely used for this purpose [35-43]. Various probe designs and labeling methods have also been 
utilized. Some groups have applied these microarray methods in an effort to perform the 
expression profiling of microRNAs in different tissues and cell types in humans and mice. Real-
time PCR has also been used to detect the expression of pre-mRNAs and mature microRNAs [44, 
45]. 
The purpose of this study is to identify microRNAs that are expressed specifically in the 
rat lung or co-expressed in the lung and one of the five other organs in the rat. In addition, this 
study aims to set up a reliable, in-house microRNA microarray platform for lung research. 
Although the expression profiling of microRNAs in human and mouse organs has been described 
by some groups, the microRNAs expression profile in rat organs has not been extensively studied. 
Furthermore, relatively little is known about the detailed functions of microRNAs in the lung, 
except in lung cancers. For this study, we designed a probe set for rat microRNAs as well as 
human and mouse microRNAs that possess conservative sequences in the rat genome, based on 
the fact that microRNAs are highly conserved in animals and in plants [46-51]. The 
67 
 
hybridizations were performed with slides printed in our laboratory. The reliability of the 
microarray platform was tested before other experiments were performed. As a result, our 
microarray allowed us to identify lung-specific microRNAs in the rat that are likely to facilitate 
studies of microRNA functions in the lung. 
2.3 Material and Methods 
2.3.1 Microarray fabrication 
Sequences of 217 mature microRNAs were downloaded from the microRNA registry 
(Wellcome Trust Sanger Institute). Among these, 177 microRNAs were from rat, and 40 non-
redundant conservative ones were from human or mouse. Sequences of some of these human and 
mouse microRNAs did not match their corresponding sequence in the rat genome exactly and 
were modified in accordance with those in the rat genome. The probes for the microRNAs had 
two copies of antisense sequences (34–50 nt) (Fig. II1A). Probe sets, which contained 5' amino 
modified C6 oligos were synthesized by Sigma-Genosys (Woodlands, TX) at 100 μM 
concentration and suspended in 3 × SSC buffer. The oligos were diluted to 25 μM with 3 × SSC 
prior to use. The probes were then printed onto epoxy-coated slides (CEL Associates, Pearland, 
TX) with an OmniGrid 100 array (GeneMachine, San Carlos, CA) at 65% humidity and then 
incubated for 48 hours at the same humidity. Each slide contained three identical blocks in a 
landscape orientation. Within each block every probe was printed 6 times in 3 separate pairs (Fig. 
II1B). The oligo set also contained one probe for U6 and 3 probes for tRNAs as positive controls 
as well as one probe for a plant microRNA as a negative control. 
2.3.2 Tissue sample and small RNA extraction 
Four male Sprague-Dawley rats (200 g, Charles River Laboratories, Inc., Wilmington, 
MA) were anaesthetized with intraperitoneal injection of Ketamine (40 mg/kg body weight) and 
Xylazine (8 mg/kg body weight). Six organs (lung, heart, brain, kidney, liver and spleen) were 
68 
 
collected and powdered in liquid nitrogen. Small RNA was enriched from the powdered samples 
using the mirVana™ miRNA isolation kit from Ambion (Austin, TX), according to the 
manufacturer's protocol. First, 200 mg powder was homogenized in 2 ml Lysis/Binding Buffer. 
Then, one-tenth of the volume of microRNA homogenate additive was added to the homogenate 
and a volume of acid-phenol: chloroform was used to extract RNA. One-third volume of 100% 
ethanol was added to the aqueous phase, and the sample was passed through a filter cartridge. 
Two-thirds volume of 100% ethanol was then added to the filtrate, and the sample was passed 
through a second filter cartridge. The second filter cartridge was subsequently washed once with 
Wash Solution 1 and then twice with Wash Solutions 2 and 3. Afterwards, the small RNA was 
eluted with 95°C nuclease-free water. Total RNA for Northern blots was also extracted from 
these organs by the aforementioned protocol. Following organic extraction, one and one-fourth 
volumes of 100% ethanol was added to the aqueous phase. The lysate/ethanol mixture was then 
passed through a filter cartridge. The cartridge was washed, and the total RNA was eluted with 
water as described above. The concentration of RNA was determined by a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Tech., Rockland, DE). The quality of enriched small RNA was 
determined on a denaturing 15% polyacrylamide gel, and the quality of total RNA was tested on a 
1% agarose gel. 
2.3.3 MicroRNA labeling and microarray hybridization 
The labeling and hybridization of microRNA were performed with the 3 DNA array900 
microRNA direct kit (Genisphere, Hatfield, PA), according to the manufacturer's protocol. 
Enriched small RNA (120 ng) was used for each hybridization. First, the microRNA was tailed 
with poly A by PAP enzyme (poly (A) polymerase). Then the capture sequence was ligated to the 
tailed microRNA. Tagged microRNA was purified with the MinElute PCR Purification Kit 
(Qiagen, Valencia, CA). All of the small RNA samples were separately labeled with Cy3 or Cy5 
capture sequence. After labeling and purification, equal amounts of small RNA from all the 
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samples, labeled with the same dye, were pooled together as a common reference. The 
hybridization was performed as previously described [52]. To each block, one labeled sample was 
hybridized along with a common reference labeled with the other dye. Dye-swap was performed 
to eliminate dye bias. Tagged microRNA hybridizations were performed at 52°C overnight, and 
then the slide was washed 15 min in pre-warmed 2 × SSC, 0.2% SDS, followed by 12 min in 2 × 
SSC at room temperature and finally for 12 min in 0.2 × SSC at room temperate. The 3 DNA 
hybridization was performed at 62°C for 4 h, and then the slide was washed and dried. 
2.3.4 Microarray data analysis 
The hybridized slides were scanned with ScanArray Express (PerkinElmer Life and 
Analytical Sciences, Boston, MA), and the images were analyzed with GenePix 5.0 pro (Axon 
Instruments, Inc. Union City, CA). The signal from each spot was normalized to the average 
signal of the whole block. The highest and lowest signals from the 6 identical probes in the same 
block were excluded from the data analysis. The geometric average of the other 4 signals was 
considered to be the signal of that particular microRNA. The ratio of the sample signal to the 
reference signal was log2 transformed. A quality test was performed with the software, Realspot, 
developed in our laboratory [53]. The microRNAs with an average quality index of <1 were 
filtered. The microRNAs that passed the quality test were analyzed with SAM (Significant 
Analysis of Microarray) in order to choose microRNAs that were significantly changed between 
different organs (q < 0.01) [54]. These microRNAs were then subject to the Tukey Honestly 
Significant Difference (HSD) test (p < 0.05) [52]. The organ specificity index (OSI) was also 
used to determine the relative specificity of microRNA in organs. The OSI was defined as the 
correlation coefficient of microRNA expression between a microRNA and a putative microRNA 
whose expression levels were given the value of 1,000 in prominent organs and a value of 0 in 
other organs [52]. 
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2.3.5 Northern blot analysis 
Total RNA from the same organ was pooled together. The probe sequences were exactly 
the same as the antisense sequences to microRNAs, except that those with sequences which 
started with C were capped with G or T at the 5' end to increase 
32
P labeling efficiency. RNA 
samples were denatured at 95°C for 4 minutes. 15 μg total RNA was separated on a 15% 
denaturing PAGE gel at 100 V for 2 h in 1 × TBE buffer. The RNA was then transferred to a 
Hybond-N
+ 
membrane (Amersham, Piscataway, NJ) using a Trans-blot SD semi-dry transfer cell 
(Bio-Rad, Hercules, CA) at 20 ~ 25 V for 1 hour using 0.25 × TBE as a transfer buffer. 
Membranes were UV crosslinked with a 120 mJ burst and then baked at 80°C for 1 hour. For 
each sample, 20 pmol antisense oligonucleotide probes were end labeled with γ32P dATP (>7000 
Ci/mmol, MP Biomedical, Irvine, CA) using T4 polynucleotide kinase (NEB, Ipswich, MA) for 4 
hours at 37°C. The reactions were stopped with 2 μl 0.5 M EDTA. The probes were then purified 
with a G-25 MicroSpin column (Amersham). Pre-hybridization and hybridization were carried 
out at 30°C using ULTRAhyb-Oligo hybridization buffer (Ambion), according to the 
manufacturer's manual. After hybridization the membranes were washed twice with 2 × SSC 0.5% 
SDS for 30 minutes at 30°C. The membranes were then exposed to a phosphor screen overnight 
and scanned with the Personal Molecular Imager
® 
FX (Bio-Rad). U6 was probed as a loading 
control and only exposed to the phosphor screen for 5 to 10 minutes. 
2.4 Results 
2.4.1 Reproducibility and specificity of the microRNA microarray platform 
In order to evaluate the reliability of the microRNA microarray, we tested the 
reproducibility of the data from multiple hybridizations (Table II1). First, equal amounts of 
enriched microRNAs from each of the 6 organs were pooled as the common reference. Then, 
microRNA from each organ (Cy3) was co-hybridized with the common reference (Cy5). The 
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maximum and minimum probe signals in the six replicates from each hybridization were 
excluded from data analysis. The microRNA signal was then calculated as the geometric average 
of the remaining 4 probe signals. The correlation coefficient of the microRNA signals of the 
common references (Cy5) between two hybridizations was calculated in order to assess the 
reproducibility of the microarray hybridization. The results are shown in Table II1. The 
correlation coefficients between two hybridizations were 0.89 – 0.98. For comparison, we also 
used one spot per block for calculations, where the correlation coefficients were 0.83 to 0.95. The 
results suggest that our arrays are highly reproducible.  
To test the specificity of the microarray, we used mismatched probes for two microRNAs, 
rno-miR-16 and rno-miR-324-5p, which were included in the control oligos provided with the 
labeling kit. The probes with one, two and three nucleotide mismatches were denoted with m1, 
m2 and m3, respectively. The microarray could not reliably distinguish those with only one 
mismatch. However, the signals from probes with two mismatches were significantly 
decreased, >20 fold less than those from probes with perfect base pairing (Fig. II2). From these 
results, we concluded that our microarray could differentiate between microRNAs with two or 
more nucleotide differences. 
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Fig. II1 microRNA microarray fabrication and hybridization strategy. (A) The probes were 
two copies of antisense oligos of mature microRNA. The 5' ends of the probes were amino 
modified. The probes were linked to epoxy-coated slides covalently. MicroRNA samples were 
tagged and hybridized to the slides. (B) Each slide contained three identical blocks and each 
block was hybridized with two-colored paired samples. There were 6 duplicated probes for each 
microRNA as shown in block A. MIR xxxx, series number. 
 
Table II1: The correlation coefficients of common reference signals between two 
hybridizations 
 
Cy3-labeled organ and Cy5-labeled common reference (pooled samples from 6 organs) were co-
hybridized. The correlation coefficients were calculated from the log2 transformed average 
signals of the common reference between two hybridizations.
Free amine 
group
Two copies of 
antisense 
strands
miRNA
Labeling 
tag
Cy3/Cy5 
capture 
sequence
A B C
M
IR
 X
X
X
sample reference
  Sample Reference 
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2.4.2 Identification of lung-specific microRNA 
In order to identify microRNAs that are prominently expressed in the rat lung or co-
expressed in the lung and another organ, microRNA samples from 6 organs of 4 rats were co-
hybridized with the common reference. A dye flip was subsequently performed by switching the 
dyes labeling the organ samples and the common reference. After scanning the slides, spots 
qualities were evaluated using the Realspot software [53]. Any microRNAs with average QI's no 
larger than 1 in any of the six organs were eliminated from data analysis. Out of 216 microRNAs, 
only 127 passed the Realspot quality test. The qualified microRNA signals were then tested by 
Significant Analysis of Microarray (SAM) to eliminate microRNAs that did not have significant 
changes between any of the six organs [54]. After the SAM test, another 21 microRNAs were 
eliminated, leaving 106 microRNAs for further study. Any microRNAs that were prominent in 
one organ or co-expressed in two organs were identified by Tukey Honestly Significant 
Difference (HSD) analysis (P < 0.05) (Tables II2, II3 and Fig. II3). Two microRNAs (rno-miR-
195 and rno-miR-200c) were identified as being expressed specifically in the rat lung. There are 5 
and 3 nucleotide differences between miR-200c, and miR-200a and miR-200b, respectively. 
Therefore, our arrays were able to detect the difference between the isoforms. The numbers of the 
prominently expressed microRNAs in the heart, brain, liver, kidney and spleen were 6, 13, 5, 2 
and 18, respectively. The numbers of co-expressed microRNAs are shown on the lines between 
the two organs in Fig. II3. The lung had more microRNAs co-expressed in the heart than with any 
other organ. This finding is likely due to the relationship between the lung and the heart in 
organogenesis. 
After HSD analysis, we calculated the organ specificity index (OSI) for organ-
microRNAs that passed the SAM test. There were 2, 5, 18, 5, 1, and 16 microRNAs prominently 
expressed in the lung, heart, brain, liver, kidney and spleen, respectively using OSI >0.90 as a 
criterion (Table II2). We also noted organ specificity if the microRNA expression in one organ 
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was at least two fold of that in all other organs. According to this two-fold definition, similar 
results were obtained (Table II2), showing the number of microRNAs exclusively expressed in 
only one of the 6 organs to be 2 (lung), 5 (heart), 14 (brain), 5 (liver), 2 (kidney), and 15 (spleen). 
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Fig. II2. Specificity of microRNA microarray hybridization. The control oligos in the 3DNA 
array900 microRNA direct kit were ligated with Cy5 capture sequence and hybridized onto one 
block. The mismatched probes had one (m1), two (m2) or three (m3) mismatched nucleotides 
with the corresponding control oligos. The signals from the slide were processed with the method 
described in Materials and Methods. Data shown were means ± S.E. from 3 hybridizations. 
 
TABLE II3: microRNAs co-expressed in two organs. The listed microRNAs co-expressed in 
two organs were identified by HSD except those marked with “†”. The symbol “√” indicates the 
microRNAs that were identified by 2 fold criteria. 
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Fig. II3 Organ-specific 
microRNAs. (A) Hot maps. 
The microRNA samples 
from 6 organs were co-
hybridized with the 
common reference. The 
signals were processed as 
described in Materials and 
Methods. The normalized 
data were subjected to the 
SAM test [67]. The 
microRNAs that passed 
SAM were further tested by the HSD test (P < 0.05) to identify organ-specific microRNAs. Each 
column represents one hybridization and each row represents one microRNA. The figure was 
drawn by Treeview. Red represents positive values, green negative values, and black zero. The 
number of microRNAs for each organ is: Lung 2; heart 6; brain 13; liver 5; kidney 2 and spleen 
18. (B) Summary of differently expressed microRNAs among 6 organs. The number beside each 
organ represents the number of microRNAs that are expressed significantly higher in this organ 
than any other organs (P < 0.05). The number on the line between any two organs is the quantity 
of microRNAs expressed significantly higher in these two organs than in other organs (P < 0.05). 
lung kidneyliverbrainheart spleen
lung
heart
brain
liver
kidney
spleen
A 
B 
lung
kidney
liver
brain heart
spleen
8
1
1
2
0
0
0
0
1
2
0
0
00
0
6
1
182
5
13
78 
 
2.4.3 Confirmation by Northern blot 
To further investigate the reliability of our microarray data, 12 microRNAs were selected 
for Northern blot confirmation (Fig. II4). Total RNA was extracted from the lung, heart, brain, 
liver, kidney and spleen from 4 rats. These were the same tissues from the rats utilized for small 
RNA extraction for the microarray experiment. Total RNA samples from the respective organs 
were pooled for the experiment. The intensities of the blots were normalized to U6 snRNA and 
the normalized intensities from Northern blots were compared with those from the arrays (Fig. 
II5). Among the 12 selected microRNAs, two were lung-specific (miR-195 and miR-200c), one 
was kidney-specific (miR-10a), and three were co-expressed in the lung and heart (miR-126, miR-
143 and miR-145) as determined by HSD, OSI and two-fold criteria. Most microRNAs had 
similar expression patterns from microarray analysis and Northern blots (Fig. II4 a-c). In a few 
cases, the Northern blot showed a higher expression in comparison with the microarray, including 
microRNA-195 in heart and microRNA-145 in kidney and spleen. We also selected additional 
microRNAs for verification: 3 microRNAs that had high expression in the lung and/or heart (Fig. 
II4d and II5d) and 33 microRNAs that were expressed in most of the 6 organs (Fig. II4e and II5d). 
Again, the results exhibited the consistency of the expression patterns between the microRNA 
array and Northern blot analysis. The correlation coefficients of 7 microRNAs between 
microarray and Northern blot were higher than 0.9. Although there were few discrepancies, it is 
clear that the microarray data agreed with the Northern blot data. 
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Fig. II4 Northern blot validation. 15 μg total RNA was separated on a denaturing 15% PAGE 
gel. The 32P labeled probes for the microRNA were hybridized to the membrane overnight. The 
U6 snRNA was probed as the loading control after the hybridization of microRNA probes. (a) 
lung-specific microRNAs; (b) kidney-specific microRNAs; (c) co-expressed microRNAs in the 
lung and heart identified by HSD; (d) microRNAs highly expressed in the lung and/or the heart. 
(e) commonly expressed microRNAs. 
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Fig. II5 Comparison between results from the microarray and Northern blots. The Northern 
blots in Figure 4 were quantitated by the Personal Molecular Imager® FX and normalized to U6. 
Y axes represent the normalized intensities in the Northern blots or the normalized ratios in the 
microarrays divided by the average of those from 6 organs. The microarray data shown are means 
± S.E. from 8 hybridizations. (a) lung-specific microRNAs; (b) kidney-specific microRNAs; (c) 
co-expressed microRNAs in the lung and heart identified by HSD; (d) microRNAs highly 
expressed in the lung and/or the heart. (e) commonly expressed microRNAs. 
2.5 Discussion and conclusion 
In this study, we designed a microRNA microarray system in our laboratory and tested its 
reliability. This method was used to compare the microRNA expression patterns of six different 
rat organs, namely the lung, heart, brain, liver, kidney and spleen. We identified 2 microRNAs 
(miR-195 and miR-200c) that were distinctively expressed in the rat lung, 8 microRNAs that were 
co-expressed in the lung and heart and 1 microRNA that was co-expressed in the lung and kidney. 
The reliability of our microarray was confirmed by the high consistence between the microarray 
and Northern blot analysis. 
Several groups have developed microRNA microarray platforms to detect the profiling of 
microRNAs. However, our platform has several unique features. First, we used two-channel co-
hybridization. We also pooled all of the samples as the common reference. Additionally, we 
performed the dye swap to eliminate the effect of dye bias. The approaches are similar to those 
used in DNA microarrays. Conversely, most of the other platforms use a single channel platform. 
Some groups have utilized synthesized oligos as the common reference in their microarrays [37, 
43], but the DNA-RNA hybridization may differ from DNA-DNA hybridization. Second, we 
have 6 replicate spots in our microarray, making us able to exclude the maximum and minimum 
values while being able to calculate the geometric average signal from the remaining 4 replicates. 
This method significantly increased the reproducibility of the data. Third, we printed slides in-
house with 3 identical blocks in each slide. This procedure allowed us to hybridize 6 samples (3 
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pairs) on a single slide. We have previously demonstrated that this approach significantly reduces 
the variance and increases the efficiency [52]. 
When comparing our data with previous studies, there are similarities as well as 
differences. For example, only one of the microRNAs we identified as lung-specific, miR-200c, 
has been reported by other groups [37]. Also, miR-195 was previously reported to be expressed 
higher in the spleen than in the lung [37], but both our microarray and Northern blot results show 
rno-miR-195 expressing much higher in the lung than in the spleen. A few factors could have led 
to these discrepancies. First, the microRNAs printed on our microarray slides were different from 
others. Some platforms did not contain all of the 217 microRNAs that we printed on our slides. 
For example, mmu-miR-375 is a newly identified microRNA expressed highly in the lung. This 
particular microRNA was not included on microarray slides in the other studies. Therefore, our 
study is supplemental and concurrent with other microRNA profiling studies. Second, the sample 
origins, hybridization conditions, and data analysis methods were different among different 
research groups. Our microRNA samples were extracted from rat organs and those of other 
groups were extracted from human and mouse organs. Although this may cause some differences, 
most microRNAs identified thus far are conserved among species. The use of different 
hybridization conditions and normalization methods may have also caused some inconsistencies 
in sensitivity and specificity. However, the methods and conditions used in our study are highly 
reproducible. Third, some microRNAs that were lung-specific were not highly expressed. This 
may have caused a disagreement with other microarray platforms. Indeed, when we compared the 
highly expressed microRNAs that we found in the rat brain to those identified by other groups, 11 
out of 13 were consistent with others [35, 37, 43, 55], suggesting that our results are reliable and 
comparable to other microRNA microarray platforms. 
There are some differences between the results from the microarray and the Northern 
blots. The most obvious reason for the variation was that the hybridization conditions and the 
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normalization methods were different between the two. The hybridization temperatures and 
buffer affected the sensitivity and specificity of the assays. The assumption for the microarray 
normalization was that the total amount of microRNA was consistent between samples from 
different organs. Realistically, this assumption was not true in some cases. The signals from the 
Northern blots were normalized to the signals of U6 snRNA with the assumption that the amount 
of U6 snRNA was the same as the amount of total RNA from the different organs. It is virtually 
impossible to provide the exact same amount of RNA between samples. 
Among the 12 microRNAs confirmed by the Northern blots, none has a known function 
except mmu-miR-375 [28]. The expression of mmu-miR-375 was reported to be limited to the 
pancreatic β cells, although we also detected it in the rat lung. It has been reported to regulate the 
secretion of insulin. Neither the secondary transduction signals nor the actin filament network are 
affected by mmu-miR-375. Mtpn was validated as a target gene of mmu-miR-375. Mtpn was 
reported to form a complex with CapZ which regulates actin polymerization [56]. In the lung, the 
alveolar epithelial type II cells secrete surfactant through exocytosis, which helps to reduce the 
surface tension of the alveolar sacs and facilitate the normal function of gas exchange. The 
mechanism of the secretion of surfactant in the lung is similar to that of the secretion of insulin in 
the pancreas. We suspect that mmu-miR-375 works in both of these exocytosis processes. We 
may find some hints as to the mechanism of exocytosis in the lung if we find more targets of miR-
375 or any of the components that interact with these targets. 
Two well-known microRNAs, miR-1 and miR-133, have highly specific expression in 
cardiac and skeletal muscle tissue [55]. In our study, we also identified these microRNAs as 
having heart-specific expression. These two microRNAs are clustered together in the mouse 
genome and both of them modulate muscle proliferation and differentiation. miR-1 promotes 
myogenesis by targeting histone deacetylase 4 (HDAC4), while miR-133 promotes myoblast 
proliferation by inhibiting serum response factor (SRF) [57]. 
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A brain-specific microRNA, miR-9, has been identified by our microarray as well as by 
microarrays from other groups. It has been shown to affect neural lineage differentiation in ES 
cells. STAT3, which is a member of the signal transducer and activator of transcription family, is 
believed to be involved in this function [27]. In presenilin-1 null mice, miR-9 has been shown to 
be down-regulated, leading to severe brain developmental defects [38]. 
The liver-specific microRNA, miR-122, likely modulates the hepatitis C virus by 
facilitating replication of the viral RNA. Mutational analysis and ectopic expression studies have 
revealed that miR-122 interacts with the 5' non-coding region of the viral genome [58]. This 
suggests that miR-122 may be a target for antiviral interaction [58]. In addition, miR-122 is a key 
regulator of cholesterol and fatty-acid metabolism in the adult liver by regulating plasma 
cholesterol levels, fatty-acid oxidation, hepatic fatty-acid synthesis as well as cholesterol 
synthesis [22]. 
Among the spleen-specific microRNAs identified, five of them belong to the mir17 
microRNA cluster, which comprise miR-17, miR-18, miR-19a, miR-19b, miR-20, miR-25, miR-92, 
miR-93, miR-106a, and miR-106b [59]. Among these 5 microRNAs, miR-17-5p, miR-17 and miR-
20 belong to one of the mir17 microRNA clusters, the mir-17–92 cistron, which is one with well 
characterized cancer association. The mir-17–92 polycistron is located at 13q31, a genomic locus 
that is often amplified in cancers. The substantial increase in the expression of microRNAs from 
this cistron has been reported in human B-cell lymphomas and human lung cancers [60, 61]. 
However, the prominent expression and function of these microRNAs in the spleen are not 
known. 
There are few studies concerning the functions of microRNAs in the lung. Several recent 
studies have given rise to a great interest in this field of research. The reduction in the expression 
of let-7 in human lung cancers is correlated to increased death rates in patients [62]. 
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Experimentally, over-expression of let-7 can inhibit lung cancer cell growth in vitro. This 
discovery shows that let-7 may have potential clinical value in treating lung cancers. Inactivation 
of Dicer results in the defect of epithelial branching [63]. This defect is independent of the 
requirement for Dicer in cell survival and does not stop the epithelial growth [63]. In the E11.5 
lung, Ago1 and Ago2 are enriched in the branching regions, which undergo the most dynamic 
changes during lung remodeling. This discovery suggests that microRNAs regulate processes 
responsible for the biogenesis of the lung [64]. Another study shows that the decrease in Dicer 
expression is associated with the poor prognosis in lung cancer patients [65]. The microRNA 
expression profiles in lung cancers correlate with the prognosis of lung adenocarcinoma patients 
[66]. 
In summary, we designed a reliable microRNA microarray platform that is low in cost 
and easy to update with highly reproducible results. The expression profiling of microRNAs in 6 
rat organs was detected with this platform. The expression patterns of lung-specific and lung co-
expressed microRNAs were confirmed by Northern blot analysis. Our platform adds to the 
implementation of detecting microRNA profiles, as no other microarray platform has been made 
for the detection of rat microRNA profiles. Furthermore, our microarray platform contains several 
recently discovered microRNAs, making it supplementary to other platforms. When applied, our 
study of the expression patterns of microRNAs in the lung should shed light on the functions of 
microRNAs in lung physiology as well as lung pathophysiology. 
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CHAPTER III 
 
 
MIR-127 MODULATES FETAL LUNG DEVELOPMENT 
3.1 Abstract 
MicroRNAs (microRNAs) are small endogenous RNAs and are widely regarded as one 
of the most important regulators of gene expression in both plants and animals. To define the 
roles of microRNAs in fetal lung development, we profiled the microRNA expression pattern 
during lung development with a microRNA microarray. We identified 21 microRNAs that 
showed significant changes in expression during lung development. These microRNAs were 
grouped into four distinct clusters based on their expression pattern. Cluster 1 contained 
microRNAs whose expression increased as development progressed, while clusters 2 and 3 
showed the opposite trend of expression. MicroRNAs in cluster 4 including microRNA-127 
(miR-127) had the highest expression at the late stage of fetal lung development. Quantitative 
real-time PCR validated the microarray results of six selected microRNAs. In situ hybridization 
demonstrated that miR-127 expression gradually shifted from mesenchymal cells to epithelial 
cells as development progressed. Overexpression of miR-127 in fetal lung organ culture 
significantly decreased the terminal bud count, increased terminal and internal bud sizes, and 
caused unevenness in bud sizes, indicating improper development. These findings suggest that 
miR-127 may have an important role in fetal lung development. 
Keywords: in situ hybridization, microarray, lung morphometry 
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3.2 Introduction 
microRNAs (microRNAs) are a class of small RNAs (∼21–24 nt) that regulate the 
expression of their target genes at the posttranscriptional level [1, 2]. In animal cells, they are first 
transcribed from microRNA genes in the genome as primary microRNAs (pri-miRNAs) and then 
processed by an RNase III enzyme, Drosha, into ∼70-nt premature microRNAs (pre-miRNAs) 
with hairpin structures [3]. With the help of Exportin 5, pre-miRNAs are then transported into the 
cytoplasm, where they are cleaved by another RNase III enzyme, Dicer [4, 5]. The cleavage 
results in double-stranded RNA duplexes. Usually, one strand of the duplex becomes mature 
microRNA [6]. Mature microRNAs are then recruited into nucleoprotein complexes called RNA-
induced silencing complexes (RISC). Based on the pairing of microRNAs and their target sites, 
the complexes can negatively regulate the expression of their genes in three ways [7]: they can 
cleave the messenger RNAs; they can inhibit the translation of the messenger RNAs; and they 
can accelerate deadenylation of the messenger RNAs, leading to the acceleration of their 
degradation [8-12]. In rare cases, microRNAs can activate translation [13, 14]. MicroRNAs are 
important regulatory molecules that modulate various biological processes including cellular 
physiology, developmental timing, cell fate determination, apoptosis, lipid and fat metabolism, 
insulin secretion, and progression of various cancers [15-17]. 
The functions of microRNAs in various aspects of lung biology are less studied but are 
subjects of several recent investigations. Studies have suggested the important roles of 
microRNAs in lung cancer. It has been found that the decrease of let-7 expression is correlated 
with an increased death rate in patients with lung cancers [18]. The expression of microRNAs in 
lung cancers has already been profiled. The results demonstrated the correlation of microRNA 
expression with the prognosis of lung adenocarcinoma patients [19]. Studies on expression of 
important molecules in microRNA processing, namely, members of the Argonaute (Ago) gene 
family, in the embryonic day (E)11.5 lung have shown that Ago1 and Ago2 are enriched in 
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branching regions, suggesting that microRNAs may play important roles in lung development 
[20]. Inactivation of Dicer, a key component in microRNA processing, was found to cause the 
inhibition of lung epithelial branching [21]. It was reported recently that transgenic 
overexpression of the miR-17-92 cluster results in the promotion of proliferation and the 
inhibition of differentiation of epithelial progenitor cells in developing lungs [22]. 
Rat lung development can be divided into five stages [23, 24]. In the first 13 days, lobar 
division takes place. This is called the embryonic phase. Following the embryonic phase is the 
glandular or pseudoglandular phase (13–18 days), in which epithelial tubes of air passages are 
formed but have little or no lumen. In the canalicular phase (18–20 days), bronchioles are 
produced and a lumen can be recognized in many tubules. With a further thinning of the 
interstitium and a flattening of the epithelium, alveolar ducts and air sacs are formed in the 
saccular phase (20 days to full term). Some epithelial cells begin to synthesize and secrete 
pulmonary surfactant. The final stage happens after birth and is termed the alveolar phase, in 
which true alveoli are formed. 
Each of the five developmental stages is coordinated by a multitude of signaling 
molecules and pathways [25]. Some of the well-studied signaling molecules include fibroblast 
growth factors, transforming growth factors (TGFs), retinoids, Wnt genes, and Sonic hedgehog 
[26-29]. However, little is known about what the role of microRNAs is in this process and how 
they regulate lung development by modulating these signaling pathways. In addition, the 
temporal and spatial expression patterns of microRNAs in rat lung development are still not 
known. 
In this study, we used a microRNA microarray platform developed in our laboratory [30] 
to profile the expression of microRNAs at different stages in rat lung development. There were 21 
microRNAs that were significantly changed during this process. Some of these microRNAs were 
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selected and validated by real-time PCR. The spatial expression patterns of selected microRNAs 
were determined by in situ hybridization. We selected miR-127 for further study based on its 
expression pattern. miR-127 overexpression in an fetal lung organ culture at an earlier stage 
resulted in lesser and defective terminal bud formation and uneven development of the lung. 
These results demonstrate a critical role of miR-127 in fetal lung development. 
3.3 Materials and methods 
3.3.1 Isolation of RNA from rat lungs. 
Whole lungs were isolated from rat fetuses on gestational days 16, 19, and 21 (E16, E19, 
and E21) and from newborn, 6-day-old, 14-day-old [postnatal day P0, P6, and P14], and 2-mo-
old adult (AD) rats. For each time point, there were three independent biological replicates (each 
from different rats). All procedures in this study followed the protocols approved by the 
Oklahoma State University Animal Care and Use committee. For the fetal lungs, pregnant 
Sprague-Dawley rats were killed with CO2. Fetuses were removed from the uterus, and the lungs 
were isolated from these fetuses. For pup and adult lungs, male Sprague-Dawley rats were 
anesthetized with Ketamine (40 mg/kg body weight) and Xylazine (8 mg/kg body weight) before 
euthanization and isolation of the lungs. Immediately after isolation, the lungs were rinsed with 
DMEM and then homogenized in the Lysis/Binding Buffer from the mirVana miRNA Isolation 
Kit (Ambion, Austin, TX). Enriched small RNA and total RNA from the lungs were isolated with 
the mirVana microRNA Isolation Kit (Ambion) according to the manufacturer's instructions. 
3.3.2 MicroRNA microarray 
The microRNA microarrays were performed on an in-house platform developed in our 
laboratory as described previously (53). There are three identical blocks on each slide and six 
identical probes for each microRNA in each block. The NCode microRNA Labeling System 
(Invitrogen, Carlsbad, CA) was used to generate labeled microRNA molecules for hybridization 
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to the microarrays. Six hundred nanograms of RNA was used in each labeling reaction. One-fifth 
of the labeled RNA was used for each hybridization. Small RNAs from the lungs at certain time 
points were co-hybridized with the common reference, which was pooled equally from small 
RNAs of all the lung samples. To each block, one labeled sample (Alexa Fluor 3 or Alexa Fluor 5) 
was co-hybridized with the common reference labeled with the other dye (Alexa Fluor 5 or Alexa 
Fluor 3). Dye swaps were performed to eliminate dye bias. The hybridized slides were scanned 
with ScanArray Express (PerkinElmer Life and Analytical Sciences, Boston, MA), and the 
images were analyzed with GenePix 5.0 pro (Axon Instruments, Union City, CA). The data were 
calculated, normalized, and qualified as described previously [30]. The signal from each spot was 
normalized to the average signal of the whole block. The highest and lowest signals from the six 
identical probes in the same block were excluded from further analysis. The geometric average of 
the other four signals was considered to be the signal of that particular microRNA. The quality of 
the signals was assessed with RealSpot software. The microRNAs with an average quality index 
(QI) < 1 were filtered. The qualified data were then analyzed with Significant Analysis of 
Microarrays software (SAM; Stanford University, http://www-stat.stanford.edu/∼tibs/SAM/) 
(multiclass response), and any microRNAs significantly changed between any two time points 
were picked up (q < 0.05). The microRNAs that passed the SAM test were clustered and viewed 
with Cluster (K-means clustering) and TreeView software (http://rana.lbl.gov/EisenSoftware.htm). 
3.3.3 Quantitative real-time PCR for microRNA. 
Quantitative real-time PCR (qRT-PCR) for miR-18, miR-20a, miR-29a, and miR-351 
was performed with the mirVana qRT-PCR microRNA Detection Kit (Ambion) and that for miR-
195 and miR-351 was performed with TaqMan MicroRNA Assays (Applied Biosystems, Foster 
City, CA) per the company's protocols. In brief, total RNA was isolated from rat lungs at different 
time points of development (E16, E19, E21, P0, P6, P14, and AD) with the mirVana microRNA 
Isolation Kit (Ambion). TURBO DNA-free (Ambion) was used to remove DNA contamination. 
96 
 
Three biological replicates were performed at each time point. For qRT-PCR using the mirVana 
qRT-PCR microRNA Detection Kit, 50 ng of RNA was used in each reverse transcription 
reaction with microRNA specific mirVana reverse transcription (RT) primers. Duplicate RT 
reactions were performed for RNA from each biological replicate and no template controls. The 
reactions were incubated in 96-well plates at 37°C for 30 min and then at 95°C for 10 min. PCR 
Master Mix (15 μl) was added to each RT reaction. qRT-PCR was performed on an Applied 
Biosystems 7500 Real-Time PCR System. The reactions were incubated at 95°C for 3 min, 
followed by 40 cycles of 95°C for 15 s and 60°C for 30 s. Dissociation analysis was performed 
after amplification to identify the characteristic peak for the specific PCR product. The threshold 
cycle (CT) was determined for each microRNA. RT and PCR for U6 snRNA were also performed 
in each plate as an endogenous control. The comparative CT method was used, and the relative 
amount of each microRNA to U6 snRNA was calculated with the equation 2
-(CTmiRNA-CTU6). For 
qRT-PCR with TaqMan MicroRNA Assays, 75 ng of total RNA was used as template in each RT 
reaction with microRNA-specific RT primers. The reactions were incubated on ice for 5 min, 
followed by 16°C for 30 min, 42°C for 30 min, and 85°C for 5 min. For each PCR reaction, 1.33 
μl of RT product was used as a template. The PCR reaction was incubated at 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. All PCR reactions were run in 
duplicate. RT and PCR for 18S in each sample were also performed as an endogenous control 
with TaqMan Ribosomal RNA Control Reagents (Applied Biosystems). Data analysis was done 
as described above. For miR-136 and miR-337, we adopted the method of Shi and Chiang (43), 
with a few modifications. Briefly, 5 μg of total RNA was polyadenylated with poly (A) 
polymerase (Ambion) at 37°C for 1 h. RT was performed with a poly(T) adaptor, 
GCGAGCACAGAATTAATACGACTCACTATAGG TTTTTTTTTTTTVN. Real-time PCR 
was performed with a universal reverse primer, GCGAGCACAGAATTAATACGACTCAC, and 
a forward primer with the same sequence as the mature microRNA. 
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3.3.4 In situ hybridization for microRNA. 
In situ hybridization for microRNA was done with 5′ DIG-labeled LNA probes (Exiqon, 
Woburn, MA). Paraffin-embedded rat lung tissues were dewaxed in xylene and rehydrated in 
descending grades of alcohol. The slides were then washed in PBS (pH 7.5) and permeabilized by 
incubating for 10 min in proteinase K (Ambion) for 5 min at 37°C. The slides were again washed 
in 0.2% glycine, fixed in 4% paraformaldehyde, rinsed in PBS, and prehybridized in 
hybridization buffer (50% formamide, 5× SSC, 0.1% Tween 20, 9.2 mM citric acid, 50 μg/ml 
heparin, and 500 μg/ml yeast RNA, pH 6) in a humidified chamber. The 5′ DIG-labeled LNA 
probes were then added to the sections at a 20 nM concentration and incubated overnight at the 
hybridization temperature [21°C lower than the melting temperature (Tm) values of the specific 
probes]. The slides were rinsed in 2× SSC and washed three times for 30 min in 50% formamide, 
2× SSC solution at the same hybridization temperature. This was followed by blocking with 2% 
sheep serum, 2 mg/ml BSA in PBS + 0.1% Tween 20 (PBST) and incubation with anti-DIG-AP 
Fab fragments antibody (1:2,000) (Roche Applied Sciences, Indianapolis, IN) overnight at 4°C in 
a humidified chamber. After washing in PBST and AP buffer (in mM: 100 Tris·HCl, pH 9.5, 50 
MgCl2, and 100 NaCl, with 0.1% Tween 20), the color reaction was carried out by incubation in 
5-bromo-4-chloro-3-indolyl phosphate (BCIP)/nitro blue tetrazolium (NBT) color solution 
(Roche Applied Sciences, Indianapolis, IN) with 1 mM Levamisole for 6–24 h at room 
temperature. The color reaction was stopped after observation of sufficient development of blue 
precipitate by washing with PBST. The slides were then mounted, coverslipped, and observed 
under a Nikon E-600 microscope. 
3.3.5 Construction of miR-127 overexpression adenoviral vector. 
Rat miR-127 with flanking sequences (∼200 base pairs at each end) was amplified from 
rat genomic DNA with the primers 5′-CCTTGTCGACCTCGAGAACCTCCAG-3′ and 5′-
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AGAATTCTTAGGCATTAAGTGGCTCCAGACCC-3′ and digested by SalI and EcoRI 
digestion. The digested PCR product was cloned into a modified pENTR/CMV-EGFP vector [31] 
between enhanced green fluorescent protein (eGFP) stop codon and SV40 poly (A) terminal 
sequences through XhoI and EcoRI restriction sites. Cytomegalovirus (CMV)-driven EGFP was 
included in the vector for the purpose of monitoring transfection efficiency. The empty vector of 
the CMV-driven EGFP was used as a vector control. The CMV-EGFP-microRNA in the pENTR 
vector was moved into an adenoviral vector by the Gateway technique (Invitrogen). Obtained 
adenoviral vectors were linearized by PacI and used to transfect HEK293A cells. Adenovirus was 
amplified by reinfecting HEK293A cells. Titer of virus was determined by making a series of 
dilutions of viral stock, infecting HEK293A cells, and counting for virus-infected cells and is 
expressed as plaque-forming units (PFU) per milliliter. 
3.3.6 Overexpression of miR-127 in fetal lung organ culture. 
E14 embryos were dissected from timed pregnant Sprague-Dawley rats. Fetal lungs were 
isolated from each fetus by removing the surrounding tissues with 21- to 24-gauge needles and 
placed in Hanks' balanced salt solution (HBSS). They were then cultured on 0.4-μm-pore size 
culture inserts (Millipore, Billerica, MA) and placed in six-well tissue culture plates for 2 days. 
Each well contained 1.5 ml of serum-free chemically defined BGJb medium (Fitton-Jackson 
modification; Invitrogen) with 0.2 mg/ml ascorbic acid, 50 U/ml penicillin, and 50 μg/ml 
streptomycin. The day of isolation (E14) was denoted as day D0, and the next 2 days of culture 
were denoted as D1 and D2, respectively. The adenoviruses containing eGFP and microRNA 
overexpression sequence or empty vector with eGFP only (virus control) were added to the 
inserts on D0 at a dose of 4.7 × 10
7
 PFU/fetal lung. As a blank control, an equal amount of 
DMEM was added on the fetal lung. Excess liquid, if any, in the insert was removed with a 
pipette after 3 h. Half of the initial dose of virus was added on D1 to maintain the overexpression 
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as tissue mass increased. The lung was photographed on each day with a digital camera mounted 
onto a Nikon-E 600 microscope at the same magnification for every lung. 
3.3.7 Morphometric analysis of lung. 
The morphometric analyses of fetal lungs were done on the images taken on D0, D1, and 
D2 at the same magnification with MetaVue software (Molecular Devices, Downingtown, PA). 
The images were coded, and analyses were performed in a blinded manner by two investigators. 
The number of terminal buds was counted by enlarging the images on the MetaVue software and 
counting those buds that were at the periphery of the lung. The number of terminal buds for each 
lung was divided by the number of terminal buds present at the time of isolation as a 
normalization procedure. The terminal and internal bud sizes were measured with the software at 
the longest diameter for each bud. The average bud sizes were calculated by randomly selecting 
at least 30 internal or terminal buds from each lung and calculating the average for each lung. 
Data were pooled from all lungs that received the same treatment. The data from at least 10 lungs 
obtained from fetuses of 3 different dams were used to measure each parameter. 
3.3.8 Statistical analysis. 
Statistical analysis of microarray data was done as described previously [30]. One-way 
ANOVA was performed for the real-time PCR study pertaining to miR-127 overexpression in 
fetal lungs, followed by Dunnett's multiple-comparison test for comparison between individual 
treatments. For all other studies, a paired t-test was done between the virus control and miR-127 
overexpression groups. A P value of <0.05 was considered significant. All values are presented as 
means ± SE. 
3.4 Results 
3.4.1 MicroRNA expression profile during lung development. 
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To detect the microRNA expression profile during rat lung development, we used the 
microRNA microarray platform developed in our laboratory [30]. The microarray contained 
probes for 227 non-redundant RNAs: 177 rat microRNAs, 5 human microRNAs, 31 mouse 
microRNAs, and 14 other kinds of RNAs and controls. Small RNAs of rat lungs from seven time 
points of lung development (E16, E19, E21, P0, P6, P14, and AD) were co-hybridized onto the 
slides with the common reference, which consisted of equal amounts of enriched small RNAs 
from each time point. Three biological replicates and dye swaps were performed for each sample. 
One hundred seven microRNAs passed the quality test by RealSpot, with an average QI > 1 [32]. 
Statistical analysis was performed with SAM. Twenty-one microRNAs were shown to have 
significant changes between at least one pair of the seven time points (q < 0.05). To identify 
microRNAs with similar expression patterns, these significantly changed microRNAs were then 
grouped into four clusters with Cluster software by K-means clustering (Fig. III1). The number of 
clusters was chosen to best reflect different expression patterns after comparing different numbers 
of clusters. Cluster 1 included let-7b, miR-29a, miR-23a, miR-22, and miR-195. Cluster 2 
included miR-298, miR-341, miR-130b, and miR-92. Cluster 3 included miR-17, miR-214, miR-
106b, miR-93, miR-290, miR-20a, miR-17-5p, and miR-18. Cluster 4 consisted of miR-127, 
miR-210, miR-19b, and miR-351. The expression patterns of the identified microRNAs are 
shown in the line charts in Fig. III2. In cluster 1, the microRNA expression increased gradually 
from fetal to adult lungs (E16 to AD). The microRNAs in clusters 2 and 3 decreased from E16 to 
AD, a large part of which markedly decreased from E16 to E19. In cluster 4, all the microRNAs 
peaked at some point between E16 and P6. For example, miR-127 reached maximum on E21 and 
miR-351 reached maximum on E19. 
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Fig. III1 Cluster analysis of microRNAs 
significantly changed during rat lung 
development. MicroRNAs from lungs on 
gestational days 16, 19 and 21 (E16, E19, 
and E21) or postnatal days 0, 6, and 14 (P0, 
P6, and P14) or adult lungs (AD) were 
cohybridized with the common reference. 
Normalized data were subjected to 
Significant Analysis of Microarrays (SAM) 
test to identify microRNAs whose expression 
was significantly changed during this process 
(q < 0.05). The identified microRNAs were 
grouped into 4 clusters by K-means 
clustering and viewed by TreeView. Each 
column represents 1 stage, and each row 
represents 1 microRNA. Each value of 
expression is the average of 6 replicates and 
is then log2 transformed. Red represents 
positive values, green negative values, and 
black zero. 
Fig. III2 microRNA expression patterns during rat lung development. The relative 
expression of microRNAs in each cluster of Fig. 1 is plotted against each stage of development. 
The relative expression level is the ratio of the sample signal to the common reference signal. 
The data shown are the means of 6 replicates. 
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3.4.2 Real-time PCR validation of microarray results. 
We wanted to validate our microarray results with a more sensitive and quantitative 
method. qRT-PCR was done to confirm the trends of expression exhibited by microRNAs from 
each of three clusters. We chose microRNAs from clusters 1, 3, and 4 because the expression of 
cluster 2 resembled cluster 3 in the general trend. We chose two microRNAs from each cluster 
based on high fold changes, their expression in lungs, and functional studies in other systems. 
miR-29a and miR-195 (Fig. III3, A and B) were chosen to represent cluster 1, while miR-18 and 
miR-20a (Fig. III3, C and D) represented cluster 3 and miR-127 and miR-351 (Fig. III3, E and F) 
represented cluster 4. All of these microRNAs followed the same trend of expression as seen in 
the microarray experiment, thus validating our microarray platform. 
The expression profiles of microRNAs miR-136 and miR-337, other members of the 
miR-127 family, were also examined. qRT-PCR demonstrated that miR-136 and miR-337 had the 
same expression patterns as miR-127 (Fig. III3, G and H). 
103 
 
 
Fig. III3 Validation of microRNA microarray results by quantitative real-time PCR 
(qRT-PCR). Total RNA was extracted from fetal lungs at E16, E19 and E21 and lungs at P0, 
P6, P14, and AD. MicroRNA levels were measured by real-time PCR. Relative expression 
levels of miR-29a (A), miR-195 (B), miR-18 (C), miR-20a (D), miR-127 (E), miR-351 (F), 
miR-136 (G), and miR-337 (H) are expressed as % of maximum expression. Error bars 
represent SE; n = 3 independent preparations, each assay performed in duplicate. Microarray 
data shown are averages from 6 replicates. 
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3.4.3 Cellular localization of microRNAs. 
In situ hybridization using 5′ DIG-labeled LNA probes was done to determine the spatial 
expression pattern of selected microRNAs in tissue sections from different stages of lung 
development. We chose miR-20a for in situ hybridization because it is a member of the miR-17-
92 cluster, which has been shown to be important in fetal lung development. The selection of 
miR-127 and miR-351 was because of their high expression at the late stage of fetal lung 
development and our interests in this stage of lung development. A U6 probe was used as a 
positive control. Positive signals were observed in nuclei of all the cells on P0 sections (Fig. 
III4A). miR-20a expression followed the trend of expression consistent with the microarray and 
qRT-PCR data (Fig. III4A). Expression was seen on E16 and not in other stages of development. 
Mesenchymal and epithelial cells were identified by immunostaining with pancytokeratin 
(epithelial cell marker) and vimentin (mesenchymal marker) on lung tissue sections adjacent to 
those used for in situ hybridization (data not shown). The signal on E16 was confined mainly to 
cells of mesenchymal origin in the interstitium, although some staining of epithelial cells was also 
noted. A probe that contained a scrambled sequence and had no known microRNA targets was 
used as a negative control. No signals were detected on E16 sections (Fig. III4A). The general 
trend of miR-127 expression for in situ hybridization and real-time PCR is similar, although the 
microarray data at E19 are less consistent with the in situ hybridization (Fig. III4B). E19 sections 
showed miR-127 expression in both epithelial and mesenchymal cells, but more in mesenchymal 
cells. In E21 sections, the expression shifted more toward the epithelial regions lining the airways. 
P0 lungs showed weaker signal intensity than E21, but the trend of expression was the same as on 
E21. Adult lung sections did not give any signals for miR-127. There was no signal from the 
lining of blood vessels (data not shown). 
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Fig. III4 In situ hybridization for microRNAs. In situ hybridization was carried out in dewaxed and 
rehydrated fetal rat lung tissue sections at E16, E19 and E21 and lungs at P0 and AD. The sections were 
hybridized with 5’ DIG-labeled LNA probes against miR-20 (A), miR-127 (B), and miR-351 (C). A probe 
with scrambled sequence unrelated to known microRNAs was used as a negative control (Neg), and a 
probe for U6 was used as a positive control (Pos). Positive signals were visualized as dark blue/purple 
color. Arrowheads denote signals from epithelial cells; arrows denote signals from mesenchymal cells; 
insets represent enlarged images. Scale bars, 40 μm. 
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The miR-351 expression pattern also corroborated the qRT-PCR and microarray data 
(Fig. III4C). E16 sections showed miR-351 expression in both epithelial and mesenchymal cells, 
but more in epithelial cells lining the future terminal airways and alveoli. Expression was highest 
at the E19 stage, when miR-351 was seen both in epithelial cells and mesenchymal cells. The 
expression was strongest in the epithelial cells lining the terminal bronchioles (Fig. III4C), while 
it was absent in the lining of blood vessels. E21 showed the same pattern of expression, although 
much weaker than E19. Also, the expression shifted more toward epithelial cells lining the alveoli 
than mesenchymal cells. The weakening of the signal continued to the P0 stage, and signal was 
seen mainly in epithelial cells lining the alveoli and terminal air spaces. In adult tissue sections, 
the signal was exclusive and specific in alveolar type II cells and could not be detected in other 
cells. In all stages, no signal was detected from the lining of blood vessels (data not shown). 
3.4.4 Effect of miR-127 overexpression on fetal lung development. 
miR-127 was selected for further functional studies because of its interesting expression 
trend. miR-127 was expressed at E19, E21, and P0, the period immediately before birth, and the 
period directly after birth. We decided to overexpress miR-127 at an earlier stage of development 
(E14) in an in vitro fetal lung culture model to see whether it causes any changes of fetal lung 
development. An adenoviral vector that overexpressed miR-127 was used to transduce E14 fetal 
lungs cultured for 2 days, as described in Materials and Methods. miR-127 overexpression and its 
effect on lung branching morphogenesis were visualized on each day (Fig. III5A). The dose of 
the virus was standardized by examining the intensities and even distribution of GFP along the 
whole lung. Since there was a significant increase in the lung tissue mass as a function of culture 
time we added half the initial dose of virus on D1, and this gave a constant and more even GFP 
expression than a single treatment on D0. The same treatment regimen was followed for both 
virus control and blank control. The overexpression was confirmed by real-time PCR (Fig. III5B). 
It was seen that there was a significant increase in miR-127 overexpression on D1 and D2. An 
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increase in the endogenous expression of miR-127 was also noted as the culture progressed. miR-
127 overexpression resulted in a larger terminal bud size compared with blank control and virus 
control (Fig. III6, A and B). Variability in the sizes of terminal buds was also plotted on a graph 
by arranging the various terminal bud sizes from at least 250 terminal buds from 10 fetal lungs 
per treatment in ascending order of their individual sizes. The sizes of the terminal buds from the 
lungs treated with miR-127 seemed to fluctuate unevenly between almost 10 and 180 relative 
units, while those treated with virus control or blank control showed a size variation that 
fluctuated in a much narrower range (20–80 relative units) (Fig. III5C). The average internal bud 
size was higher for miR-127, as in the case of terminal buds compared with controls (Fig. III5D). 
We defined internal buds as those buds that were not at the periphery of the developing lung. 
They were enclosed and not tubular, and they budded out from the secondary tubular formations 
in the developing lung. The terminal bud count, another important indicator of proper lung 
branching, showed that miR-127 overexpression decreased the number of terminal buds (Fig. 
III5E). Overall, miR-127 overexpression resulted in larger terminal buds, yet in lesser numbers, 
that showed a high amount of variability between bud sizes, and this trend was reflected in 
internal buds, too. These results clearly demonstrate that miR-127, if overexpressed at an early 
stage, causes defective lung branching morphogenesis. 
3.5 Discussion 
In the present work, we described the microRNA expression profile during lung 
development and identified four clusters of microRNAs that showed specific trends of expression. 
Expression levels of 21 microRNAs were found to be significantly changed during the course of 
lung development. The microRNA microarray results were validated by qRT-PCR analysis and in 
situ hybridization of the selected microRNAs. The overexpression of miR-127 in a fetal lung 
organ culture system caused defective lung development characterized by decreased terminal bud 
counts and varied bud sizes. 
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Fig. III5 miR-127 overexpression in 
fetal lung culture. A: E14 fetal lungs 
were cultured in an insert. miR-127 
overexpression adenovirus or virus 
control (VC) was added to the culture 
on day 0 (D0), and culture continued 
for 2 days (D1 and D2). The blank 
control (BC) was treated with 
medium alone. Images and green 
fluorescent protein (GFP) 
fluorescence were taken at D0–D2. 
Each treatment was carried out in at 
least 10 lungs from 3 different 
mothers in 3 separate experiments. B: 
qRT-PCR to quantify overexpression 
of miR-127. Total RNAs from D1 and 
D2 of the fetal lung culture were 
isolated. miR-127 levels were 
measured by qRT-PCR. Error bars 
represent SE; n = 3 independent 
preparations, each assay performed in 
duplicate. *P < 0.05 vs. VC, **P ≤ 
0.02 vs. VC. 
109 
 
 
Fig. III6 Effect of miR-127 overexpression on fetal lung development. E14 fetal lungs 
cultured in inserts were treated with miR-127 overexpression adenovirus or VC or BC for 2 
days. Images were taken at the end of culture. A: enlarged image from Fig. 5A. B: terminal 
bud width was measured with MetaVue software. The width of each bud was measured at its 
longest diameter and expressed in relative units. C: variability in terminal bud width. 
Terminal bud width values were arranged in ascending order in each treatment and plotted 
against the number of buds to demonstrate variability in terminal bud size. Data were obtained 
from >250 terminal buds from at least 10 fetuses obtained from 3 mothers. D: average internal 
bud width was calculated with MetaVue software and the same measuring parameter for 
terminal buds. The value is expressed in relative units. E: no. of terminal buds formed at the 
end of D2 in miR-127-overexpressed lungs was compared with VC and BC after normalizing 
with the terminal buds on D0. Number of terminal buds was counted in a blinded manner by 
at least 2 different individuals, and the relative number at the end of D2 was expressed as a 
ratio to number of terminal buds on D0. At least 25 terminal or random internal buds from 
each lung were used for the respective analyses. Error bars represent SE. *P < 0.05 vs. VC, 
**P ≤ 0.02 vs. VC. 
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microRNAs have rapidly emerged as one of the key regulatory molecules that control 
various biological processes ranging from development to disease. Various microRNAs have 
been implicated in regulating developmental timing and controlling left/right neuronal asymmetry 
in [33, 34], insulin secretion [35], lipid metabolism [36], proliferation and apoptosis [37, 38], 
stem cell division [39, 40], and B-cell differentiation [41]. Involvement of microRNAs in 
progression of various cancers has been extensively investigated [18, 19, 42-45], but studies on 
their role in the normal physiology of the lung have been very limited. Some important proteins 
involved in microRNA processing, such as Ago1, Ago2, and Dicer, have been shown to be 
important to lung morphogenesis [20, 21]. These discoveries suggest the importance of 
microRNAs in the lung. Our previous study [30] showed that two microRNAs, namely, miR-195 
and miR-200c, are specifically expressed in the lung. It has been shown that the expression levels 
of some microRNAs are changed after lipopolysaccharide-induced inflammation, and miR-146a 
can regulate the inflammatory response in lung alveolar epithelial cells [46, 47]. 
Williams et al. [48] compared microRNA expression between fetal (pooled from 18–29 
weeks) and adult (2 time points: 1 fetal and 1 adult) human lungs with real-time PCR. They found 
that 13 microRNAs were up-regulated in human fetal lungs and 8 microRNAs in human adult 
lungs. These authors also performed similar studies in newborn and adult mouse lungs (3 
postnatal time points: 1-, 14-, and 60-day-old mice). Fourteen microRNAs were expressed at 
higher levels in neonatal mouse lungs, and thirty microRNAs were more highly expressed in the 
adult mouse lungs. In our studies, we mainly focused on the dynamic changes in microRNA 
expression because rat fetal lung develops with selected time points that pertain to different stages 
of development (E16, pseudoglandular; E19, canalicular; E21, saccular; P0, P6, and P14, alveolar; 
and AD). The changes of let-7b, miR-23a, miR-29a, and miR-195 in mouse lungs and miR-214 
and miR-29a in human lungs were similar to these in rat lungs from our present studies. In 
addition to the microRNAs that increase or decrease from early lung development to adult, we 
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also identified a microRNA cluster in which their expression was the highest in the later stage of 
fetal lung development, compared with the early stage of fetal lung development and adult lungs. 
The first cluster we identified included miR-29a and miR-195. Their expression remained 
low during all stages of fetal lung development and was high in adult lung. The higher expression 
of miR-29a in both mouse and human adult lungs and miR-195 in adult mouse lungs compared 
with fetal or newborn stages has been observed previously [22, 48]. miR-29a showed a similar 
trend of expression during development of the brain, i.e., low in embryonic brain tissue and high 
in adult cortex and striatum [49]. Overexpression of the miR-29 family in lung cancer cell lines 
has been shown to inhibit tumorigenicity both in vitro and in vivo [50]. miR-195, on the other 
hand, has been identified as a key regulator of cardiac growth and function. The overexpression 
of miR-195 in cardiomyocytes led to abnormal cardiac remodeling and heart failure [51]. Its low 
expression during lung development may be an important factor that helps in the controlled 
proliferation and differentiation of cells in the lung. This cluster also contained let-7b, a member 
of the let-7 family known to regulate developmental timing in Drosophila [52]. 
Clusters 2 and 3 contained microRNAs whose expression decreased as development 
progressed. Interestingly, cluster 3 contained miR-17-5p, miR-18, and miR-20a, all of which are 
encoded by the miR-17-92 cluster, a conserved gene that encodes seven microRNAs. A recent 
study in mouse embryonic lung development has shown a similar trend of expression for these 
three microRNAs from E11.5 to adult lungs [22]. Our in situ hybridization of miR-20a indicated 
its expression mainly in the mesenchymal region at E16. The expression rapidly disappeared as 
development progressed. Analysis of predicted targets of the miR-17-92 cluster showed that 
almost 58% of their predicted targets were transcription factors, regulators of nucleotide or 
nucleic acid metabolism or cellular protein metabolism, all of which are key features in driving 
the developmental process in the right direction. 
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The miR-17-92 cluster has been found to be overexpressed in lung cancers and has been 
demonstrated to promote proliferation and inhibit differentiation of lung epithelial progenitor 
cells [22, 53-55]. This cluster has also been demonstrated to influence the translation of the E2F 
family of transcription factors, which are important in regulation of the cell cycle and apoptosis 
[56]. A recent study has shown that miR-20a has an important role in the regulation of E2F2 and 
E2F3 expression [57]. The same study found that E2F1, E2F2, and E2F3 could bind directly to 
the promoter of the miR-17-92 cluster and act as an autoregulatory feed loop mechanism. miR-
20a also seemed to have an anti-apoptotic role in this study, in which its overexpression 
decreased apoptosis in a prostate cancer cell line and its inhibition caused increased cell death. 
Another group found that E2F3 was the primary E2F family member that bound to the promoter 
of miR-17-92. They have proposed that the miR-17-92 cluster is also pro-proliferative because it 
shifts the transcriptional balance more toward the proliferative E2F3 network than the pro-
apoptotic E2F1 network [58]. The anti-apoptotic role of miR-20a and miR-17-5p was further 
confirmed in another study in which their inhibition caused increased apoptosis in lung cancer 
cells [55]. These studies have concentrated on the effect of microRNAs on cancer cell lines. Their 
role in affecting the expression of E2F factors in normal cells of a developing organ has not been 
studied. Since controlled cell death, proliferation, and differentiation go hand in hand in the 
development of any organ system and since these microRNAs seem to regulate these processes, 
we believe that they have a critical role in regulating lung development as well. This view is 
strengthened by another study in which the members of the miR-17-92 family were also 
implicated in the promotion of adipocyte differentiation by negatively regulating Rb2/p130, the 
retinoblastoma genes that also interact with E2F transcription factors [59]. 
Cluster 4 contained miR-127 and miR-351, which showed the highest expression just 
before and after birth in the saccular-alveolar stage. Many dramatic events including 
differentiation of alveolar epithelial type I and type II cells, the initiation of formation of alveoli, 
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and progressive decrease in the interstitial tissue occur in these stages [23, 60]. The other 
members of this microRNA cluster in the rat genome including miR-136 and miR-337 had the 
same expression patterns as miR-127, indicating that these microRNAs may be under the 
transcriptional control of the same promoter and transcription factors. In situ hybridization 
showed that both miR-127 and miR-351 tend to shift from the mesenchymal compartment of the 
developing lung to the epithelial cells, which may indicate a role for these microRNAs in the 
cellular reorganization process and differentiation of alveolar epithelial cells or mesenchymal to 
epithelial transition. 
miR-127 is embedded in a CpG island and remains methylated in most tissues except 
sperm. It shows an imprinted expression in the mouse [61, 62]. The functional studies on miR-
127 so far have identified it as a potential tumor suppressor whose expression goes down in 
cancer cell lines and in a significant number of primary tumors [63]. With treatment with 
chromatin-modifying drugs miR-127 expression was up-regulated, and this, in turn, inhibited the 
expression of its target, the proto-oncogene BCL6. Modulation in the miR-127 expression pattern 
in the context of organ development has not yet been reported. The overexpression of miR-127 in 
E14 fetal lung cultures significantly affected normal branching and terminal bud formation, 
indicating its role in fetal lung development. 
miR-127 expression was lower in the early than the late stage of fetal lung development. 
We chose to overexpress it at an earlier stage. The rationale for our approach was twofold: 1) if 
miR-127 differential expression is important in lung development, overexpressing it at a stage 
where it is supposed to be expressed at low levels should alter the lung development process and 
2) during the later stage of fetal lung development, the branching in the in vitro fetal lung organ 
culture becomes so complicated that it is almost impossible to count the individual branches and 
to perform morphometric analysis. Thus examining the effects of the reduction of miR-127 at the 
later stage of development on lung development is not practical with in vitro organ culture. 
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However, it is noteworthy that the present approach has its limitation, i.e., the overexpression of 
miR-127 at an earlier stage does not define specific roles of miR-127 up-regulation at the later 
stage of fetal lung development. 
Together, our results have demonstrated the reliability of a microRNA microarray 
platform to identify the microRNA profile during fetal lung development. We have also 
confirmed the expression profile and localization of selected microRNAs and have demonstrated 
that miR-127 overexpression results in defective fetal lung development. Since microRNAs are 
believed to have multiple targets and because there are many signaling pathways that are involved 
in the lung development process, it is likely that the microRNAs regulate multiple mechanisms of 
control of lung development. 
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CHAPTER IV 
 
 
MIR-375 REGULATES ALVEOLAR EPITHELIAL CELL TRANS-DIFFERENTIATION BY 
INHIBITING WNT/β-CATENIN PATHWAY 
 
4.1 Abstract 
Alveolar epithelial cell trans-differentiation is a process by which type II alveolar 
epithelial cells (AEC II) trans-differentiate into type I alveolar epithelial cells (AEC I) during 
lung recovery after various injuries, in which AEC I are damaged. This process is critical for lung 
tissue repair. MicroRNAs (microRNAs) are a group of small RNAs that regulate gene expression 
at the post-transcriptional level. They have the potential to regulate almost every aspect of cell 
physiology. However, whether alveolar epithelial cell trans-differentiation is regulated by 
microRNAs is completely unknown. In this study, we identified miR-375 as the most down-
regulated microRNA during alveolar epithelial cell trans-differentiation using a microRNA 
microarray platform. We also found that miR-375 was highly expressed in the lung, particularly 
in AEC II. The overexpression of miR-375 with an adenoviral vector inhibited alveolar epithelial 
trans-differentiation as indicated by an increase in the AEC II marker, SP-C, and decreases in the 
AEC I markers, T1α and RAGE. This effect occurs via inhibition of the Wnt/β-catenin pathway
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through direct targeting of Frizzled 8. Silencing of β-catenin mimicked miR-375 effects on 
alveolar epithelial cell trans-differentiation, while stabilized β-catenin blocked the effect of miR-
375. In summary, our results demonstrate that miR-375 can regulate alveolar epithelial cell trans-
differentiation by the inhibition of the Wnt/β-catenin pathway through direct targeting of Frizzled 
8. The discovery of these components in the regulation of trans-differentiation may provide new 
targets for therapeutic intervention to benefit lung recovery from injuries. 
Key words: miR-375, AEC trans-differentiation, Wnt/β-catenin signaling pathway, Frizzled 8 
4.2 Introduction 
The discovery of microRNAs (miRNAs) has opened up new avenues of research into 
regulation of gene expression and mechanism of diseases. MicroRNAs are a group of endogenous 
noncoding regulatory RNAs. They are about 22 nt long and regulate the expression of their target 
genes at the post-transcriptional level by cleavage of a target mRNA, translational inhibition, and 
mRNA deadenylation [1-4]. So far, more than one thousand microRNAs have been discovered in 
humans. The known functions of microRNAs in animals have covered almost every aspect of cell 
physiology, including regulation of development timing, cell proliferation and differentiation, 
apoptosis, fat and lipid metabolisms, and exocytosis. MicroRNAs are also known to be involved 
in the pathogenesis of cancers, diabetes, and other diseases [5-7]. According to computational 
analysis, a majority of mammalian mRNAs are under selective pressure to be conserved targets of 
microRNAs [8]. 
miR-375 has previously been reported to be a pancreatic islet-specific microRNA. It can 
regulate insulin secretion and pancreatic islet development [9-11]. The identified targets of miR-
375 include 3’phosphoinositide-dependent protein kinase-1 (PDK1) and myotrophin (Mtpn). 
Recently, miR-375 has been shown to be a proliferation inhibitor and a tumor suppressor. The 
involved targets include yes-associated protein (YAP), Janus kinase 2 (JAK2), and PDK1 [12-
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14]. We have previously reported that miR-375 is expressed in the rat lung [15]. The question of 
what is the function of miR-375 in the lung is of particular interest to us. 
The epithelium of the lung is composed of cuboidal type II alveolar epithelial cells (AEC 
II) and squamous type I alveolar epithelial cells (AEC I). AEC II are multifunctional cells 
involved in surfactant synthesis and secretion, fluid transport, and recovery from lung injury [16]. 
The main functions of AEC I are gas exchange and fluid transport [17]. AEC I can also protect 
lung epithelium from hyperoxic injury [18].  
During the saccular phase of lung development, columnar epithelial cells differentiate 
into AEC II, which contain distinctive lamellar bodies in the cytoplasm. As the air sacs expand, 
AEC I begin to derive from AEC II and undergo a thinning process. The squamous type I 
epithelium and the capillary endothelium form a thin air-blood barrier. Under a variety of disease 
conditions, AEC I are damaged and AEC II proliferate. Some of these AEC II keep their 
morphologic characteristics, while others trans-differentiate into AEC I [19-21]. Radioactive 
tracing experiment after injury reveals that tritiated thymidine is first incorporated in AEC II and 
is subsequently observed in AEC I, which further confirms the AEC II as progenitor cells of AEC 
I [22, 23]. When cultured in plastic dishes, AEC II gradually lose their morphologic 
characteristics and the ability to synthesize and secrete surfactant. On the other hand, these cells 
acquire the characteristics of AEC I, which include the squamous appearance and expression of 
all known AEC I markers such as T1α and advanced glycosylation end product-specific receptor 
(RAGE) [24-27]. This is a well-established in vitro model that mimics the alveolar epithelial cell 
trans-differentiation in vivo. We have previously reported that TGF-β regulates the alveolar 
epithelial cell trans-differentiation through the Smad pathway [27]. However, the functions of 
microRNAs in the regulation of this trans-differentiation process are completely unknown. 
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The Wnt/β-catenin signaling pathway plays a critical role in the regulation of lung 
epithelial fate determination. In the canonical Wnt/β-catenin pathway, Wnt ligands bind to 
transmembrane receptors, Frizzled (FZD) and the co-receptors LRP5/6 [28, 29]. This binding 
leads to the activation of Dishevelled (DVL), which results in the inhibition of β-catenin 
phosphorylation by glycogen synthase kinase-3β (GSK-3β) and degradation of β-catenin. The 
stabilized β-catenin then translocates into the nucleus, binds with TCF/LEF (T cell 
factor/lymphoid-enhancing factor) transcriptional factors, and regulates the expression of 
downstream β-catenin dependent genes, such as cyclin D1 and c-myc. In respiratory epithelial 
cells, Wnt/β-catenin signaling is necessary for branching morphogenesis and distal airway cell 
specification [30-32]. Some Wnt ligands including Wnt5a and Wnt7b are expressed in the lung 
epithelium [33-35]. FZD8 is also found in the lung epithelium [36]. A recent study has 
demonstrated that Wnt/β-catenin promotes trans-differentiation in the alveolar epithelial cell 
culture model [37].  
In this study, we performed microRNA expression profiling during alveolar epithelial cell 
trans-differentiation using a microRNA microarray platform. miR-375 was significantly down-
regulated during this process. Furthermore, we provided evidence that miR-375 can regulate 
alveolar epithelial trans-differentiation through the Wnt/β-catenin pathway by direct targeting of 
FZD8. 
4.3 Materials and Methods 
4.3.1 Isolation of AEC II 
AEC II were isolated from male Sprague-Dawley rats (200-250 g) as previously 
described [27]. All the animal experiments in this study followed the protocols approved by the 
Oklahoma State University Animal Care and Use committee. In brief, the rat lungs were perfused 
and isolated. They were then lavaged, and digested with elastase. The lung lobes were chopped 
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and incubated with DNase. The mixture was then filtered through a 160-μm, 37-μm, and 15-μm 
nylon mesh in sequence. The cells were incubated in rat IgG-coated plastic dishes twice for 30 
min each. Cells were then pelleted and resuspended in complete medium (MEM supplemented 
with 10% FBS). The cell purity was > 90% as determined by the modified Papanicolaou staining. 
4.3.2 Alveolar epithelial trans-differentiation 
Freshly isolated AEC II were seeded into 35-mm tissue culture dishes at a density of 0.8 
× 10
6
/dish. Cells were treated with different conditions after seeding and cultured for 1-5 days 
with medium changed on Day 1 and every other day. 
4.3.3 RNA Extraction 
Small RNA and total RNA were extracted from freshly isolated AEC II and cultured 
AEC II using mirVana
TM
 miRNA isolation kit (Ambion, Austin, TX) following the 
manufacturer’s instructions. For quantitative real-time PCR (qRT-PCR), total RNA was treated 
with TURBO DNA-free
TM
 (Ambion) to eliminate genomic DNA contamination. 
4.3.4 Fetal lung isolation 
Whole lungs were isolated from rat fetuses on gestational day 16, 19, 21 (E16, E19, E21), 
new born (P0), postnatal day 6 and 14 (P6 and P14), and adult (AD) rats. For fetal lungs, pregnant 
Sprague-Dawley rats were sacrificed with CO2 and the lungs were isolated from the fetuses. For 
pup and adult lungs, male rats were anesthetized with Ketamine (40 mg/kg body weight) and 
Xylazine (8 mg/kg body weight) and sacrificed before isolation of the lungs. The lungs were 
homogenized immediately after isolation and total RNA was extracted as described above. 
4.3.5 MicroRNA microarray 
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microRNA expression profiling was performed as previously described with a microRNA 
microarray platform developed in our lab [15]. For each sample, 600 ng enriched small RNA was 
labeled with NCode microRNA Labeling system (Invitrogen, Carlsbad, CA). In each 
hybridization, labeled RNA recovered from 120 ng small RNA was co-hybridized with a 
common reference which came from a pool of equal amounts of all the samples. Dye swaps were 
performed to eliminate dye bias. After hybridization, the scanned images were analyzed with 
GenePix 5.0 pro (Axon Instruments, Inc. Union City, CA). The data was analyzed as previously 
described [15]. The signal from each spot was normalized to the average signal of the whole 
block and the highest and lowest signals from the 6 identical probes in the same block were 
excluded from further analysis. The geometric average of the remaining 4 signals was calculated 
as the signal of that particular microRNA. The signals were qualified with Realspot software [38] 
and all the microRNAs that passed the quality test were subjected to SAM analysis (Significant 
Analysis of Microarrays, Stanford University, http://www-stat.stanford.edu/~tibs/SAM/). 
4.3.6 qRT-PCR 
qRT-PCR was performed with TaqMan® MicroRNA Assays (Applied Biosystems, 
Foster City, CA) as per the manufacturer’s instructions. In each RT reaction, 75 ng of total RNA 
was used as the template. The reactions were incubated on ice for 5 min, 16°C for 30 min, 42°C 
for 30 min, and 85°C for 5 min. The RT products were diluted 1:3 and 5 μl of diluted RT product 
was used as the template in each PCR reaction. The PCR reactions were incubated at 95°C for 10 
min, followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. qRT-PCR for 18S rRNA was also 
performed for each sample as an endogenous control. Each PCR reaction was performed in 
duplicate. The comparative CT method was used and the relative expression of microRNA was 
calculated with the equation 2
-(CTmicroRNA-CT18s).  
4.3.7 In situ hybridization 
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In situ hybridization for miR-375 was performed with 5’ DIG-labeled LNA probes 
(Exiqon, Woburn, MA), following the manufacturer’s instructions. The scrambled sequence for 
the negative control is GTGTAACACGTCTATACGCCCA. In brief, paraffin-embedded adult 
lung tissues were dewaxed in xylene and rehydrated. The slides were permeabilized by incubating 
with Proteinase K for 10 min at 37°C. The reaction was stopped with 0.2% glycine. Then, the 
slides were fixed with 4% paraformaldehyde and prehybridized in hybridization buffer for 1 h. 
After that, the tissues were incubated with 20 nM 5’ DIG-labeled probes at 60°C overnight in a 
humidified chamber. After stringent rinses, they were blocked with blocking buffer, followed by 
incubation with anti-DIG-AP Fab fragments antibody (1:2000, Roche Applied Sciences, 
Indianapolis, IN) at 4°C overnight. The color reaction was carried out in 5-bromo-4-chloro-3-
indolyl phosphate (BCIP)/nitro blue tetrazolium (NBT) color solution (Roche Applied Sciences). 
After washing, the slides were mounted and observed under a Nikon E-600 microscope. 
4.3.8 Construction of adenoviral vectors 
The pre-miRNA sequence of hsa-miR-375 with flanking sequences of 350 nt on both the 
5’ and 3’ ends was PCR-amplified from human genomic DNA with the following primers: 
forward primer cacctcgagGCACAGCCTCTCCCACCCGTA and reverse primer 
gagaattcCGTGTCAGCCGCAGATGCGT. The sequence was inserted into the pENTR plasmid 
(Invitrogen), downstream of the CMV-GFP [39, 40]. The insert was then switched to the 
adenoviral vector through LR recombination. After digestion by Pac I, the vector was transfected 
into 293A cells to produce adenovirus overexpressing miR-375 (Ad-miR-375). A control virus 
was also constructed from an empty vector with GFP only. For the β-catenin silencing adenovirus 
vector (si-β-catenin), we used a new method developed in our laboratory [41]. Four short hairpin 
RNAs were driven by four different promoters: mU6, hU6, H1, and 7SK. The four small RNA 
sequences for β-catenin silencing were: GGACCAGGTGGTCGTTAATAA, 
GTGGATTCCGTACTGTTCTAC, GAATGCCGTTCGCCTTCATTA, and 
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ACTGTTGGATTGATCCGAAAC. The expression cassette was then cloned into the adenovirus 
vector as described above [41]. A vector expressing four non-relevant siRNA sequences was used 
as a control (si-control). For the Ad-∆GSK-β-catenin adenoviral vector, the eGFP-∆GSK-β-
catenin expression sequence was transferred from pEGFP-C1 vector into a pENTR vector. This 
sequence contained mutations at four GSK3β phosphorylation sites (Ser33, Ser37, Thr41, and 
Ser45) [42]. The pEGFP-C1 vector expressing ∆GSK-β-catenin was a gift of Dr. Angela Barth 
from Stanford University. 
4.3.9 3’-UTR luciferase assay 
The 3’-UTR of rat FZD8 was PCR-amplified and cloned into pGL3 vector downstream 
of a firefly luciferase reporter gene. The following primers for PCR were used: forward, 
CGCGAATTCCTGAACGGAAGCCCAGAAG, and reverse, 
GACTCTAGAGCTGCTGTTAGTGTAAGTGGC. The forward primer includes an EcoRI 
restriction site and the reverse primer contains an XbaI restriction site. One day after plating 
293A cells in a 96-well plate, 50 ng microRNA overexpression plasmid pENTR-miR-375 was co-
transfected into 239A cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) together with 5 
ng of the reporter construct and 0.4 ng control pRL-TK, which contains a Renilla luciferase gene 
(Promega). The cells were harvested and luciferase activities were detected 48 h post-transfection 
using Dual Luciferase Reporter Assay System (Promega). In brief, 35 μl passive lysis buffer was 
applied to each well. After shaking, 7 μl cell lysate was taken for the dual-luciferase reporter 
assay. Firefly luciferase activity and Renilla luciferase activity were measured by the FLUOstar 
OPTIMA microplate fluorometer (BMG LABTECH, Offenburg, Germany).  
4.3.10 Western blotting  
The following primary antibodies were used in Western blotting and 
immunocytochemistry: mouse monoclonal anti-T1α  (1:2000) from Dr. Mary Williams (Boston 
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University), mouse monoclonal anti-PCNA (ab29, 1:5000) from AbCam (Cambridge, MA), 
mouse monoclonal anti-ABC (#05-665, 1:500) from Millipore (Billerica, MA), mouse 
monoclonal anti-β-catenin (#610154, 1:2000) from BD (Franklin Lakes, NJ), rabbit polyclonal 
anti-CSNK2A1 (#2656, 1:1000) from Cell Signaling (Danvers, MA), goat polyclonal anti-FZD8 
(sc-33504, 1:200) from Santa Cruz (Santa Cruz, CA), rabbit polyclonal anti-PDK1 (#3062, 
1:1000) from Cell Signaling, and rabbit polyclonal anti-β-actin from Sigma (A-2066, 1:2000). 
For Western blots, 35 μg of protein was loaded for each sample. After incubation with primary 
antibodies, the membranes were washed with Tris-Buffered Saline and 0.05% Tween 20 (TBS-T) 
and incubated with horseradish peroxidase-conjugated anti-mouse or rabbit secondary antibodies 
(1:2000) for 1 h. The target proteins were visualized and quantitated with SuperSignal West Pico 
Chemiluminescent Substrate (Pierce) and Molecular Imager VersaDoc MP 5000 System (Bio-
Rad), respectively.  
4.3.11 Immunocytochemistry 
The cultured cells were fixed in 4% paraformaldehyde, permeabilized with 0.4% Triton 
X-100, and then blocked in 10% FBS. The cells were incubated with mouse anti-T1α (1:250) or 
rabbit polyclonal anti-SP-C (Santa Cruz, sc-13979, 1:100) antibodies at 4°C overnight followed 
by incubation with Alexa 546-conjugated anti-mouse or anti-rabbit secondary antibodies (1:250). 
After washing, the cells were examined under a Nikon Eclipse E600 fluorescence microscope. 
4.3.12 Chromatin immunoprecipitation assay 
The ChIP assay was performed with EZ-ChIP™ Chromatin immunoprecipitation kit 
from Millipore (Billerica, MA). Briefly, freshly isolated AEC II or cultured cells were fixed in 
1% formaldehyde. The crosslinked DNA was then sheared into ~200-1000 base pair fragments 
with sonication. One percent of the sheared DNA was set aside as an input control. Anti-β-catenin 
antibody or normal mouse IgG was incubated with sheared DNA at 4°C overnight with rotation. 
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Protein G Agarose was then added. Protein/DNA complexes were then eluted from the agarose 
and the crosslinking then was reversed to free DNA. Purified DNA was then analyzed with PCR 
using the primers flanking LEF1 biding site in the CCND1 promoter. The GAPDH promoter 
without LEF1 biding sites was used as a negative control. The following primers were used: 
CCND1 forward TTCTCTGCCCGGCTTTGAT, CCND1 reverse 
CACAGGAGCTGGTGTTCCATG, GAPDH forward GTGCAAAAGACCCTGAACAATG, and 
GAPDH reverse GAAGCTATTCTAGTCTGATAACCTCC. 
Statistical Analysis- All experiments were performed with at least 3 independent replicates. The 
statistical analysis of microarray data was carried out as described in the microRNA microarray 
section. For all the other assays, student t-test was used and p<0.05 was considered significant. 
All values were shown as means ± S.E. 
4.4 Results 
4.4.1 MicroRNA expression profiling during alveolar epithelial trans-differentiation 
In order to determine which microRNAs are important in the regulation of alveolar 
epithelial cell trans-differentiation, we utilized the microRNA microarray platform developed in 
our laboratory to profile the expression of microRNAs during this process. Enriched small RNAs 
from freshly isolated AEC II and those cultured in plastic dishes for 1~5 days (D0, D1, D3, and 
D5) were co-hybridized on the array slides together with the common reference. Among all the 
up-regulated and down-regulated microRNAs, miR-375 is of particular interest. This microRNA 
has previously been reported to be a pancreas specific microRNA and a regulator of insulin 
secretion [9]. However, we have previously reported that it is also highly expressed in the lung 
[15]. The expression of miR-375 was decreased significantly during alveolar epithelial trans-
differentiation. On Day 1, the expression of miR-375 was decreased 2-fold. On Day 3 and Day 5, 
it was decreased 10-fold and 16-fold, respectively. This result was confirmed by qRT-PCR (Fig. 
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IV1a). According to qRT-PCR, this decrease of miR-375 was much larger (100-fold on Day 5). 
We also determined the expression levels of other microRNAs by qRT-PCR (Fig. IV1b). The 
miR-351 decreased markedly starting on day1 while miR-346 was unchanged on day 1 and 
decreased to about ~50% of starting levels at day 3 and day 5. miR-20a showed a modest increase 
on day 1 and a decrease on day 5. miR-21 had a 2-fold increase on Day 3. miR-27b and miR-34a 
exhibited only a modest decrease on Day 1. The expression patterns of these microRNAs suggest 
that expression of microRNAs undergoes dynamic changes during alveolar epithelial cell trans-
differentiation. 
4.4.2 miR-375 is enriched in AEC II 
In order to determine the cellular location of miR-375, in situ hybridization using 5’ DIG-
labeled LNA probe for miR-375 was done in adult lung tissue sections. A probe with a scrambled 
sequence was used as a negative control. Positive signals were observed in different areas of the 
lung, including airway and alveolar epithelium and mesenchyme. More signals were observed at 
the corners of the alveolar spaces where AEC II exist (shown by the arrow) (Fig. IV2a). In order 
to confirm the enrichment of miR-375 in AEC II, the relative expression of miR-375 in AEC II 
and the whole lung was measured using qRT-PCR. The relative expression level of miR-375 was 
2.8-fold higher than that in the whole lung (Fig. IV2b). 
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Fig. IV1 The expression pattern of miR-375 and other microRNAs in the alveolar 
epithelial cell trans-differentiation. Freshly isolated AEC II were cultured for 0, 1, 3, or 5 
days (D0, D1, D3, or D5) on plastic dishes. (a) Relative expression of miR-375 was 
determined by both microarray and qRT-PCR. The expression level of miR-375 at each time 
point was expressed as the fraction of that on D0. Data shown are means ± S.E from 3 
independent cell preparations and technical replicates of 4 (microarray) or 2 (qRT-PCR). (b) 
Relative expression of miR-20a, 21, 27b, 34a, 346, and 351 was determined by qRT-PCR. 
Data shown are means ± S.E. from 3 independent cell preparations. 
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Fig. IV2 Localization of miR-375 in the 
lung. (a) Detection of miR-375 in adult 
lung by in situ hybridization. Paraffin-
embedded adult lung tissues were 
hybridized with a 5’ DIG-labeled LNA 
probe containing the complementary 
sequence to miR-375. The expression 
pattern of miR-375 was assessed under 
different magnification (4x and 40x). 
Different areas showed positive signals, 
including the epithelium of the alveoli and 
airways. A 5’DIG-labed LNA probe 
containing a scrambled sequence was 
hybridized to the lung tissues as a negative 
control (Neg). The arrow points to a type II cell. (b) Detection of the expression of miR-375 in 
isolated AEC II and the whole lung by qRT-PCR. The expression levels of miR-375 were 
normalized to 18S rRNA. Data shown are means ± S.E. from 3 independent replicates. * 
p<0.0001. 
 
Fig. IV3 The expression pattern of 
miR-375 during fetal lung 
development. Whole lungs were 
isolated from rat fetuses on gestational 
day 16, 19, 21 (E16, E19, E21), new 
born (P0), postnatal day 6 and 14 (P6 
and P14), and adult (AD) rats. The 
expression levels of miR-375 were 
detected with qRT-PCR. Expression 
data were normalized to 18S rRNA. * 
p<0.001. Data shown are means ± 
S.E. from 3 independent replicates. 
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4.4.3 Expression patterns of miR-375 in lung development 
In order to study the functions of miR-375 in alveolar epithelial trans-differentiation, we 
also determined the expression of miR-375 during fetal lung development that involves trans-
differentiation using qRT-PCR. The development of the fetal lung can be divided into 4 stages: 
the embryonic phase, the glandular or pseudoglandular phase, the canalicular phase, and the 
saccular phase. We selected different time points that represent different stages of lung 
development and determined the expression of miR-375 at these time points. In rat, the 
canalicular phase starts on Day 18 and ends on Day 20. The saccular phase lasts from Day 20 to 
full term. AEC II first appear in the transition from the canalicular to the saccular phase. During 
the saccular stage, the differentiation of AEC II becomes more evident. As determined by qRT-
PCR, the expression of miR-375 increased at this late stage (E21 and P0), which could result 
from more differentiated AEC II in the lung. The amount of miR-375 increased two-fold from 
P14 to AD. In the adult lung, the percentage of AEC II is much higher than that in the fetal lung, 
which could explain why the expression of miR-375 is much higher in adult lungs than in fetal 
lungs. 
4.4.4 miR-375 inhibits alveolar epithelial cell trans-differentiation 
The expression of miR-375 is significantly decreased during alveolar epithelial trans-
differentiation. It is reasonable to expect that the decrease of endogenous miR-375 is important 
for this process. In order to study the function of miR-375 in this process, an adenovirus 
overexpressing miR-375 was used to transduce AEC II. The overexpression efficiency was 
assessed by eGFP signaling on Day 4 and qRT-PCR for miR-375 on Day 2. Nearly 100% of the 
cells were expressing eGFP (Fig. IV4a). The expression of miR-375 was increased more than 40-
fold, compared with that in cells transduced with the control virus (Fig. IV4b). 
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Fig. IV4 Effect of miR-375 overexpression on the trans-differentiation of AEC II to AEC I. 
Freshly isolated AEC II were transduced with a miR-375 overexpression virus or a virus control 
(VC) (multiplicity of infection or MOI=100) or none (NVC) and cultured for 4 days if not 
mentioned otherwise. (a) Bright-field and GFP fluorescence of miR-375-transduced cells. (b) 
miR-375 levels on Day 2 revealed by real-time PCR. Data are normalized to 18S rRNA. (c) 
Immunofluorescence of T1α and SP-C using anti-T1α and anti-SP-C antibodies. Because of GFP, 
double-labeling is not practical. (d) The expression of T1α was detected and quantitated with 
Western blots. Data were normalized to β-actin. (e) The mRNA levels of T1α and RAGE were 
determined by qRT-PCR. (f) The expression of PCNA was detected and quantitated with Western 
blots. Data were normalized to β-actin. Data shown are means ± S.E. from 3 independent cell 
preparations. * p<0.001. 
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The effect of miR-375 overexpression on alveolar epithelial cell trans-differentiation was 
monitored after culturing for 4 days. T1α, a marker protein for AEC I, and SP-C, a marker protein 
for AEC II were detected with immunofluorescence. In non-virus and virus controls, SP-C 
disappeared and T1α increased significantly, indicating that AEC II trans-differentiated into AEC 
I (Fig. IV4c). In cells overexpressing miR-375, T1α was significantly decreased and SP-C was 
increased in comparison with controls (Fig. IV4c). The expression level of T1α was further 
determined using Western blots. The amount of T1α in cells overexpressing miR-375 decreased 
significantly compared with that in cells transduced with the control virus (p<0.001). The control 
virus had no effects on T1α expression (Fig. IV4d). In addition, the mRNA levels of T1α and 
RAGE, an AEC I marker were dramatically increased during trans-differentiation and were 
significantly inhibited by miR-375 (Fig. IV4e). These results suggest that alveolar epithelial 
trans-differentiation is inhibited by miR-375. The effect of miR-375 on cell proliferation was also 
determined by detecting the expression of the proliferation marker, PCNA. The expression level 
of PCNA was not changed by miR-375 overexpression (Fig. IV4f), indicating that miR-375 does 
not affect cell proliferation. 
4.4.5 miR-375 inactivates Wnt/β-catenin pathway 
It has been shown that the Wnt/β-catenin signaling pathway can promote alveolar 
epithelial cell trans-differentiation in vitro [37]. We tested whether this pathway was affected by 
miR-375. In freshly isolated AEC II, there was almost no β-catenin detected. After culturing for 4 
days, there was an abundance of β-catenin protein (Fig. IV5a). Interestingly, the mRNA level of 
β-catenin did not change during culture (Fig. IV5c). The overexpression of miR-375 slightly but 
not significantly decreased the total amount of β-catenin. The active form of β-catenin (ABC) can 
be detected with the antibody that recognizes β-catenin dephosphorylated on Ser37 or Thr41. 
Activated β-catenin (ABC) was decreased significantly after miR-375 overexpression (Fig. 
IV5b). 
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Cyclin D1 (CCND1) is a direct transcriptional target of the β-catenin/LEF-1 pathway. 
The expression of CCND1 is regulated by this pathway through a LEF-1 binding site in the 
CCND1 promoter [43]. We further used the chromatin immunoprecipitation (ChIP) assay to 
detect the binding of β-catenin to the promoter of CCND1 during the process of trans-
differentiation after transduction of miR-375 or control virus (VC). Fractions of the sheared DNA 
samples were set aside as input controls. The rest of the DNA was precipitated with the β-catenin 
antibody or mouse normal IgG. The purified DNAs from the precipitations were amplified using 
the primers for LEF1 binding site and the flanking sequences of the CNND1 promoter. As 
expected, the overexpression of miR-375 eliminated the association between β-catenin and the 
promoter of CCND1 (Fig. IV5d). β-catenin did not bind to the GAPDH promoter that does not 
have the LEF1 binding sites. The negative control using normal IgG did not yield signals. These 
data provided evidence that miR-375 can inhibit the canonical Wnt/β-catenin pathway. 
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Fig. IV5 Effect of miR-375 on the Wnt/β-catenin pathway. Freshly isolated AEC II (D0) were 
transduced with Ad-miR-375 (miR-375) or control virus (VC) (MOI=100), or none (NVC) and 
cultured for 4 days. The relative amounts of total β-catenin and activated β-catenin (ABC) were 
detected with Western blots (a, b) and qRT-PCR (c) after miR-375 overexpression in the alveolar 
epithelial cell trans-differentiation. Data shown are means ± S.E. from 3 independent replicates. * 
p<0.01. (d) ChIP assays were used to detect the association of β-catenin with the promoter of 
CCND1 in AEC II transduced with Ad-miR-375 or the virus control and cultured for 4 days. 
Mouse normal IgG was used as a negative control. The promoter of GAPDH was used as another 
negative control. 
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4.4.6 Knockdown of β-catenin inhibits alveolar epithelial cell trans-differentiation 
In order to test whether the inhibition of alveolar epithelial trans-differentiation by miR-
375 is caused by inhibition of the Wnt/β-catenin pathway, we decided to knockdown β-catenin to 
block this pathway. We utilized a novel method to construct an adenovirus vector that expresses 4 
shRNAs targeting to β-catenin (si-β-catenin) [41]. AEC II were treated with si-β-catenin, or 
control virus, on D0 with a MOI of 100. The cells were collected on Day 4 and the expression of 
β-catenin was detected by Western blot. As shown in Fig. IV6, the expression of β-catenin was 
reduced by more than 90%. The silencing of β-catenin led to the decrease in T1α, indicating the 
inhibition of alveolar epithelial cell trans-differentiation. 
4.4.7 Stabilized β-catenin blocks the effect of miR-375 
In order to demonstrate that the regulation of miR-375 on the alveolar epithelial cell 
trans-differentiation occurs through down-regulation of activated β-catenin, we transduced AEC 
II with adenovirus Ad-∆GSK-β-catenin, which expressed a stabilized form of β-catenin without 
GSK3β phosphorylation sites (∆GSK-β-catenin) [42]. The expression of ∆GSK-β-catenin was 
confirmed by Western blots with ABC antibody (Fig. IV7a). The expression of T1α was 
decreased by miR-375 overexpression in the absence of ∆GSK-β-catenin. In the cells treated with 
Ad-∆GSK-β-catenin, the expression of T1α was no longer affected by miR-375 (Fig. IV7b). 
These data showed that expression of stabilized β-catenin and thus constitutively activation of 
Wnt/β-catenin pathway blocked the effect of miR-375 on AEC trans-differentiation. 
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Fig. IV6 Effect of silencing β-catenin on AEC trans-differentiation. AEC II were transduced 
with β-catenin silencing virus (si-β-catenin) or control virus (si-control) and then cultured for 4 
days. The expression of β-catenin and T1α was detected with Western blots. The signals were 
quantitated and the expression levels were shown as the fractions of those in the si-controls. Data 
shown are means ± S.E. from 3 independent replicates. * p<0.01 vs. si-control. 
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Fig. IV7 Effect of stabilized β-catenin on the trans-differentiation. Freshly isolated AEC II 
were transduced with Ad-miR-375 or virus control with or without the expression of eGFP-
∆GSK β-catenin as indicated in the figure (Ad-miR-375 MOI=50 and Ad-∆GSK β-catenin 
MOI=5). Cells were then cultured for 4 days. (a) The expression of T1α and eGFP-∆GSK β-
catenin was detected by Western blots using anti-T1α and anti-ABC antibodies, respectively. (b) 
The Western blots were quantitated. The expression of T1α with miR-375 overexpression was 
normalized to that in the virus control. Data shown were means ± S.E. from 4 independent 
experiments. * p<0.001. 
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4.4.8 FZD8 is a target of miR-375 in the Wnt/β-catenin pathway 
The web-based software TargetScan and PicTar predicted FZD8 as a target of miR-375. 
To verify the prediction, we produced a reporter construct by fusing the 3’-UTR of FZD8 with a 
firefly luciferase reporter gene. The microRNA-375 overexpression plasmid and the luciferase 
reporter construct were transfected into 293A cells together with a control vector pRL-TK, which 
contains a Renilla luciferase gene. As shown in Fig. IV8a, the luciferase activity of the reporter 
construct containing the 3’-UTR of FZD8 was significantly decreased by miR-375.In order to 
confirm that endogenous FZD8 is regulated by miR-375, we examined the effects of miR-375 on 
the expression of FZD8 during alveolar epithelial cell trans-differentiation. The protein level of 
FZD8 was decreased significantly by miR-375 as shown in Fig. IV8b. The mRNA level of FZD8 
was also decreased by 60% after miR-375 overexpression compared to cells infected with the 
control virus (Fig. IV8c). Altogether, miR-375 inhibits the expression of FZD8 at both protein 
and mRNA levels. 
CSNK2A1 (casein kinase II, alpha 1 polypeptide) is another predicted target of miR-375 
in the canonical Wnt signaling pathway. However, the protein expression of CSNK2A1 was also 
not affected by miR-375 overexpression (Fig. IV8d). These data ruled out the possibility that 
miR-375 regulates Wnt/β-catenin signaling through CSNK2A1 during alveolar epithelial cell 
trans-differentiation. 
It has been reported that PDK1 is a direct target of miR-375 in gastric carcinomas [14]. In 
order to test whether it is the same in our case, we also examined the expression of PDK1 during 
AEC trans-differentiation (Fig. IV8e). The expression of PDK1 was not changed during the trans-
differentiation (from D0 to D4), and was not decreased by miR-375 overexpression. These data 
indicate that PDK1 is not the target of miR-375 in AEC probably because of differences in the 
cell environment. 
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Fig. IV8 Identification of target genes. (a) Luciferase assay. 3’-UTR of FZD8 was fused with 
the firefly luciferase gene. miR-375 overexpression plasmids were co-transfected with the 
luciferase-3’-UTR constructs into 293A cells. Luciferase activity was determined 48 h post-
transfection. The firefly luciferase activity was first normalized to the Renilla luciferase activity 
and then expressed as a ratio of the control plasmid. (b,c) Effect of miR-375 on the expression of 
endogenous FZD8. AEC II were transduced with Ad-miR-375 or virus control (MOI=100) and 
then cultured for 4 days. The protein and mRNA levels of FZD8 were detected with Western 
blots (b) and qRT-PCR (c). The expression levels of CSNK2A1 (d) and PDK1 (e) were detected 
with Western blots. Data represent means ± S.E. from at least 3 replicates. * p<0.01, ** p<0.001. 
The blots shown are representatives of 3 independent replicates. 
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4.4.9 miR-375 is down-regulated in IPF 
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease, 
characterized by fibrosis and excessive deposition of collagen in the pulmonary interstitium [44]. 
IPF is also characterized by AEC II hyperplasia [44, 45]. A role of alveolar epithelial injury, AEC 
II proliferation and trans-differentiation in IPF pathogenesis and progression has been 
demonstrated [44]. In this study, we determined the expression of miR-375 in lung samples from 
IPF patients using qRT-PCR. The expression of miR-375 was decreased in severe IPF (50-80% 
forced vital capacity (FVC) and <50% FVC) compared to less severe IPF (>80%) (Fig. IV9). This 
result is consistent with our discovery that miR-375 is decreased during AEC II trans-
differentiation. 
4.5 Discussion 
In this study, we carried out microRNA expression profiling during alveolar epithelial 
cell trans-differentiation by using the microRNA microarray platform. Among all the microRNAs 
whose expression levels were changed during this process, miR-375 was one of the most down-
regulated microRNAs. Further studies demonstrated that miR-375 inhibited the process of trans-
differentiation when it was over-expressed in isolated AEC II. miR-375 also inactivated the 
Wnt/β-catenin pathway, whereas constitutively activated β-catenin reversed the miR-375 effects, 
indicating that miR-375 acts up-stream of β-catenin. FZD8 was identified as a direct target of 
miR-375. Together, these data indicate that miR-375 inhibits alveolar epithelial cell trans-
differentiation through the inactivation of Wnt/β-catenin pathway, by direct targeting of FZD8 
(Fig. IV10). 
 144 
 
 
 
 
 
Fig. IV10 miR-375 inhibits alveolar epithelial cell trans-differentiation through inactivation 
of the Wnt/β-catenin pathway. 
Fig. IV9 The expression of miR-375 is 
down-regulated in IPF. The 
expression of miR-375 in the lungs of 
patients with different stages of IPF 
was determined with qRT-PCR. n=10 
for <50% FVC, n=10 for 50-80% FVC, 
and n=8 for >80% FVC. *p<0.05. 
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To our knowledge, this is the first report studying the function of miR-375 in the lung 
epithelial cell differentiation. When miR-375 was first identified, it was reported to be expressed 
only in pancreatic islets but not in other tissues [9]. However, we have shown that miR-375 is 
highly expressed in the rat lung in comparison with heart, liver, kidney, spleen, and brain [15]. 
This result was verified by Northern blots. In this study, we discovered that miR-375 was 
enriched in AEC II, and that the expression of miR-375 was dramatically down-regulated during 
trans-differentiation of AEC II to AEC I. In addition, miR-375 expression in fetal lungs was 
lower than that in the adult lung. All of the expression data suggest a potential role of miR-375 in 
the lung. 
There have been several studies regarding the function of miR-375 in the pancreas. miR-
375 suppresses insulin secretion by direct targeting of the mRNA of myotrophin (Mtpn) [9]. miR-
375 not only regulates the function of the pancreatic islet but also affects the development of 
pancreatic islets. Knockdown of miR-375 results in aberrant formation of the pancreas islet [10]. 
In addition, miR-375 is reported to maintain normal pancreatic α and β cell mass and therefore 
normal glucose homeostasis [46]. 
In spite of all these studies in the pancreas, there are few functional studies of miR-375 in 
other organs. It has been reported that the expression of miR-375 is down-regulated in 
hepatocellular tumors [47, 48]. An expression ratio of miR-221:miR-375 showed a high 
sensitivity and specificity for head and neck squamous cell carcinoma, indicating that miR-375 
may be used as a diagnostic marker for certain cancers [47]. 
We have demonstrated that miR-375 inhibits pulmonary surfactant secretion from AEC 
II. This inhibition is carried out via the reorganization of cytoskeleton, rather than effects on 
surfactant synthesis or the formation of lamellar bodies [40]. The result is reminiscent of the 
function of miR-375 in the regulation of insulin secretion in pancreas islets [9]. 
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The Wnt signaling pathway has been proven to have widespread roles in tissue 
differentiation and organogenesis [49] including fetal lung development. This pathway regulates 
branching morphogenesis and epithelial cell differentiation [30, 31]. Wnt7b and Wnt5a induce 
lung branching morphogenesis through epithelial-mesenchymal communications, possibly via N-
myc, BMP4, and FGF signaling. An activated form of β-catenin causes ectopic differentiation of 
AEC II-like cells in airways, indicating a critical role for the Wnt/β-catenin signaling pathway in 
the differentiation of lung epithelial cells [32].  
A recent study, which used the same AEC II culture model that we did, has shown the 
pivotal function of the β-catenin pathway during alveolar epithelial trans-differentiation [37]. 
Constitutive β-catenin signaling cannot be detected in adult AEC II in vivo or in freshly isolated 
AEC II. This signaling is activated after the lung is subjected to bleomycin-induced injury or 
during the culture of AEC II. Activation of the Wnt/β-catenin pathway promotes AEC trans-
differentiation, while forced inhibition of this pathway leads to an increase in cell death [37]. In 
our study, we also found that this pathway was activated during the process of trans-
differentiation and that silencing of β-catenin inhibited trans-differentiation. Total β-catenin 
protein could not be detected in freshly isolated AEC II and increased markedly in cultured AEC 
II. However, the mRNA level of β-catenin did not change in freshly isolated and cultured AEC II. 
This could result from detachment of β-catenin from cell-cell adhesion complex and degradation 
by proteasomes during AEC II isolation. 
It has been reported that miR-8 negatively regulates the Wnt/Wingless pathway at 
multiple levels by directly targeting wntless and CG32767 and by repressing the protein level of 
TCF in Drosophila [50]. The depression of Wnt signaling by miR-8 leads to promotion of 
adipogenesis in mammals [50]. Canonical Wnt signaling is important for osteoblast 
differentiation. miR-29a modulates osteoblast differentiation by directly targeting to the negative 
regulators of Wnt/β-catenin signaling, namely Dkk1, Kremen2, and sFRP2. On the other hand, 
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the miR-29a promoter activity is under the regulation of the canonical Wnt pathway [51]. 
Activation of the canonical Wnt pathway induces miR-29a transcription, which subsequently 
down-regulates Wnt antagonists and induces Wnt signaling even further. 
Although we are the first to report that the Wnt/β-catenin pathway is regulated by miR-
375, we are not the only group that is interested in the relation between miR-375 and this 
pathway. The down-regulation of miR-375 is associated with β-catenin mutations in 
hepatocellular tumors [48], suggesting that the activation of β-catenin signaling represses miR-
375. Our results showed that miR-375 can inhibit the activation of the Wnt/β-catenin pathway. 
During trans-differentiation, miR-375 is down-regulated and β-catenin signaling is activated, 
which could lead to further depression of miR-375. It is quite likely that miR-375 regulates AEC 
trans-differentiation through this positive feedback loop. In this process, miR-375 may work as a 
switch of trans-differentiation. Once miR-375 decreases at the beginning of trans-differentiation, 
the Wnt/β-catenin signaling is activated, which leads to further depression of miR-375 expression 
and prevents the process from going backward. 
In investigating the mechanism of how miR-375 regulates alveolar epithelial cell trans-
differentiation through the Wnt/β-catenin pathway, we identified FZD8 as a target of miR-375. 
FZD8 is one of the Wnt receptors. The binding of Wnt ligands to the FZD8 receptor leads to the 
stabilization of cytoplasmic β-catenin and activation of the canonical Wnt pathway. Whole-mount 
RNA in situ hybridizations have shown that FZD8 is highly expressed throughout the epithelium 
during the early stage of mouse lung development [36]. We demonstrate in this study that miR-
375 down-regulates the mRNA and protein levels of FZD8 during alveolar epithelial cell trans-
differentiation, leading to the inactivation of the Wnt/β-catenin pathway.  
FZD8 is not likely to be the only target of miR-375. TargetScan software predicts 141 
and 117 targets for human and rat miR-375, respectively. However, it should be noted that many 
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of these predictions cannot be verified experimentally. Furthermore, the relationship between 
microRNAs and targets is also cell content- and developmental stage-dependent. One of the 
components of Wnt/β-catenin signaling, CSNK2A1 (casein kinase II), is another predicted target 
of miR-375; PDK1 has been experimentally verified as a direct target of miR-375 in gastric 
carcinomas [11]. However, both CSNK2A1 and PDK1 protein levels were unchanged during the 
trans-differentiation of type II cells to type I cells and thus these factors are not likely targets of 
miR-375 in alveolar epithelial cells. Other targets identified in the literature, including YAP, 
HuD, RASD1 and Mtpn are not obviously related to Wnt/β-catenin signaling [12, 52, 53]. 
Alveolar epithelial cell trans-differentiation is involved in the pathogenesis of IPF and 
progression. It has been reported that the Wnt/β-catenin pathway is significantly activated in AEC 
II from IPF patients [54, 55]. Increased Wnt/β-catenin signaling induces alveolar epithelial cell 
proliferation and probably trans-differentiation. In other words, a process similar to alveolar 
epithelial cell trans-differentiation is involved in IPF. There is a negative correlation between the 
expression of miR-375 and activation of Wnt/β-catenin signaling in IPF, which further indicates 
that miR-375 may modulates alveolar epithelial cell trans-differentiation through the regulation of 
the canonical Wnt signaling pathway in the diseased state. 
Alveolar epithelial cell trans-differentiation is very important for the recovery of injured 
alveolar epithelium resulting from a variety of disease conditions. Thus, the findings from this 
study may shed light on the recovery from lung injuries. The discovery that down-regulation of 
miR-375 and activation of the Wnt/β-catenin pathway are necessary for this process may provide 
potential targets for therapeutic intervention. In addition, it is also well known that abnormal 
activation of Wnt signaling resulting from several different genetic defects causes cancers [56]. It 
is possible that the inhibition of Wnt signaling by miR-375 can be used as a therapeutic method to 
treat cancers. 
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In summary, we identified a new function of miR-375 in alveolar epithelial cell trans-
differentiation. The regulation of AEC trans-differentiation by miR-375 is through the inhibition 
of the canonical Wnt pathway by direct targeting of FZD8. This discovery may provide potential 
targets for therapeutic intervention in the recovery from lung injuries. 
Acknowledgements 
We thank Dr. Mary Williams (Boston University) and Dr. Angela Barth (Stanford 
University) for kindly providing anti-T1α antibodies and ∆GSK-β-catenin construct. This study 
utilized biological specimens and data provided by the Lung Tissue Research Consortium 
(LTRC), supported by the National Heart, Lung, and Blood Institute (NHLBI). This work was 
supported by the National Institutes of Health [HL071628, HL087884, and HL095383 (LL)]. 
Yang Wang, Tingting Weng, and Yujie Guo were supported by American Heart Association 
predoctoral fellowships [08100162], [06101432], and [09PRE2300211]. 
 150 
 
4.6 References 
1. Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 
2004. 116(2): p. 281-97. 
2. He, L. and G.J. Hannon, MicroRNAs: small RNAs with a big role in gene 
regulation. Nat Rev Genet, 2004. 5(7): p. 522-31. 
3. Wang, Y., et al., MicroRNA: past and present. Front Biosci, 2007. 12: p. 2316-29. 
4. Filipowicz, W., S.N. Bhattacharyya, and N. Sonenberg, Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight? Nat Rev 
Genet, 2008. 9(2): p. 102-14. 
5. Ambros, V., The functions of animal microRNAs. Nature, 2004. 431(7006): p. 
350-5. 
6. Garzon, R., G.A. Calin, and C.M. Croce, MicroRNAs in Cancer. Annu Rev Med, 
2009. 60: p. 167-79. 
7. Gangaraju, V.K. and H. Lin, MicroRNAs: key regulators of stem cells. Nat Rev 
Mol Cell Biol, 2009. 10(2): p. 116-25. 
8. Friedman, R.C., et al., Most mammalian mRNAs are conserved targets of 
microRNAs. Genome Res, 2009. 19(1): p. 92-105. 
9. Poy, M.N., et al., A pancreatic islet-specific microRNA regulates insulin 
secretion. Nature, 2004. 432(7014): p. 226-30. 
10. Kloosterman, W.P., et al., Targeted inhibition of miRNA maturation with 
morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS 
Biol, 2007. 5(8): p. e203. 
11. El Ouaamari, A., et al., miR-375 targets 3'-phosphoinositide-dependent protein 
kinase-1 and regulates glucose-induced biological responses in pancreatic beta-
cells. Diabetes, 2008. 57(10): p. 2708-17. 
12. Liu, A.M., R.T. Poon, and J.M. Luk, MicroRNA-375 targets Hippo-signaling 
effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res 
Commun, 2010. 394(3): p. 623-7. 
13. Ding, L., et al., MiR-375 frequently downregulated in gastric cancer inhibits cell 
proliferation by targeting JAK2. Cell Res, 2010. 20(7): p. 784-93. 
14. Tsukamoto, Y., et al., MicroRNA-375 is downregulated in gastric carcinomas and 
regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res, 2010. 
70(6): p. 2339-49. 
15. Wang, Y., et al., Identification of rat lung-specific microRNAs by micoRNA 
microarray: valuable discoveries for the facilitation of lung research. BMC 
Genomics, 2007. 8: p. 29. 
16. Fehrenbach, H., Alveolar epithelial type II cell: defender of the alveolus revisited. 
Respir Res, 2001. 2(1): p. 33-46. 
 151 
 
17. Williams, M.C., Alveolar type I cells: molecular phenotype and development. 
Annu Rev Physiol, 2003. 65: p. 669-95. 
18. Chen, J., et al., Alveolar type I cells protect rat lung epithelium from oxidative 
injury. J Physiol, 2006. 572(Pt 3): p. 625-38. 
19. Adamson, I.Y. and D.H. Bowden, The type 2 cell as progenitor of alveolar 
epithelial regeneration. A cytodynamic study in mice after exposure to oxygen. 
Lab Invest, 1974. 30(1): p. 35-42. 
20. Crandall, E.D. and M.A. Matthay, Alveolar epithelial transport. Basic science to 
clinical medicine. Am J Respir Crit Care Med, 2001. 163(4): p. 1021-9. 
21. Kasper, M. and G. Haroske, Alterations in the alveolar epithelium after injury 
leading to pulmonary fibrosis. Histol Histopathol, 1996. 11(2): p. 463-83. 
22. Evans, M.J., et al., Renewal of alveolar epithelium in the rat following exposure 
to NO2. Am J Pathol, 1973. 70(2): p. 175-98. 
23. Evans, M.J., et al., Transformation of alveolar type 2 cells to type 1 cells 
following exposure to NO2. Exp Mol Pathol, 1975. 22(1): p. 142-50. 
24. Dobbs, L.G., M.C. Williams, and A.E. Brandt, Changes in biochemical 
characteristics and pattern of lectin binding of alveolar type II cells with time in 
culture. Biochim Biophys Acta, 1985. 846(1): p. 155-66. 
25. Cheek, J.M., M.J. Evans, and E.D. Crandall, Type I cell-like morphology in tight 
alveolar epithelial monolayers. Exp Cell Res, 1989. 184(2): p. 375-87. 
26. Dobbs, L.G., Isolation and culture of alveolar type II cells. Am J Physiol, 1990. 
258(4 Pt 1): p. L134-47. 
27. Bhaskaran, M., et al., Trans-differentiation of alveolar epithelial type II cells to 
type I cells involves autocrine signaling by transforming growth factor beta1 
through the Smad pathway. J Biol Chem, 2007. 282(6): p. 3968-76. 
28. Nelson, W.J. and R. Nusse, Convergence of Wnt, beta-catenin, and cadherin 
pathways. Science, 2004. 303(5663): p. 1483-7. 
29. MacDonald, B.T., K. Tamai, and X. He, Wnt/beta-catenin signaling: components, 
mechanisms, and diseases. Dev Cell, 2009. 17(1): p. 9-26. 
30. Mucenski, M.L., et al., beta-Catenin is required for specification of 
proximal/distal cell fate during lung morphogenesis. J Biol Chem, 2003. 278(41): 
p. 40231-8. 
31. Shu, W., et al., Wnt/beta-catenin signaling acts upstream of N-myc, BMP4, and 
FGF signaling to regulate proximal-distal patterning in the lung. Dev Biol, 2005. 
283(1): p. 226-39. 
32. Mucenski, M.L., et al., Beta-catenin regulates differentiation of respiratory 
epithelial cells in vivo. Am J Physiol Lung Cell Mol Physiol, 2005. 289(6): p. 
L971-9. 
33. Li, C., et al., Wnt5a participates in distal lung morphogenesis. Dev Biol, 2002. 
248(1): p. 68-81. 
 152 
 
34. Weidenfeld, J., et al., The WNT7b promoter is regulated by TTF-1, GATA6, and 
Foxa2 in lung epithelium. J Biol Chem, 2002. 277(23): p. 21061-70. 
35. Morrisey, E.E., Wnt signaling and pulmonary fibrosis. Am J Pathol, 2003. 162(5): 
p. 1393-7. 
36. De Langhe, S.P., et al., Dickkopf-1 (DKK1) reveals that fibronectin is a major 
target of Wnt signaling in branching morphogenesis of the mouse embryonic lung. 
Dev Biol, 2005. 277(2): p. 316-31. 
37. Flozak, A.S., et al., Beta-catenin/T-cell factor signaling is activated during lung 
injury and promotes the survival and migration of alveolar epithelial cells. J Biol 
Chem, 2010. 285(5): p. 3157-67. 
38. Chen, Z. and L. Liu, RealSpot: software validating results from DNA microarray 
data analysis with spot images. Physiol Genomics, 2005. 21(2): p. 284-91. 
39. Bhaskaran, M., et al., MicroRNA-127 modulates fetal lung development. Physiol 
Genomics, 2009. 37(3): p. 268-78. 
40. Zhang, H., et al., Micro-RNA-375 inhibits lung surfactant secretion by altering 
cytoskeleton reorganization. IUBMB Life, 2009. 62(1): p. 78-83. 
41. Gou, D., et al., A novel approach for the construction of multiple shRNA 
expression vectors. J Gene Med, 2007. 9(9): p. 751-63. 
42. Barth, A.I., D.B. Stewart, and W.J. Nelson, T cell factor-activated transcription is 
not sufficient to induce anchorage-independent growth of epithelial cells 
expressing mutant beta-catenin. Proc Natl Acad Sci U S A, 1999. 96(9): p. 4947-
52. 
43. Shtutman, M., et al., The cyclin D1 gene is a target of the beta-catenin/LEF-1 
pathway. Proc Natl Acad Sci U S A, 1999. 96(10): p. 5522-7. 
44. Meltzer, E.B. and P.W. Noble, Idiopathic pulmonary fibrosis. Orphanet J Rare 
Dis, 2008. 3: p. 8. 
45. Willis, B.C., et al., Induction of epithelial-mesenchymal transition in alveolar 
epithelial cells by transforming growth factor-beta1: potential role in idiopathic 
pulmonary fibrosis. Am J Pathol, 2005. 166(5): p. 1321-32. 
46. Poy, M.N., et al., miR-375 maintains normal pancreatic alpha- and beta-cell 
mass. Proc Natl Acad Sci U S A, 2009. 106(14): p. 5813-8. 
47. Avissar, M., et al., MicroRNA expression ratio is predictive of head and neck 
squamous cell carcinoma. Clin Cancer Res, 2009. 15(8): p. 2850-5. 
48. Ladeiro, Y., et al., MicroRNA profiling in hepatocellular tumors is associated 
with clinical features and oncogene/tumor suppressor gene mutations. 
Hepatology, 2008. 47(6): p. 1955-63. 
49. Logan, C.Y. and R. Nusse, The Wnt signaling pathway in development and 
disease. Annu Rev Cell Dev Biol, 2004. 20: p. 781-810. 
50. Kennell, J.A., et al., The microRNA miR-8 is a conserved negative regulator of 
Wnt signaling. Proc Natl Acad Sci U S A, 2008. 
 153 
 
51. Kapinas, K., et al., miR-29 modulates Wnt signaling in human osteoblasts through 
a positive feedback loop. J Biol Chem, 2010. 285(33): p. 25221-31. 
52. Abdelmohsen, K., et al., miR-375 inhibits differentiation of neurites by lowering 
HuD levels. Mol Cell Biol, 2010. 30(17): p. 4197-210. 
53. de Souza Rocha Simonini, P., et al., Epigenetically deregulated microRNA-375 is 
involved in a positive feedback loop with estrogen receptor alpha in breast cancer 
cells. Cancer Res, 2010. 70(22): p. 9175-84. 
54. Chilosi, M., et al., Aberrant Wnt/beta-catenin pathway activation in idiopathic 
pulmonary fibrosis. Am J Pathol, 2003. 162(5): p. 1495-502. 
55. Konigshoff, M., et al., Functional Wnt signaling is increased in idiopathic 
pulmonary fibrosis. PLoS One, 2008. 3(5): p. e2142. 
56. Polakis, P., Wnt signaling and cancer. Genes Dev, 2000. 14(15): p. 1837-51. 
 154 
 
CHAPTER V 
 
 
MIR-124 REGULATES FETAL PULMONARY EPITHELIAL CELL MATURATION BY 
TARGETING NFIB 
 
5.1 Abstract 
MicroRNAs are a family of small non-coding RNAs that regulate the expression of their 
target proteins at the post-transcriptional level. Their functions cover almost every aspect of cell 
physiology and are involved in lung diseases, liver diseases, cardiovascular diseases, and cancers. 
However, the functions of microRNAs in fetal lung development remain largely unknown. In this 
study, we discovered that the expression of miR-124 was dramatically down-regulated during 
fetal lung development, which corresponds to the increase in expression of surfactant proteins. 
Overexpressing miR-124 led to the inhibition of fetal lung epithelium maturation in both fetal 
lung organ culture and fetal lung epithelial cell culture as indicated by the decrease in surfactant 
protein expression and the increase in the cellular glycogen pool. miR-124 also modulates several 
important signaling pathways, including the NFκB and Wnt signaling pathways. We further 
determined that NFIB, which is known to regulate fetal lung epithelium maturation, is a direct 
target of miR-124 by 3’ UTR reporter assay and endogenous NFIB expression. In conclusion, 
miR-124 inhibits fetal epithelium maturation through the inhibition of NFIB.
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5.2 Introduction 
The development of the rat lung can be divided into 5 stages: the embryonic stage (0-13 
days), glandular stage (13-18 days), the canalicular stage (18-20 days), the saccular stage (20 
days to full term), and the alveolar stage (after birth) [1]. In the embryonic stage, a pair of lung 
rudiments arise from the primitive esophagus. In the glandular stage, the air passage tubes are 
formed by dichotomous branching of the terminal buds, the lung appears like a gland, and the 
epithelium switches from pseudostratified cells to columnar cells. At the canalicular stage, the 
mesenchymal tissue becomes thin and bronchioles appear, epithelial cells become cuboidal, and 
glycogen content also increases. In the saccular stage, some cells flatten and other cells remain 
cuboidal, the cuboidal cells lose glycogen and begin to synthesize surfactant, and alveolar ducts 
and air sacs form. The formation of true alveoli occurs in the alveolar stage after birth. The 
transcriptional control of fetal lung development has been studied for a long time. However, the 
functions of microRNAs in the regulation of epithelial development and maturation are still 
largely unknown. 
MicroRNAs are a group of small RNAs (~22 nt) that regulate protein expression at the 
post-transcriptional level. They bind to the mRNA of target genes directly and usually down-
regulate their expression by cleavage of the target mRNA, translational inhibition, or mRNA 
deadenylation [2-5]. To date, thousands of microRNAs have been discovered in humans and 
other animals. According to a study in silico, more than half of the mammalian mRNAs are under 
selective pressure and are conserved targets of microRNAs [6]. So far, the known functions of 
microRNAs have covered almost every aspect of cell physiology, including cell proliferation and 
differentiation, apoptosis, and lipid and fat metabolism. MicroRNAs are implicated in cancer, 
diabetes, and many other diseases [7-9]. 
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There have been some reports on microRNA functions in fetal lung development. 
Conditional deletion of Dicer, an enzyme required for the maturation of microRNAs, in lung 
epithelium resulted in branching arrest, indicating the important role of microRNAs in fetal lung 
morphogenesis [10]. The miR-17-92 cluster is also important in fetal epithelial development [11]. 
The cluster is highly expressed at early stages of development and down-regulated at later stages. 
Overexpression of this cluster in fetal lung epithelium results in increased epithelial progenitor 
cell proliferation and inhibition of differentiation. In addition, another study has shown that miR-
17-92 null mice develop severely hypoplastic lungs [12]. In our previous study, we showed that 
the expression levels of 21 microRNAs change during different stages of fetal lung development, 
which suggests the importance of microRNAs in the regulation of lung development [13]. We 
further found that overexpression of miR-127 results in the disruption of fetal lung 
morphogenesis, with a decrease in the number of terminal buds but an increase in the bud size. 
However, in spite of these studies, the functions of microRNAs in lung development are still 
largely unknown.  
miR-124 is preferentially expressed in the brain [14]. It has been reported that miR-124 
drives the gene expression profile toward that of the brain [15]. It helps to define and maintain the 
cell specificities in the brain. At least two mechanisms are involved in this regulation. First, miR-
124 directly targets PTBP1 (polypyrimidine tract binding protein 1), which is a global repressor 
of nervous system-specific pre-mRNA splicing. miR-124 inhibits the expression of PTBP1, 
leading to the differentiation from progenitor cells to neuronal cells [16]. Another mechanism 
involves SCP1 (small C-terminal domain phosphatase 1), which is an anti-neural phosphatase. 
During neurogenesis, miR-124 depresses the expression of SCP1 and antagonizes the 
REST/SCP1 pathway [17]. However, so far, no one has reported the functions of miR-124 in lung 
development. 
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In this study, we discovered that the expression of miR-124 was significantly down-
regulated during fetal lung development. Overexpression of miR-124 inhibited fetal lung 
epithelium maturation as indicated by decreased expression of surfactant proteins (SP-A, SP-B, 
and SP-C) and increased amount of glycogen pool. Several signaling pathways were affected by 
miR-124 overexpression. In addition, we identified nuclear factor I/B (NFIB), a transcriptional 
factor known to regulate fetal lung epithelium maturation, as a direct target of miR-124. Taken 
together, we demonstrated that miR-124 inhibited fetal lung epithelium maturation by directly 
targeting NFIB. 
5.3 Materials and methods 
5.3.1 qRT-PCR 
Total RNAs were isolated from fetal lung explants and cells using the mirVana
TM
 
miRNA isolation kit (Ambion, Austin, TX) and then treated with TURBO DNA-free
TM
 (Ambion) 
to eliminate any genomic DNA contamination. For each reverse transcription reaction, 1 μg of 
total RNA was reverse-transcribed into cDNA using MMLV reverse transcriptase. Real-time 
PCR was performed using SYBR Green master mix from Eurogentec (Seraing, Belgium) on an 
ABI 7500 Fast system (Applied Biosystems, Foster City, CA). The primers used in this study are 
listed in Table V1.  
Table V1: Primers for qRT-PCR. SP-A/B/C, surfactant protein A/B/C; T1α, podoplanin; CCSP, 
Clara cell secretory protein; eGFP, enhanced green fluorescent protein; FAS, fatty acid synthase. 
SP-A forward GATCAAACATCAGATTCTGCAAACA 
SP-A reverse TCCTGCTCTGGTACACATCTCTTTA 
SP-B forward AATGACCTGTGCCAAGAGTGTG 
SP-B reverse AGGACCAGCTTGTTCAGCAGAG 
SP-C forward AGCTCCAGGAACCTACTGCTACAT 
SP-C reverse AGGACTTGGCCTGGAAGTTCTT 
T1α forward GCCATCGGTGCGCTAGAAGATGATCTT 
T1α reverse GTGATCGTGGTCGGAGGTTCCTGAGGT 
CCSP forward CTAATTATGAGGCAGCCCTGAAG 
CCSP reverse GTCTCCTGTGGGAGGGTATCC 
eGFP forward CTGCTGCCCGACAACCA 
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eGFP reverse GAACTCCAGCAGGACCATGTG 
FAS forward TCAGAGGTTACACTGTGTTAGGTGTTG 
FAS reverse CCCATCCCTGAGCAGATGAA 
18s forward TCCCAGTAAGTGCGGGTCATA 
18s reverse CGAGGGCCTCACTAAACCATC 
MicroRNA qRT-PCR for miR-124 was performed with the TaqMan
®
 MicroRNA Assay 
kit (Applied Biosystems). In each reverse transcription reaction, 75 ng of total RNA was used as 
template for cDNA synthesis. The reactions were kept on ice for 5 min and then incubated at 
16°C for 30 min, 42°C for 30 min, and 85°C for 5 min. The PCR reactions were carried out at 
95°C for 10 min, and then 40 cycles of 95°C for 15 s and 60°C for 60 s. The expression of 18S 
rRNA was also detected as an internal control. The relative expression of miR-124 was calculated 
with the formula 2
-(CTmicroRNA-CT18s). 
5.3.2 In situ hybridization 
In situ hybridization of miR-124 was performed with 5’ DIG-labeled LNA probes from 
Exiqon (Woburn, MA). A probe with a scrambled sequence 
(GTGTAACACGTCTATACGCCCA) was used as a negative control. Paraffin sections of rat 
fetal lung tissues were dewaxed in xylene and rehydrated. The sections were then permeabilized 
with 10 µg/ml of Proteinase K at 37°C for 5 min, followed by incubation in 0.2% Glycine to stop 
the reaction. The sections were then fixed in 4% paraformaldehyde and prehybridized in 
hybridization buffer for 2 h. After that, the sections were hybridized with 20 nM probes in 
hybridization buffer at 60°C overnight. After stringent washes, the sections were blocked in 
blocking buffer for 1 h and then incubated with anti-DIG-AP Fab fragments (1:2000, Roche 
Applied Sciences, Indianapolis, IN) at 4°C overnight. After washing with Phosphate Buffered 
Saline with 0.05% Tween 20 (PBST) and Alkaline Phosphatase (AP) buffer, the sections were 
incubated in 5-bromo-4-chloro-3-indolyl phosphate (BCIP)/nitro blue tetrazolium (NBT) color 
solution (Roche Applied Sciences) until desired blue color developed. 
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5.3.3 Adenovirus construction  
The construction of miR-124 overexpression adenoviral vector (Ad-miR-124) was 
performed as previously described [13]. The pre-miRNA sequence of miR-124-1 with flanking 
sequences at both the 5’ and the 3’ end was cloned from human genomic DNA. The primers used 
were as follows: forward primer CACCTCGAGCACACGCACCGTCTACACTTC, reverse 
primer GAGAATTCTATTTGCACAGGCGGGAACTAC. This sequence was then inserted into 
the pENTR vector (Invitrogen, Carlsbad, CA) downstream of the CMV-GFP through XhoI and 
EcoRI restriction sites and switched to the adenoviral vector plasmid through LR recombination. 
This plasmid was digested by Pac I and transfected into 293A cells to produce adenovirus. Virus 
containing cells and medium were harvested and the crude adenoviral lysate was prepared by 
three freeze/thaw cycles and centrifugation. The adenoviral stock was amplified by infecting 
293A cells with 100 μl of crude adenoviral lysate. In order to titer the amplified adenovirus stock, 
the virus stock was diluted 10
4
 times with serial dilutions. 293A cells were infected with the 
diluted virus and the infected cells with eGFP signals were counted 48 h after infection. The virus 
titer is expressed as plaque-forming units (PFU) per ml. The virus made from empty pENTR 
vector with CMV-GFP was used as a control. 
5.3.4 Fetal lung organ culture 
For timed pregnancy, the day on which vaginal plugs were discovered was denoted as 
gestational Day 0. Female Sprague-Dawley timed pregnant rats on gestational Day 15 were 
euthanized with CO2. Fetal lungs were dissected from fetuses without surrounding tissues. They 
were then transferred to transwell inserts (Millipore, Billerica, MA) in 6-well plates. Each well 
contained 1.5 ml culture medium. The culture medium consisted of BGJb medium supplemented 
with 0.2 mg/ml ascorbic acid, 50 U/ml penicillin, and 50μg/ml streptomycin. Three hours later, 
the medium were removed and replaced with fresh culture medium. Adenovirus (10
8
 pfu) was 
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pre-incubated with 0.1 mg/ml of protamine for 15 min. The total volume of the mixture was 40 μl. 
After the incubation, the mixture was added to each fetal lung explants. This day was denoted as 
D0. Medium with viruses was removed 24 h later and culture medium was changed every day 
until sample collection at day 5 (D5). The second virus treatment at the same dose was given to 
each fetal lung explant on D2. The protocols used in the animal experiments in this study were 
approved by the Oklahoma State University Animal Care and Use Committee. 
5.3.5 Fetal AEC II isolation and culture 
Fetal alveolar epithelial type II cells (AEC II) were isolated as described by Batenburg et 
al [18]. Timed pregnant Sprague-Dawley rats on gestational day 18 were euthanized with CO2. 
Ten to fourteen fetal lungs were dissected from the fetuses and chopped into 1-mm
3
 pieces. Cells 
were dissociated by digestion with 10 ml of a solution consisting of 1 mg/ml Collagenase, 1 
mg/ml Trypsin, and 0.4 mg/ml DNase I in MEM for 10 min at 37°C. The lung tissue was then 
pelleted by spinning at 70 g for 1 min and the supernatant was collected. The digestion was 
repeated 3 times. The supernatant was collected and pooled together. The resulting cell 
suspension was filtered through 160- and 37-μm nylon filters. Cells were then seeded in a 20-cm 
plastic dish and incubated for 45 min x 4 times to remove fibroblasts. The cell suspension was 
then filtered through a 15-μm nylon filter. Two million fetal AEC II were plated on 500 μl 
Matrigel (BD Matrigel™ Basement Membrane Matrix High Concentration, Growth Factor 
Reduced, Cat # 354263, Lot # 99301, 18.7 mg/ml, 1:1 dilution) in each well of a 6-well plate and 
infected with adenovirus expressing miR-124 (Ad-miR-124) or control virus with a multiplicity 
of infection (MOI) of 100. The medium used on Day 0 was MEM supplemented with 10% Fetal 
Bovine Serum (FBS, Atlanta Biologicals, Lawrenceville, GA) and 1% Penicillin/Streptomycin 
(Invitrogen, penicillin 5000 IU/ml, streptomycin 5mg/ml). On the second day, the medium was 
changed to the defined medium which consisted of DMEM supplemented with d-biotin (100 
µg/L), ethanolamine (30 µg/L), phosphoethanolamine (70 µg/L), putrescine/bitane-1,4-diamile 
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(20 mg/L), transferrin (5 mg/L), CuSO4 (25 µg/L), FeCl3 (1 mg/L), ZnCl2 (30 µg/L), MnCl2 (10 
µg/L), Na selenite (10 µg/L), 1% MEM non-essential amino acids (Invitrogen), and 1% 
penicillin/streptomycin. Cells were cultured on Matrigel for 2 days. After that, Matrigel was 
dissolved by incubation with 1 ml of Dispase (50 caseinolytic units/ml, BD Biosciences, Bedford, 
MA) for 1 h. Cells were then collected for RNA extraction with the mirVana
TM
 microRNA 
isolation kit. 
5.3.6 Anthrone assay 
Glycogen content was determined as previously described [19, 20]. Briefly, cultured fetal 
lung explants were boiled in 100 μl 30% KOH for 30 min. The resulting slurry was diluted with 
1.5 ml H2O and mixed completely. A 400-μl aliquot of this diluted sample was then mixed with 
800 μl of 0.2% anthrone reagent in 95% H2SO4 in a cold water bath. The mixture was boiled for 
10 min and cooled down to room temperature in a cold water bath. The OD was read at 620 nm 
with a UV spectrophotometer.  
5.3.7 Pathway screening 
Pathway analysis was performed with Cignal™ Reporter Assays (SABiosciences, 
Frederick, MD). Nine pathways known to be involved in development, including Notch, Wnt, 
Myc/Max, NFκB, TGF-β, C/EBP, cAMP/PKA, MAPK/ERK, and MAPK/JNK, were screened 
using reporter luciferase assays. In brief, HEK 293T cells were transfected with 50 ng pathway 
reporter vector and 100 ng microRNA overexpression plasmid or control plasmid, with or without 
corresponding stimuli. The cells were harvested 48 h post-transfection and the firefly and Renilla 
luciferase activities were determined using Dual Luciferase Reporter Assay System (Promega) by 
the FLUOstar OPTIMA microplate fluorometer (BMG LABTECH, Offenburg, Germany). Firefly 
signals were normalized with Renilla signals. 
5.3.8 3’ UTR luciferase assay 
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The 3’ untranslated region (3’ UTR) of rat GNAI3 (G protein α inhibiting polypeptide 3), 
Foxa2 (forkhead box A2), SOS1 (son of sevenless homolog 1), NRAS (neuroblastoma ras 
oncogene), AKT2 (v-akt murine thymoma viral oncogene homolog 2), GRB2 (growth factor 
receptor bound protein 2), PIK3C2A (phosphoinositide-3-kinase, class 2, α polypeptide), NFIB, 
and ADCY9 (adenylate cyclase 9) were PCR-amplified from rat genomic DNA with Advantage® 
2 Polymerase Mix (Clontech, Mountain View, CA) and cloned into pmirGLO Dual-Luciferase 
microRNA Target Expression Vector (Promega, Madison, WI) using NheI and SalI restriction 
sites except for ADCY9, for which SacI and SalI were used. The primers used for PCR were 
listed in Table V2. 
Table V2 Primers for pmirGLO dual-luciferase microRNA target expression vector construction. 
The restriction sites were underlined. 
GNAI3 forward TCAGCTAGCTGTGGCCTTTTTTGCTAGGAGAC 
GNAI3 reverse TCAGTCGACGACAATCTTCAGACAGCTTTGG 
SOS1 forward TCTGCTAGCGACCTAAGCTGAGCCAAGAGAATAC 
SOS1 reverse TCAGTCGACTGTGGGCTATATAAGGCATTTT 
NRAS forward TCAGCTAGCAAGGACCCTTTAAAAGTTCTGT 
NRAS reverse TCAGTCGACGGTTTGAAGAATCATTAATCAC 
AKT2 forward ATAGCTAGCTCTGCCACCACAGGACACAGCAT 
AKT2 reverse TCAGTCGACCTAAGGCTTCCTTGTTCCACAC 
GRB2 forward TCAGCTAGCTTAAAGAAAGTGAAAAGTTGAG 
GRB2 reverse TCAGTCGACTTATTCACAGTTAATCACTACC 
PIK3C2A forward TATGCTAGCTGTTGACTCCTACCAATTCCAA 
PIK3C2A reverse ATAGTCGACGAAGTCACATTCAATTCACTGA 
NFIB forward TCAGCTAGCTGGTTCCTTTTCAAGTGTCAAA 
NFIB reverse TCAGTCGACGGTCAATTAAAACAAACAAACA 
ADCY9 forward TCAGAGCTCCTCTGCTTGTCCAAACACAATA 
ADCY9 reverse TCTGTCGACTCAGCTGTGTCCTTTGCAAACT 
For each 3’ UTR, 50 ng of microRNA overexpression plasmid pENTR-miR-124 was 
transfected into HEK293T cells using Lipofectamine 2000 (Invitrogen) together with 5 ng of the 
pmirGLO reporter construct. The cells were harvested 48 h post-transfection and the firefly and 
Renilla luciferase activities were detected as described above. Empty pmirGLO reporter plasmid 
was also used for normalization purpose. For data analysis, first, the firefly luciferase activities 
were normalized to the Renilla luciferase activities. The fold changes of the normalized luciferase 
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activities with or without miR-124 overexpression were then divided by that of the pmirGLO 
empty vector. 
5.3.9 Western blotting 
The following primary antibodies were used in Western blotting: mouse monoclonal anti-
PIK3C2A (Santa Cruz, sc-136298, 1:200), rabbit polyclonal anti-SOS1 (Santa Cruz, sc-256, 
1:200), rabbit polyclonal anti-NFIB (Active Motif, Carlsbad, CA, 39091, 1:1000), rabbit 
polyclonal anti-SP-C (Santa Cruz, sc-13979, 1:500), and rabbit polyclonal anti-β-actin from 
Sigma (A-2066, 1:2000). For Western blots, 35 μg of protein was loaded into each well. The 
membranes were incubated with primary antibodies at 4°C overnight. After washing with Tris-
Buffered Saline and 0.05% Tween 20 (TBS-T), they were then incubated with horseradish 
peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies (Jackson ImmunoResearch 
Laboratories, West Grove, PA, 1:2000) for 1 h. The blots were developed using SuperSignal 
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL) and visualized and quantitated 
with Molecular Imager VersaDoc MP 5000 System (Bio-Rad, Hercules, CA). 
5.4 Results 
5.4.1 miR-124 is down-regulated during fetal lung development 
We measured the expression levels of miR-124 at different stages of fetal lung 
development, including gestational day 16, 19, and 21 (E16, E19, and E21), postnatal day 0, 6, 
and 14 (P0, P6, and P14), and 2 months after birth (AD), with microRNA qRT-PCR (Fig. V1a). 
The expression of miR-124 was remarkably decreased from E16 to E19 and continued to 
decrease gradually from E19 to adult. The localization of miR-124 in E16 fetal lung was 
determined by microRNA in situ hybridization. As shown in Fig. V1b, miR-124 was mainly 
expressed in the epithelial cells of E16 lungs.  
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Fig. V1 The expression of miR-124 during rat fetal lung development. a) The mRNA 
expression patterns of miR-124 at different stages of fetal lung development (E16, E19, E21, 
P0, P6, P14, and AD) were determined using qRT-PCR. Data shown are means ± S.E. from 3 
independent replicates. b) In situ hybridization for miR-124 in E16 fetal lung. Neg: negative 
control using a scrambled sequence. Scale bar: 100 µm. 
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5.4.2 miR-124 inhibits alveolar epithelial cell maturation. 
In order to identify the functions of miR-124 during fetal lung development, we 
overexpressed miR-124 ectopically with an adenovirus in fetal lung organ culture. To improve 
the transduction efficiency, we pre-incubated adenovirus with protamine, which neutralizes the 
charges on the viruses and cells, and has been shown to improve the adenoviral transduction 
efficiency [21]. 
Fetal lungs on gestational day 15 were transduced with miR-124 overexpressing 
adenovirus (Ad-miR-124) in the presence of with 0.1 mg/ml of protamine and cultured for 5 days. 
The expression of miR-124 was detected with qRT-PCR (Fig.V2a). Viral overexpression 
increased the expression of miR-124 more than 10-fold. 
In order to determine whether miR-124 influences the alveolar epithelial cell 
differentiation, we then determined the mRNA expression of several cell marker genes. The 
expression levels of SP-A, SP-B, SP-C and FAS, an important enzyme in surfactant synthesis, 
were significantly decreased in the miR-124 treated lungs (Fig. V2b). Western blots revealed that 
the SP-C protein was also decreased by miR-124 overexpression (Fig. V2c). However, the 
alveolar epithelial type I cell (AEC I) marker, T1α and the Clara cell marker, CCSP were not 
significantly changed. 
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Fig. V2 miR-124 overexpression 
and alveolar epithelial cell 
maturation. Fetal lungs on 
gestation Day 15 were infected 
with miR-124 overexpression 
virus or virus control (VC) and 
were cultured for 5 days. a) The 
expression level of miR-124 was 
detected after miR-124 
overexpression. b) The mRNA 
levels of cell type marker genes 
were determined with qRT-PCR. 
Data shown are percentages of the 
control. c) The protein levels of 
SP-C were determined with 
Western blots. d) The glycogen 
content was detected with anthrone 
reagent. e) PAS staining. Red and 
black arrows indicate positive and 
negative staining. Data shown are 
means ± S.E. from at least 3 
independent replicates. * p<0.01 
vs. VC. 
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Glycogen content was also measured to confirm the inhibition of AEC II maturation (Fig. 
V2d). During AEC II maturation, glycogen disappears from the pre AEC II. We performed an 
anthrone assay to measure the glycogen content in the fetal lung organ culture. The glycogen 
content was higher in the Ad-miR-124 transduced fetal lungs (Fig. V2d). In addition, the 
glycogen was also detected with periodic acid-Schiff (PAS) staining. The amount of glycogen 
was significantly increased in the Ad-miR-124 treated lungs (Fig. V2e). Taken together, these 
results indicate that miR-124 inhibited AEC II maturation, while AEC I and Clara cells were not 
affected. 
5.4.3 miR-124 inhibits the expression of surfactant proteins in fetal AEC II culture. 
In order to determine whether miR-124 inhibits AEC II maturation without the 
participation of mesenchyme, we isolated fetal AEC II cells from pregnant rats on gestational day 
18 and transduced them with Ad-miR-124 or control virus in the presence of 0.1 mg/ml of 
protamine. It has been reported that isolated fetal rat AEC II can differentiate in defined medium 
on a basement membrane matrix, with formation of lamellar bodies and the expression of 
surfactant proteins [22]. The isolated fetal AEC II were cultured on Matrigel for 2 days and the 
expression of SP-A, SP-B, and SP-C was detected with qRT-PCR (Fig. V3). Consistent with 
results from fetal lung organ culture, the expression of SP-A, SP-B, and SP-C was significantly 
decreased. The decrease of surfactant proteins indicated the inhibition of AEC II maturation. 
These results indicate that miR-124 can inhibit fetal AEC II maturation without participation of 
mesenchyme. 
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Fig. V3 Expression of surfactant proteins in cultured fetal AEC II. E18 fetal AEC II were 
infected with Ad-miR-124 or control virus (VC) (MOI= 100) and cultured on Matrigel for 2 days. 
The mRNA expression of SP-A, SP-B, and SP-C were detected with qRT-PCR. Data shown are 
mean ± S.E. from 3 independent replicates. (*p<0.05, ** p<0.005 vs. VC) 
Fig. V4 Luciferase assays for screening of pathways affected by miR-124. The activities of 9 
development pathways after miR-124 overexpression with or without stimuli were determined 
using luciferase reporter assays in HEK 293T cells. The activities were expressed as fractions of 
the control using an empty overexpression vector. Data shown are means ± S.E. * p<0.005. 
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5.4.4 miR-124 inhibits NFκB, cAMP/PKA and MAP/ERK pathways 
In order to figure out how miR-124 regulates epithelium maturation in fetal lung 
development, we screened several development pathways with reporter vectors to identify which 
pathways are regulated by miR-124. The Wnt, NFκB, TGF-β, C/EBP, cAMP, MAPK/ERK, and 
MAPK/JNK pathways were stimulated with Wnt3a conditioned medium, tumor necrosis factor α 
(TNFα, 0.01 ng/μl), transforming growth factor, beta 1 (TGF-β1, 0.005 ng/μl), PD98059 (2.67 
ng/μl), forskolin (1 ng/μl), epidermal growth factor (EGF, 0.1 ng/μl), and phorbol 12-myristate 
13-acetate (PMA, 0.01 ng/μl), respectively. The luciferase reporter assays revealed that NFκB, 
cAMP/PKA, and MAPK/ERK pathways under stimulated conditions are significantly depressed 
by miR-124, while the Wnt and TGF-β pathways were stimulated by miR-124 at both basal and 
stimulated states (Fig. V4). 
According to target prediction with TargetScan (http://www.targetscan.org/) and pathway 
analysis with DAVID (http://david.abcc.ncifcrf.gov/), some predicted targets of miR-124 were 
nested in miR-124-depressed pathways, including GNAI3 and ADCY9 in the cAMP/PKA 
pathway, SOS1, NRAS, and GRB2 in the MAPK/ERK pathway, and AKT2 and PIK3C2A in the 
upstream of the NFκB pathway. The 3’ UTR dual luciferase assays revealed that SOS1 and 
PIK3C2A were significantly inhibited by miR-124 and all others were not affected (Fig. V5a). 
However, when we overexpressed miR-124 in MLE15 cells, the protein levels of SOS1 and 
PIK3C2A were not changed (Fig. V5b), suggesting that these two proteins are not targeted by 
miR-124 in lung epithelial cells. 
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Fig. V5 Verification of predicted targets. a) Luciferase assays for 3’ UTR verification. HEK 
293T cells were transfected with miRGlo reporter constructs containing the 3’UTR of 
predicted targets of miR-124, together with the miR-124 overexpression pENTR plasmid or 
the control plasmid. Luciferase activities were determined 48 h post-transfection. Data shown 
were means ± S.E. from 3 replicates and are expressed as fractions of the control. * p<0.001 
vs. control. miRGlo, empty miRGlo vector without any 3’ UTR sequence. b) MLE15 cells 
were transduced with Ad-miR-124 or control virus (VC) and were collected 72 h after 
transduction. The protein levels of SOS1 and PIK3C2A were measured with Western blots. 
Blots shown are representatives of 6 independent replicates. Blots were quantitated and data 
shown are means ± S.E. and are represented as fractions of VC. 
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Fig. V6 miR-124 inhibits expression of NFIB at the protein level. a) Schematic of 2 putative 
miR-124 binding sites in the 3’ UTR of NFIB. b) 3’UTR luciferase assay. pmirGLO luciferase 
reporter vectors with NFIB 3’UTR (NFIB), mutated 3’ UTR at the first or second binding sites 
(Mut1 and Mut2), or without any 3’ UTR insert (miRGlo) were transfected into HEK 293T cells. 
pENTR-miR-124 (124) or pENTR-Control (control) was co-transfected with the reporter vectors. 
Luciferase activities were determined 48 h after transfection and are expressed as fractions of the 
control. Data shown are normalized with miRGlo and are means ± S.E. from 6 replicates. c) 
MLE15 cells were transduced with Ad-miR-124, or virus control (VC). Cells were collected 72 h 
after treatment. The protein levels of NFIB were determined with Western blots. d) The blots 
were quantitated. Data shown are means ± S.E. from 6 independent replicates. 
 172 
 
5.4.5 miR-124 directly inhibits the expression of NFIB 
It has been reported that NFIB can regulate epithelium maturation in fetal lung 
development [23]. TargetScan predicts NFIB as a target of miR-124, with 2 conserved binding 
sites (Fig. V6a). It is possible that miR-124 inhibits fetal lung epithelium maturation through the 
depression of NFIB. In order to confirm this hypothesis, we performed luciferase reporter assays 
with NFIB 3’ UTR. As shown in Fig. V6b, the luciferase activity of the reporter vector with 
NFIB 3’ UTR was decreased by about 50%. Furthermore, we mutated the 2 predicted binding 
sites in NFIB 3’ UTR in order to identify whether they are responsible for the inhibition of 
expression. If binding site 1 or site 2 was mutated, the luciferase activity was decreased 25% and 
35%, respectively. This result suggests that both binding sites are functional in the inhibition of 
NFIB expression (Fig. V6b). When miR-124 was overexpressed in MLE15 cells with adenovirus 
Ad-miR-124, the protein level of NFIB was also decreased by 50% (Fig. V6c and V6d). 
5.5 Discussion 
In this study, we found that miR-124 was predominantly expressed in epithelial cells in 
fetal lung on gestation day 16 and is down-regulated during fetal lung development. 
Overexpression of miR-124 inhibits pulmonary epithelium maturation as indicated by the 
decrease in surfactant proteins, FAS, and increase of glycogen content. In addition, we identified 
NFIB as a direct target of miR-124. 
To our knowledge, this is the first report studying the function of miR-124 in fetal lung 
development. In addition, we are the first to identify NFIB as a direct target of miR-124. miR-124 
is preferentially expressed in brain and retina [24-26].  Most of the studies on miR-124 focused 
on the neural system. It has been reported that miR-124 plays important roles in neurogenesis, 
neuronal differentiation, plasticity, and microglia quiescence [16, 17, 27-37]. miR-124 is also 
involved in brain cancers, including medulloblastoma and glioblastoma [38, 39]. In addition, 
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miR-124 has been shown to be involved in intracellular signaling in pancreatic beta cells, 
hepatocellular carcinoma, haematological malignancies, cervical cancer, oral squamous cell 
carcinoma, acute lymphoblastic leukemia, and gastrulation of embryonic stem cells [40-46]. 
Many proteins have been identified as targets of miR-124, including Foxa2, CDK6, ROCK2, 
EZH2, CREB, ITGB, NeuroD1, C/EBP-α, Sox9, Lhx2, JAG1, IκBζ, SLUG, and IQGAP1 [30, 32, 
33, 35-38, 43, 44, 46, 47]. In this study, we added NFIB to this growing list of miR-124 targets. 
Lung epithelial cell differentiation becomes more evident at the saccular stage of lung 
development. At this stage, cuboidal epithelial cells begin to synthesize pulmonary surfactant. 
The increase of surfactant protein expression corresponds with the decrease of miR-124 at this 
period. As indicated by in situ hybridization, miR-124 is mainly expressed in epithelial cells in 
E16 lungs. This suggests that the disappearance of miR-124 from epithelial cells may be 
necessary for epithelial cell maturation. Our data support this assumption, as ectopic expression 
of miR-124 in fetal lung organ culture inhibits epithelium maturation. The decrease of miR-124 
and synthesis of surfactant proteins also corresponds with the increase of NFIB in the epithelial 
cells. The decrease of miR-124 in epithelial cells is critical for the increase of NFIB and thus 
epithelial cell maturation. 
Nuclear factor I (NFI) is a family of transcription factors that bind to the consensus 
palindromic binding site TTGGCN5GCCAA in double-stranded DNA as homo- and hetero-
dimers [48-50]. In vertebrates, there are 4 NFI genes (Nfia, Nfib, Nfic, and Nfix) [51, 52]. These 
genes have unique but overlapping expression patterns. Depending on the cellular context and 
alternative splicing of NFI mRNAs, NFI can activate or depress the expression of target genes 
[53]. The importance of NFI proteins in development has been demonstrated with knockout mice. 
Loss of Nfia results in perinatal lethality and defects in brain development [54]. Nfib deficient 
mice die early after birth with severe lung hypoplasia and defects in lung maturation [55, 56]. 
These mice also show defects in brain development similar to Nfia deficient mice. NFIB is 
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expressed predominantly in mesenchymal cells at early stages of fetal lung development and is 
expressed in both epithelium and mesenchyme at late stages. Loss of Nfib affects the expression 
of a number of genes involved in extracellular matrix and cell adhesion. Loss of Nfib also leads to 
a decreased expression of pulmonary surfactant proteins, including SP-A, SP-B, and SP-C, and 
the increase of fibroblast growth factor 10 (Fgf10) [23, 56]. Fgf10 is expressed in mesenchymal 
cells and is known to regulate lung epithelial cell proliferation and differentiation. 
Overexpression of Fgf10 in the embryonic lung results in interruption of fetal lung branching 
morphogenesis and distal epithelial cell differentiation [57, 58]. Nfic null mice showed defects in 
tooth root development [59]. 
From the results of the development pathway study, it is clear that miR-124 has important 
roles in development. It dramatically affects activity of the Wnt, NFκB, TGF-β, cAMP/PKA, and 
MAPK/ERK signaling pathways. However, no components in the NFκB, cAMP/PKA, or 
MAPK/ERK pathways can be confirmed as direct targets of miR-124. It is quite possible that 
miR-124 regulates these pathways indirectly or by actions on unidentified targets. Since we have 
identified the transcriptional factor, NFIB as a direct target of miR-124, whether NFIB can 
regulate these pathways is of particular interest in the future study. 
In summary, we demonstrated that miR-124 was down-regulated during late stages of 
fetal lung development and NFIB was a direct target of miR-124. miR-124 regulates fetal lung 
epithelium maturation. These results will help to understand fetal lung development from a new 
perspective and may provide potential targets for therapeutic intervention to promote epithelial 
cell maturation in premature infants. 
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9. miR-124 inhibits fetal epithelium maturation by directly targeting NFIB. 
 
